fusn-10q_20200930.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-20-052755.txt : 20201110 0001564590-20-052755.hdr.sgml : 20201110 20201110083045 ACCESSION NUMBER: 0001564590-20-052755 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001805890 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39344 FILM NUMBER: 201299716 BUSINESS ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 BUSINESS PHONE: 289-799-0891 MAIL ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 10-Q 1 fusn-10q_20200930.htm 10-Q fusn-10q_20200930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to __________________

Commission File Number: 001-39344

Fusion Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

Canada	Not Applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
270 Longwood Rd., S. Hamilton, ON, Canada	L8P 0A6
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (289) 799-0891

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common shares, no par value per share

FUSN

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 3, 2020, the registrant had 41,725,797 common shares, with no par value per share, outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets (Unaudited)	1
	Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	2
	Condensed Consolidated Statements of Non-controlling Interest, Convertible Preferred Shares and Shareholders’ Equity (Deficit) (Unaudited)	3
	Condensed Consolidated Statements of Cash Flows (Unaudited)	5
	Notes to (Unaudited) Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	42
Item 4.	Controls and Procedures	43
PART II.	OTHER INFORMATION	44
Item 1.	Legal Proceedings	44
Item 1A.	Risk Factors	44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	45
Item 3.	Defaults Upon Senior Securities	46
Item 4.	Mine Safety Disclosures	46
Item 5.	Other Information	46
Item 6.	Exhibits	47
Signatures		48

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

FUSION PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

(Unaudited)

	September 30, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	248,793		$	65,344
Restricted cash		280			280
Short-term investments		43,159			—
Prepaid expenses and other current assets		4,652			929
Total current assets		296,884			66,553
Property and equipment, net		1,981			1,272
Deferred tax assets		106			78
Restricted cash		1,465			1,497
Long-term investments		11,102			—
Other non-current assets		521			—
Total assets	$	312,059		$	69,400
Liabilities, Non-Controlling Interest, Convertible Preferred Shares and Shareholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$	956		$	830
Accrued expenses		4,353			3,326
Income taxes payable		—			117
Total current liabilities		5,309			4,273
Deferred rent, net of current portion		3			28
Preferred share tranche right liability		—			5,741
Income taxes payable, net of current portion		293			293
Special voting shares redemption right liability (Notes 2 and 7)		—			—
Total liabilities		5,605			10,335
Commitments and contingencies (Note 12)
Non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited (Notes 2 and 7)		—			20,961
Convertible preferred shares, no par value; 0 shares and 132,207,290 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 0 shares and 73,125,790 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $77,965 as of September 30, 2020 and December 31, 2019, respectively		—			71,592
Shareholders’ equity (deficit):
Common shares, no par value, unlimited shares authorized as of September 30, 2020 and December 31, 2019; 41,702,384 and 1,929,555 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively		—			—
Additional paid-in capital		406,273			1,286
Accumulated other comprehensive income		(1	)		—
Accumulated deficit		(99,818	)		(34,774	)
Total shareholders’ equity (deficit)		306,454			(33,488	)
Total liabilities, non-controlling interest, convertible preferred shares and shareholders’ equity (deficit)	$	312,059		$	69,400

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FUSION PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Operating expenses:
Research and development	$	4,529		$	2,238		$	12,231		$	7,216
General and administrative		5,790			1,922			14,105			4,864
Total operating expenses		10,319			4,160			26,336			12,080
Loss from operations		(10,319	)		(4,160	)		(26,336	)		(12,080	)
Other income (expense):
Change in fair value of preferred share tranche right liability		—			3,485			(32,722	)		3,707
Change in fair value of preferred share warrant liability		—			—			(6,399	)		—
Interest income (expense), net		80			247			249			395
Refundable investment tax credits		41			44			139			132
Other income (expense), net		20			(29	)		148			76
Total other income (expense), net		141			3,747			(38,585	)		4,310
Loss before (provision) benefit for income taxes		(10,178	)		(413	)		(64,921	)		(7,770	)
Income tax (provision) benefit		185			(181	)		(27	)		(213	)
Net loss		(9,993	)		(594	)		(64,948	)		(7,983	)
Unrealized loss on investments		(1	)		—			(1	)		—
Comprehensive loss		(9,994	)		(594	)		(64,949	)		(7,983	)
Reconciliation of net loss to net loss attributable to common shareholders:
Net loss		(9,993	)		(594	)		(64,948	)		(7,983	)
Dividends paid to preferred shareholders in the form of warrants issued		—			—			(1,382	)		—
Net loss attributable to common shareholders	$	(9,993	)	$	(594	)	$	(66,330	)	$	(7,983	)
Net loss per share attributable to common shareholders—basic and diluted	$	(0.24	)	$	(0.31	)	$	(4.30	)	$	(4.18	)
Weighted-average common shares outstanding—basic and diluted		41,682,797			1,929,555			15,422,375			1,910,695

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FUSION PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF NON-CONTROLLING INTEREST, CONVERTIBLE PREFERRED SHARES

AND SHAREHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share amounts)

(Unaudited)

	Non-Controlling Interest in Fusion Pharmaceuticals (Ireland)			Class A and B Convertible Preferred Shares						Common Shares				Additional Paid-in			Accumulated			Accumulated Other Comprehensive			Total Shareholders’
	Limited			Shares			Amount			Shares		Amount		Capital			Deficit			Income (Loss)			Equity (Deficit)
Balances at December 31, 2019	$	20,961			73,125,790		$	71,592			1,929,555	$	—	$	1,286		$	(34,774	)	$	—		$	(33,488	)
Issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs of $93		—			6,598,917			9,907			—		—		—			—			—		$	—
Initial fair value of Class B convertible preferred share tranche right liability		—			—			(1,105	)		—		—		—			—			—		$	—
Issuance of warrants to purchase Class B convertible preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders		—			—			—			—		—		(1,286	)		(96	)		—		$	(1,382	)
Share-based compensation expense		—			—			—			—		—		358			—			—		$	358
Net loss		—			—			—			—		—		—			(10,222	)		—		$	(10,222	)
Balances at March 31, 2020		20,961			79,724,707			80,394			1,929,555		—		358			(45,092	)		—			(44,734	)
Issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs of $6		—			36,806,039			55,769			—		—		—			—			—			—
Issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs of $2		6,722			—			—			—		—		—			—			—			—
Reclassification of Class B convertible preferred share and preferred exchangeable share tranche right liability upon settlement		4,257			—			35,311			—		—		—			—			—			—
Conversion of Class A and B preferred exchangeable shares into Class A and B convertible preferred shares		(31,940	)		28,874,378			31,940			—		—		—			—			—			—
Conversion of Class A and B convertible preferred shares into common shares		—			(145,405,124	)		(203,414	)		27,234,489		—		203,414			—			—			203,414
Conversion of convertible preferred share warrants into common share warrants		—			—			—			—		—		7,781			—			—			7,781
Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees of $19,447		—			—			—			12,500,000		—		193,053			—			—			193,053
Share-based compensation expense		—			—			—			—		—		426			—			—			426
Net loss		—			—			—			—		—		—			(44,733	)		—			(44,733	)
Balances at June 30, 2020		—			—			—			41,664,044		—		405,032			(89,825	)		—			315,207
Issuance of common shares upon exercise of common share warrants		—			—			—			38,340		—					—			—			—
Share-based compensation expense		—			—			—			—		—		1,241			—			—			1,241
Unrealized loss on investments		—			—			—			—		—		—			—			(1	)		(1	)
Net loss		—			—			—			—		—		—			(9,993	)		—			(9,993	)
Balances at September 30, 2020	$	—			—			—			41,702,384	$	—	$	406,273		$	(99,818	)	$	(1	)	$	306,454

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FUSION PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF NON-CONTROLLING INTEREST, CONVERTIBLE PREFERRED SHARES – CONTINUED

AND SHAREHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share amounts)

(Unaudited)

	Non-Controlling Interest in Fusion Pharmaceuticals (Ireland)			Class A and B Convertible Preferred Shares					Common Shares				Additional Paid-in		Accumulated			Accumulated Other Comprehensive		Total Shareholders’
	Limited			Shares		Amount			Shares		Amount		Capital		Deficit			Income (Loss)		Equity (Deficit)
Balances at December 31, 2018	$	15,168			42,918,661	$	32,371			1,872,975	$	—	$	668	$	(18,585	)	$	—	$	(17,917	)
Issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs of $299		—			30,207,129		45,476			—		—		—		—			—		—
Issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs of $13		6,711			—		—			—		—		—		—			—		—
Initial fair value of Class B convertible preferred share and preferred exchangeable share tranche right liability		(918	)		—		(6,255	)		—		—		—		—			—		—
Share-based compensation expense		—			—		—			—		—		102		—			—		102
Net loss		—			—		—			—		—		—		(3,933	)		—		(3,933	)
Balances at March 31, 2019		20,961			73,125,790		71,592			1,872,975		—		770		(22,518	)		—		(21,748	)
Issuance of common shares upon exercise of stock options		—			—		—			56,580		—		—		—			—		—
Share-based compensation expense		—			—		—			—		—		88		—			—		88
Net loss		—			—		—			—		—		—		(3,456	)		—		(3,456	)
Balances at June 30, 2019		20,961			73,125,790		71,592			1,929,555		—		858		(25,974	)		—		(25,116	)
Share-based compensation expense		—			—		—			—		—		138		—			—		138
Net loss		—			—		—			—		—		—		(594	)		—		(594	)
Balances at September 30, 2019	$	20,961			73,125,790	$	71,592			1,929,555	$	—	$	996	$	(26,568	)	$	—	$	(25,572	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FUSION PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities:
Net loss	$	(64,948	)	$	(7,983	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		2,025			328
Depreciation and amortization expense		373			213
Non-cash rent expense		3			(2	)
Change in fair value of preferred share tranche right liability		32,722			(3,707	)
Change in fair value of preferred share warrant liability		6,399			—
Amortization of premiums (accretion of discounts) on investments, net		24			—
Deferred tax benefit		(28	)		—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(3,792	)		16
Other non-current assets		(521	)		—
Accounts payable		150			408
Accrued expenses		1,025			719
Income taxes payable		(117	)		151
Net cash used in operating activities		(26,685	)		(9,857	)
Cash flows from investing activities:
Purchases of investments		(54,286	)		—
Purchases of property and equipment		(1,063	)		(340	)
Net cash used in investing activities		(55,349	)		(340	)
Cash flows from financing activities:
Proceeds from issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs		65,676			45,476
Proceeds from issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs		6,722			6,711
Proceeds from the issuance of common shares upon closing of initial public offering, net of underwriter fees		197,625			—
Payment of offering costs		(4,572	)		—
Net cash provided by financing activities		265,451			52,187
Net increase in cash, cash equivalents and restricted cash		183,417			41,990
Cash, cash equivalents and restricted cash at beginning of period		67,121			29,080
Cash, cash equivalents and restricted cash at end of period	$	250,538		$	71,070
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	280		$	40
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	$	—		$	4
Issuance of common shares upon net settlement of stock option exercise	$	—		$	57
Issuance of warrants to purchase Class B preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders	$	1,382		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FUSION PHARMACEUTICALS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.	Nature of the Business and Basis of Presentation

Fusion Pharmaceuticals Inc., together with its consolidated subsidiaries (“Fusion” or the “Company”), is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. The Company was formed and subsequently incorporated as Fusion Pharmaceuticals Inc. in December 2014 under the Canada Business Corporations Act. The Company was founded to advance certain intellectual property relating to radiopharmaceuticals that had been developed by the Centre for Probe Development and Commercialization, a radiopharmaceutical research and good manufacturing practice production center. The Company is headquartered in Hamilton, Ontario, Canada.

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 pandemic, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly-owned subsidiary, Fusion Pharmaceuticals US Inc., and majority-owned subsidiary, Fusion Pharmaceuticals (Ireland) Limited. As a result of consolidating this majority-owned subsidiary, the Company reflected a non-controlling interest on the consolidated balance sheets; however, the Company does not recognize a non-controlling interest in the consolidated statements of operations and comprehensive loss as the majority-owned subsidiary has no operating activities and is an extension of the parent company (see Note 2). All intercompany accounts and transactions have been eliminated in consolidation.

Closing of Class B Preferred Share Financing and Settlement of Class B Preferred Share Tranche Right Liability

On May 15, 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right (see Note 7), which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 36,806,039 Class B preferred shares at a price of $1.5154 per share and 4,437,189 Class B special voting shares at a price of $0.000001 per share and the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share, for aggregate gross proceeds of $62.5 million.

The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Reverse Share Split

On June 19, 2020, the Company effected a one-for-5.339 reverse share split of its issued and outstanding common shares and a proportional adjustment to the existing conversion ratios for each class of the Company’s Preferred Shares (see Note 7) and Preferred Exchangeable Shares (see Note 7). Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse share split and adjustment of the preferred share conversion ratios.

Initial Public Offering

On June 25, 2020, the Company completed an initial public offering (“IPO”) of its common shares and issued and sold 12,500,000 common shares at a public offering price of $17.00 per share, resulting in net proceeds of $193.1 million after deducting underwriting fees, and after deducting offering costs.

Upon closing of the IPO, the Company’s outstanding Preferred Exchangeable Shares automatically converted into convertible preferred shares then the outstanding convertible preferred shares automatically converted into shares of common shares (see Note 7). Upon conversion of the convertible preferred shares, the Company reclassified the carrying value of the convertible preferred shares to common shares and additional paid-in capital. In addition, the warrants to purchase the Company’s Series B convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase the Company’s common shares upon the closing of the IPO. As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) (see Note 3).

In connection with the IPO on June 25, 2020, the Company filed an amended and restated articles of the corporation under laws governed by the Canada Business Corporations Act to authorize unlimited common shares with no par value.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of its convertible preferred shares, including borrowings under a convertible promissory note, which converted into convertible preferred shares, proceeds from sales of its Ireland subsidiary’s preferred exchangeable shares, and most recently with the proceeds from the IPO completed in June 2020. The Company has incurred recurring losses since its inception, including net losses of $10.0 million and $64.9 million for the three and nine months ended September 30, 2020, respectively and net losses of $0.6 million and $8.0 million for the three and nine months ended September 30, 2019, respectively. In addition, as of September 30, 2020, the Company had an accumulated deficit of $99.8 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.

Impact of the COVID-19 Pandemic

The COVID-19 pandemic, which began in December 2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain.

In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to enroll additional patient cohorts on its planned timeline due to disruptions at its clinical trial sites and is unable to predict how the COVID-19 pandemic may affect its ability to successfully progress its clinical programs in the future. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing.

The Company is monitoring the potential impact of the COVID-19 pandemic on its business and condensed consolidated financial statements. To date, the Company has not experienced material business disruptions or incurred impairment losses in the carrying values of its assets as a result of the pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these condensed consolidated financial statements.

2.	Summary of Significant Accounting Policies

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of common shares, stock options, preferred share tranche rights and preferred share warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of September 30, 2020, the condensed consolidated statement of operations and comprehensive loss, and the condensed consolidated statement of non-controlling interest, convertible preferred shares and shareholders’ equity (deficit) for the three and nine months ended September 30, 2020 and 2019, and the condensed consolidated statement of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2020 and the results of its operations for three and nine months ended September 30, 2020 and 2019 and its cash flows for the nine months ended September 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2020 and 2019 are also unaudited. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.

The accompanying balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements for the year ended December 31, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto as of December 31, 2019 and for each of the three years in the period ended December 31, 2019 included in the Company’s Registration Statement on Form S-1, as amended, on file with the SEC.

Foreign Currency and Currency Translation

The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s operating company in Canada, operating company in the U.S. and non-operating company in Ireland is also the U.S. dollar. As a result, the Company records no cumulative translation adjustments related to translation of unrealized foreign exchange gains or losses.

For the remeasurement of local currencies to the U.S. dollar functional currency of the Canadian and Irish entities, assets and liabilities are translated into U.S. dollars at the exchange rate in effect on the balance sheet date, and income items and expenses are translated into U.S. dollars at the average exchange rate in effect during the period. Resulting transaction gains (losses) are included in other income (expense), net in the consolidated statements of operations and comprehensive loss, as incurred.

Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss, as incurred.

During the three and nine months ended September 30, 2020, the Company recorded less than ($0.1) million of foreign currency losses in the consolidated statements of operations and comprehensive loss for both periods. During the three and nine months ended September 30, 2019, the Company recorded less than ($0.1) million and $0.1 million of foreign currency gains (losses) in the consolidated statements of operations and comprehensive loss for both periods.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of standard checking accounts, money market accounts, and all highly liquid investments with an original maturity of three months or less at the date of purchase.

As of September 30, 2020 and December 31, 2019, the Company was required to maintain a separate cash balance of $0.3 million to collateralize corporate credit cards with a bank, which was classified as restricted cash (current) on its condensed consolidated balance sheets.

In connection with the Company’s lease agreement entered into in October 2019 (see Note 12), the Company maintains a letter of credit of $1.5 million for the benefit of the landlord. As of September 30, 2020 and December 31, 2019, the underlying cash balance collateralizing this letter of credit was classified as restricted cash (non-current) on its condensed consolidated balance sheets based on the release date of the restrictions of this cash.

As of September 30, 2020 and 2019, the cash, cash equivalents and restricted cash of $250.5 million and $71.1 million, respectively, presented in the condensed consolidated statements of cash flows included cash and cash equivalents of $248.8 million and $69.3 million, respectively, and restricted cash of $1.7 million and $1.8 million, respectively.

Investments

The Company determines the appropriate classification of its investments in debt securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company classifies its investments as current or non-current based on each instrument’s underlying maturity date. Investments with original maturities of greater than three months and less than twelve months are classified as current and are included in short-term investments in the condensed consolidated balance sheets. Investments with original maturities greater than one year from the balance sheet date are classified as non-current and are included in long-term investments in the condensed consolidated balance sheets. The Company’s investments are classified as available-for-sale, are reported at fair value and consist of U.S. government agency securities, corporate bonds, and commercial paper. Unrealized gains and losses included in other comprehensive income (loss) as a component of shareholders’ equity (deficit) until realized. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains and losses on debt securities are included in other income (expense), net.

If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company’s condensed consolidated statements of operations and comprehensive loss.

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction to the carrying value of the preferred exchangeable shares or convertible preferred shares or in shareholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. The Company did not record any deferred offering costs as of September 30, 2020 or December 31, 2019. Offering costs of $4.6 million incurred during 2020 have been recorded in shareholders’ equity (deficit) as a reduction of the gross proceeds generated from the Company’s initial public offering of common shares.

Business Combinations

In determining whether an acquisition should be accounted for as a business combination or asset acquisition, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is not deemed to be a business, and is instead deemed to be an asset. If this is not the case, the Company then further evaluates whether the single identifiable asset or group of similar identifiable assets and activities includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the single identifiable asset or group of similar identifiable assets and activities is a business.

The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is subject to testing for impairment at least annually. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Transaction costs related to business combinations are expensed as incurred. Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets.

During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.

To date, the Company has not recorded any asset acquisitions as a business combination.

Asset Acquisitions

The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire IPR&D with no alternative future use is charged to expense at the acquisition date.

Contingent consideration in asset acquisitions payable in the form of cash is recognized when payment becomes probable and reasonably estimable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the asset acquisition cost when acquired. Contingent consideration payable in the form of a fixed number of the Company’s own shares is measured at fair value as of the acquisition date and recognized when the issuance of the shares becomes probable. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets, or, if related to IPR&D with no alternative future use, charged to expense.

Fair Value Measurements

Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Prior to the settlement of the Company’s preferred share tranche right liability and prior to the conversion of the Company’s preferred share warrant liability, these instruments were carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (see Note 3). The Company’s cash equivalents and investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s amounts due for refundable investment tax credits and Canadian harmonized sales tax, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.

Preferred Share Tranche Right Liability

The subscription agreements for the Company’s Class B convertible preferred shares (see Note 7) and its Ireland subsidiary’s Class B preferred exchangeable shares (see Note 7) provides investors the right, or obligates investors, to participate in subsequent offerings of Class B convertible preferred shares or Class B preferred exchangeable shares together with Class B special voting shares in the event that specified development or regulatory milestones are achieved (the “Class B preferred share tranche right liability”).

The Company classifies these preferred share tranche rights as a liability on its consolidated balance sheets as each preferred share tranche right is a freestanding financial instrument that may require the Company to transfer assets upon the achievement of specified milestone events. Each preferred share tranche right liability was initially recorded at fair value upon the date of issuance of each preferred share tranche right and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share tranche right liability are recognized as a component of other income (expense) in the consolidated statement of operations and comprehensive loss. Changes in the fair value of the preferred share tranche right liability will continue to be recognized until the respective preferred share tranche right is settled upon achievement of the specified milestones or expires.

The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Preferred Share Warrant Liability

The Company classifies warrants to purchase its convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited as a liability on its consolidated balance sheets as these warrants are freestanding financial instruments that may require the Company to transfer assets upon exercise (see Note 7). The preferred share warrant liability, which consists of warrants to purchase Class B convertible preferred shares of the Company and warrants to purchase Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited, was initially recorded at fair value upon the date of issuance of each warrant and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share warrant liability are recognized as a component of other income (expense) in the consolidated statement of operations and comprehensive loss. Changes in the fair value of the preferred share warrant liability will continue to be recognized until each respective warrant is exercised, expires or qualifies for equity classification.

Upon the closing of the IPO, the warrants to purchase its convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase shares of the Company’s common shares. As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) as the warrants qualify for equity classification.

Research, Development and Manufacturing Contract Costs and Accruals

The Company has entered into various research, development and manufacturing contracts with research institutions and other companies. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.

Net Loss per Share

The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common shareholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

Basic net income (loss) per share attributable to common shareholders is computed by dividing the net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) attributable to common shareholders is computed by adjusting net income (loss) attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common shareholders is computed by dividing the diluted net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, warrants and convertible preferred shares are considered potential dilutive common shares.

The Company’s convertible preferred shares contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common shareholders, such losses are not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common shareholders, diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common shareholders for the three and nine months ended September 30, 2020 and 2019.

Recently Adopted Accounting Pronouncements

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the existing disclosure requirements for fair value measurements in ASC 820. The new disclosure requirements include disclosure related to changes in unrealized gains or losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of each reporting period and the explicit requirement to disclose the range and weighted average of significant unobservable inputs used for Level 3 fair value measurements. The other provisions of ASU 2018-13 include eliminated and modified disclosure requirements. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. For all entities, this guidance is required to be adopted for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020. The adoption of ASU 2018-13 had no impact on the Company’s consolidated financial statements and accompanying notes.

Recently Issued Accounting Pronouncements

The Company qualifies as “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to “opt in” to the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or financing lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing leases. Leases with a term of 12 months or less may be accounted for similar to prior guidance for operating leases today. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented. This guidance is effective for the Company for annual periods beginning after December 15, 2021, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. This guidance is effective for the Company for annual periods beginning after December 15, 2022, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.

3.	Fair Value Measurements

The following tables present information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values (in thousands):

	Fair Value Measurements as of September 30, 2020 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	28,670	$	—	$	—	$	28,670
Commercial paper		—		2,999		—		2,999
Corporate bonds		—		1,862		—		1,862
U.S. Government agencies		—		20,998		—		20,998
Investments:
Commercial paper		—		6,994		—		6,994
Corporate bonds		—		905		—		905
U.S. Government agencies		—		46,362		—		46,362
	$	28,670	$	80,120	$	—	$	108,790

	Fair Value Measurements as of December 31, 2019 Using:
	Level 1		Level 2		Level 3		Total
Liabilities:
Preferred share tranche right liability	$	—	$	—	$	5,741	$	5,741
	$	—	$	—	$	5,741	$	5,741

During the year ended December 31, 2019 and the nine months ended September 30, 2020, there were no transfers between Level 1, Level 2 and Level 3.

Valuation of Preferred Share Tranche Right Liability

The preferred share tranche right liability in the table below is composed of the fair value of rights to purchase Class B convertible preferred shares and Class B preferred exchangeable shares with Class B special voting shares (see Note 7). The fair value of the preferred share tranche right liability was determined based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The fair value of the preferred share tranche right liability was determined using the forward contract pricing model, which considered as inputs the probability and timing of achieving the specified milestones as of each valuation date, the estimated fair value of the preferred shares as of each valuation date, and the risk-free interest rate.

The most significant assumption in the forward contract pricing model impacting the fair value of the preferred share tranche right liability is the fair value of the Company’s Class B convertible preferred shares as of each measurement date. The Company determines the fair value per share of the underlying Class B convertible preferred shares by taking into consideration the most recent sales of its convertible preferred shares, results obtained from third-party valuations and additional factors the Company deems relevant. As of June 2, 2020, the date of final measurement as described below, and December 31, 2019, the fair value of each Class B convertible preferred share was $2.47 per share and $1.45 per share, respectively. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time period of achievement of the specified milestones underlying the preferred share tranche rights.

The preferred share tranche right liability was initially recorded at fair value upon the date of issuance of each preferred share tranche right and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share tranche right liability are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Changes in the fair value of the preferred share tranche right liability will continue to be recognized until the respective preferred share tranche right is settled upon achievement of the specified milestones or expires.

The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Valuation of Preferred Share Warrant Liability

The preferred share warrant liability in the table below is composed of the fair value of warrants to purchase Class B convertible preferred shares of the Company and warrants to purchase Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited that were issued in January 2020 in connection with the Company’s Class B preferred share financing (see Note 7). The fair value of the preferred share warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.

The fair value of the preferred share warrant liability was determined using a hybrid method, which is a probability-weighted expected return method, or PWERM, where the equity value in one or more of the scenarios is calculated using an option-pricing model, or OPM. The PWERM is a scenario-based methodology that estimates the fair value of the Company’s different classes of equity based upon an analysis of future values for the Company, assuming various outcomes. Under both models, assumptions and estimates are used to value the preferred share warrants. The Company assesses these assumptions and estimates on a quarterly basis as additional information impacting the assumptions is obtained. The quantitative elements associated with the Company’s Level 3 inputs impacting the fair value measurement of the preferred share warrant liability include the fair value per share of the underlying Class B convertible preferred shares, the timing, form and overall value of the expected exits for the shareholders, the risk-free interest rate, the expected dividend yield and the expected volatility of the Company’s shares. The most significant assumption impacting the fair value of the preferred share warrant liability is the fair value of the Company’s Class B convertible preferred shares as of each measurement date. The Company determines the fair value per share of the underlying Class B convertible preferred shares by taking into consideration the most recent sales of its preferred shares, results obtained from third-party valuations and additional factors it deems relevant. In January 2020, upon issuance of the preferred share warrants, the fair value of each Class B convertible preferred share was $1.45 per share. As of June 2, 2020, the date of final measurement of the preferred share tranche right liability as described below, the fair value of each Class B convertible preferred share was $2.47 per share. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company estimated a 0% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared cash dividends.

The preferred share warrant liability was initially recorded at fair value upon the date the warrants were issued and exercisable and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share warrant liability are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Changes in the fair value of the preferred share warrant liability will continue to be recognized until each respective warrant is exercised, expires or qualifies for equity classification.

The following table provides a roll-forward of the aggregate fair value of the Company’s preferred share tranche right liability and preferred share warrant liability, for which fair value is determined using Level 3 inputs (in thousands):

	Preferred Share Tranche Right Liability			Preferred Share Warrant Liability
Balance as of December 31, 2019	$	5,741		$	—
Initial fair value of Class B preferred share tranche right liability		1,105			—
Initial fair value of Class B preferred share warrant liability		—			1,382
Change in fair value of Class B preferred share tranche right liability		32,722			—
Change in fair value of Class B preferred share warrant liability		—			6,399
Reclassification of Class B preferred share tranche right liability upon settlement		(39,568	)		—
Conversion of Class B preferred shares warrants into common share warrants		—			(7,781	)
Balance as of September 30, 2020	$	—		$	—

4.	Investments

Investments consisted of the following (in thousands):

	September 30, 2020
	Amortized Cost		Fair Value
Due within one year or less	$	43,160	$	43,159
Due after one year through three years		11,102		11,102
	$	54,262	$	54,261

As of September 30, 2020, the amortized cost and estimated fair value of investments, by contractual maturity, was as follows (in thousands):

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Current		Non-Current
Commercial paper	$	6,994	$	—	$	—		$	6,994	$	6,994	$	—
Corporate bonds		905		—		—			905		905		—
U.S. Government agencies		46,363		1		(2	)		46,362		35,260		11,102
	$	54,262	$	1	$	(2	)	$	54,261	$	43,159	$	11,102

The Company did not hold any investments as of December 31, 2019.

5.	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Prepaid clinical trial expenses	$	—	$	94
Prepaid insurance		3,136		11
Prepaid software subscriptions		173		129
Income tax receivable		109		—
Interest receivable		229		62
Canadian harmonized sales tax receivable		238		252
Refundable investment tax credits		315		176
Other		452		205
	$	4,652	$	929

6.	Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Accrued employee compensation and benefits	$	1,524	$	991
Accrued external research and development expenses		1,715		1,565
Accrued professional and consulting fees		1,048		744
Other		66		26
	$	4,353	$	3,326

Equity

Common Shares

On June 19, 2020, the Company effected a one-for-5.339 reverse share split of its issued and outstanding common shares and a proportional adjustment to the existing conversion ratios for each class of the Company’s Preferred Shares and Preferred Exchangeable Shares. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse share split and adjustment of the preferred share conversion ratios.

On June 30, 2020, the Company closed its IPO of common shares and issued and sold 12,500,000 shares of common shares at a public offering price of $17.00 per share, resulting in net proceeds of approximately $193.1 million after deducting underwriting fees and offering costs.

Upon the closing of the IPO, all outstanding voting and non-voting common shares were converted to a single class of common shares authorized by the Company’s articles of the corporation, as amended and restated.

As of September 30, 2020, the Company’s articles of the corporation, as amended and restated, authorized the Company to issue unlimited common shares, each with no par value per share.

Each common share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders. Common shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through September 30, 2020, no cash dividends had been declared or paid by the Company.

Convertible Preferred Shares

Prior to the IPO, the Company has issued Class A convertible preferred shares (the “Class A preferred shares”) and Class B convertible preferred shares (the “Class B preferred shares” and, together with the Class A preferred shares, the “Preferred Shares”). As of December 31, 2019, the Company’s articles of the corporation, as amended and restated, authorized the Company to issue an aggregate of 132,207,290 Preferred Shares, respectively, each with no par value per share.

In March 2019, the Company completed its first closing of its Class B preferred shares and issued and sold 30,207,129 Class B preferred shares at a price of $1.5154 per share for gross proceeds of $45.8 million (the “2019 Preferred Share Financing”).

In January 2020, the Company executed the First Amendment to the Class B Subscription Agreement (“Amended Class B Subscription Agreement”) whereby the Canada Pension Plan Investment Board (“CPP”) agreed to purchase an aggregate of $20.0 million of Class B preferred shares, at a price of $1.5154 per share, in two tranches. In January 2020, the Company issued and sold to CPP 6,598,917 Class B preferred shares, resulting in gross proceeds of $10.0 million (the “Additional Class B Closing”). The Company incurred issuance costs of $0.1 million in connection with this transaction.

The rights and preferences of the Class B preferred shares sold under the Additional Class B Closing are the same as the rights and preferences of the Class B preferred shares issued and sold by the Company in March 2019. Accordingly, under the terms of the Amended Class B Subscription Agreement, upon the earlier occurrence of a specified development or specified regulatory milestone, CPP was obligated to purchase an additional 6,598,917 Class B preferred shares at a price of $1.5154 per share. The Company concluded that these rights or obligations of CPP to participate in the Milestone Financing of Class B preferred shares met the definition of a freestanding financial instrument that was required to be recorded as a liability at fair value as (i) the instruments are legally detachable and separately exercisable from the Class B preferred shares and (ii) the rights will require the Company to transfer assets upon future closings of the Class B preferred shares.

Upon the Additional Class B Closing in January 2020, the Company recorded an additional liability for the preferred share tranche right of $1.1 million and a corresponding reduction to the carrying value of the Class B preferred shares.

In May 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right, which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 36,806,039 Class B preferred shares at a price of $1.5154 per share for aggregate proceeds of $55.8 million.

The Class B preferred share tranche right liability was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Upon the closing of the IPO, the Company converted the then outstanding Class A and Class B preferred shares into common shares at a conversion ratio of 5.339 Preferred Share to one common share.

Preferred Exchangeable Shares and Special Voting Shares

In connection with each issuance and sale of its Class A preferred shares and Class B preferred shares, the Company’s Ireland subsidiary, Fusion Pharmaceuticals (Ireland) Limited, issued and sold Class A and Class B preferred exchangeable shares (together, the “Preferred Exchangeable Shares”) to investors. Simultaneously with the issuance and sale of the Preferred Exchangeable Shares, the Company issued and sold its Class A and Class B special voting shares (together, the “Special Voting Shares”) to the same investors. Prior to the IPO, the Company’s Ireland subsidiary’s amended constitution authorized it to issue an aggregate of 28,874,378 Preferred Exchangeable Shares and 29,747,987 Preferred Exchangeable Shares, respectively, with a par value of $0.001 per share. Prior to the IPO, the Company’s articles of the corporation, as amended and restated, authorized the Company to issue an aggregate of 28,874,378 Special Voting Shares and 29,747,987 Special Voting Shares, respectively, with a cash redemption value of $0.000001 per share.

In March 2019, in connection with the first closing of Class B preferred shares, as described above, the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share and the Company issued and sold 4,437,189 Class B special voting shares at a price of $0.000001 per share for aggregate gross proceeds of $6.7 million (the “2019 Preferred Exchangeable Share Financing”).

In May 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right, which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 4,437,189 Class B special voting shares at a price of $0.000001 per share and the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share, for aggregate gross proceeds of $6.7 million.

Upon the closing of the IPO, the Company converted all of the outstanding Class A and Class B preferred exchangeable shares and Special Voting Shares into Class A and Class B preferred shares on a one-for-one basis then converted the Class A and Class B preferred shares into common shares at a conversion ratio of 5.339 Preferred Share to one common share.

Warrants

In January 2020, in conjunction with the Company’s execution of the Amended Class B Subscription Agreement, the Company issued to the existing holders of Class B convertible preferred shares (excluding the investor in the Additional Class B Closing in January 2020) warrants to purchase 3,126,391 Class B convertible preferred shares, at an exercise price of $1.5154 per share, and Fusion Pharmaceuticals (Ireland) Limited issued to the existing holders of Class B preferred exchangeable shares warrants to purchase 873,609 Class B preferred exchangeable shares, at an exercise price of $1.5154 per share (collectively the “Preferred Share Warrants”). If the warrants to purchase Class B preferred exchangeable shares are exercised, at that same time, the shareholder is obligated to purchase from the Company an equal number of Class B special voting shares at a price of $0.000001 per share. The Preferred Share Warrants were issued for no consideration, and the specified exercise prices of each warrant are subject to adjustment for share dividends, share splits, combination or other similar recapitalization transactions as provided under the terms of the warrants.

The Preferred Share Warrants were immediately exercisable and expire two years from the date of issuance or upon the earlier occurrence of specified qualifying events, which include the consummation of a Deemed Liquidation Event and the closing of a qualifying share sale (as defined in the articles of the corporation, as amended and restated). Upon the closing of a qualified public offering, on specified terms, all outstanding warrants to purchase Class B convertible preferred shares of the Company and warrants to purchase Class B preferred exchangeable shares of Fusion Pharmaceutics (Ireland) Limited will become warrants to purchase common shares of the Company.

Upon issuance of the Preferred Share Warrants in January 2020, the Company recorded on its consolidated balance sheet a preferred share warrant liability of $1.4 million, equal to the issuance-date fair value of the Preferred Share Warrants, as well as a corresponding decrease of $1.3 million to additional paid-in capital, reducing that to zero, and an increase of $0.1 million to accumulated deficit for the remainder.

The issuance of the Preferred Share Warrants was treated as a deemed dividend to existing preferred shareholders for purposes of the Company’s calculation of net loss per share attributable to common shareholders, and, as such, the aggregate value of the dividend to existing preferred shareholders was deducted from the Company’s net loss when computing net loss per share attributable to common shareholders (see Note 11). The Company remeasures the fair value of the liability associated with the Preferred Share Warrants at each reporting date (see Note 3) and records any adjustments as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Upon the closing of the IPO, the warrants to purchase 3,126,391 of its convertible preferred shares and warrants to purchase 873,609 preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase 749,197 shares of the Company’s common shares at an exercise price of $8.10 per share. As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) as the warrants qualify for equity classification (see Note 3). For the nine months ended September 30, 2020, the Company recognized a loss of $6.4 million as a component of other income (expense) in the condensed consolidated statement of operations and comprehensive loss to reflect an increase in fair value of the Preferred Share Warrant.

On August 17, 2020, a holder of common share warrants exercised 97,381 common share warrants through a cashless exercise and the Company issued 38,340 common shares with the remaining 59,041 warrants being cancelled to settle the exercise price. As of September 30, 2020, 651,816 common share warrants remained outstanding.

8.	Share-based Compensation

2020 Stock Option and Incentive Plan

On June 18, 2020, the Company’s board of directors adopted the 2020 Stock Option and Incentive Plan (the “2020 Plan”), which became effective on June 24, 2020. The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, non-employee directors and consultants. The number of shares initially reserved for issuance under the 2020 Plan was 4,273,350, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 4% of the number of the Company’s common shares outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s compensation committee of the board of directors. The common shares underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of shares, expire or are otherwise terminated (other than by exercise) under the 2020 Plan and the 2017 Plan will be added back to the common shares available for issuance under the 2020 Plan.

The total number of common shares reserved for issuance under the 2020 Plan was 4,273,350 shares as of September 30, 2020.

As of September 30, 2020, 2,933,366 shares, remained available for future grant under the 2020 Plan. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2020 Plan.

2017 Equity Incentive Plan

The Company’s 2017 Equity Incentive Plan (the “2017 Plan”) provides for the Company to grant incentive stock options or nonqualified stock options, restricted share awards and restricted share units to employees, officers, directors and non-employee consultants of the Company.

The total number of common shares reserved for issuance under the 2017 Plan was 0 and 4,700,393 shares as of September 30, 2020 and December 31, 2019, respectively.

As of September 30, 2020 and December 31, 2019, 0 shares and 1,598,512 shares, respectively, remained available for future grant under the 2017 Plan. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2020 Plan.

2020 Employee Share Purchase Plan

On June 18, 2020, the Company’s board of directors adopted the 2020 Employee Share Purchase Plan (the “ESPP”), which became effective on June 24, 2020. A total of 450,169 common shares were reserved for issuance under this plan. In addition, the number of common shares that may be issued under the ESPP will automatically increase on January 1, 2021 and each January 1 thereafter by the lesser of (i) 900,338 common shares, (ii) 1% of the number of the Company’s common shares outstanding on the immediately preceding December 31 and (iii) such lesser number of shares as determined by the Company’s compensation committee of the board of directors.

As of September 30, 2020, no shares were issued under the ESPP.

Stock Option Valuation

The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected share volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Risk-free interest rate		0.33	%		1.58	%		0.70	%		1.58	%
Expected term (in years)		6.0			5.9			6.0			5.9
Expected volatility		67.0	%		64.5	%		65.5	%		64.5	%
Expected dividend yield		0	%		0	%		0	%		0	%

Stock Options

The following table summarizes the Company’s stock option activity since December 31, 2019:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding as of December 31, 2019		3,045,301		$	1.66		8.4	$	2,112
Granted		2,346,645			11.50
Forfeited/cancelled		(125,480	)		5.63
Outstanding as of September 30, 2020		5,266,466		$	5.95		8.4	$	37,696
Vested and expected to vest as of September 30, 2020		5,266,466		$	5.95		8.4	$	37,696
Options exercisable as of September 30, 2020		1,810,276		$	1.51		7.0	$	18,699

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common shares for those options that had exercise prices lower than the fair value of the Company’s common shares. There were no stock options exercised during the nine months ended September 30, 2020 and 2019. The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2020 and 2019 was $11.54 and $2.33 per share, respectively.

Share-based Compensation

Share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	288	$	37	$	506	$	110
General and administrative expenses		953		101		1,519		218
	$	1,241	$	138	$	2,025	$	328

As of September 30, 2020, total unrecognized share-based compensation expense related to unvested share-based awards was $15.8 million, which is expected to be recognized over a weighted-average period of 3.0 years.

9.	License Agreements and Asset Acquisitions

License Agreement with the Centre for Probe Development and Commercialization Inc.

In November 2015, the Company entered into a license agreement with the Centre for Probe Development and Commercialization Inc. (“CPDC”), a related party (see Note 13) (the “CPDC Agreement”). Under the agreement, the Company was granted an exclusive, sublicensable, nontransferable, worldwide license under CPDC’s patent rights related to CPDC’s radiopharmaceutical linker technology to develop, market, make, use and sell certain products for all disease indications and uses in humans, whether diagnostic or therapeutic. The Company has the right to grant sublicenses of its rights. The CPDC Agreement was amended in 2017; however, there were no material changes to the terms of the CPDC Agreement. Also in 2017, the Company entered into a second license agreement with CPDC, under which the Company was granted an exclusive, sublicensable, worldwide license under CPDC’s patent rights related to certain CPDC radiopharmaceutical linker technology to develop, market, make, use and sell certain products for all disease indications and uses in humans. The Company has the right to grant sublicenses of its rights.

Under all agreements with CPDC, the Company has no obligations to make any milestone payments or to pay any royalties or annual maintenance fees to CPDC.

During the three and nine months ended September 30, 2020 and 2019, the Company did not make any payments to CPDC or recognize any research and development expenses under the license agreements with CPDC.

License Agreement with ImmunoGen, Inc.

In December 2016, the Company entered into a license agreement with ImmunoGen, Inc. (“ImmunoGen”) (the “ImmunoGen Agreement”). Under the agreement, the Company was granted an exclusive, sublicensable, worldwide license under ImmunoGen’s patent rights to use, develop, manufacture and commercialize any radiopharmaceutical conjugate that includes a certain compound and any resulting commercialized products. The Company has the right to grant sublicenses of its rights.

Under the ImmunoGen Agreement, the Company paid an upfront fee of $0.2 million to ImmunoGen. In addition, the Company is obligated to make aggregate milestone payments to ImmunoGen of up to $15.0 million upon the achievement of specified development and regulatory milestones and of up to $35.0 million upon the achievement of specified sales milestones. The Company is also obligated to pay tiered royalties of a low to mid single-digit percentage based on annual net sales by the Company and any of its affiliates and sublicensees. Royalties will be paid by the Company on a country-by-country basis beginning upon the first commercial sale in such country until ten years following the date of the first commercial sale in the United States and five years following the date of the first commercial sale in all non-U.S. countries. In addition, the Company is responsible for all costs and expenses incurred related to the development, manufacture, regulatory approval and commercialization of all licensed products.

Prior to regulatory approval of a licensed product in any country, the Company has the right to terminate the agreement upon 90 days’ prior written notice to ImmunoGen. Upon receipt of its first regulatory approval of a licensed product in any country, the Company has the right to terminate the agreement upon 180 days’ prior written notice to ImmunoGen. If the Company or ImmunoGen fails to comply with any of its obligations or otherwise breaches the agreement, the other party may terminate the agreement. The ImmunoGen Agreement expires upon the expiration date of the last-to-expire royalty term.

During the nine months ended September 30, 2019, the Company made a payment to ImmunoGen of $0.5 million upon the achievement of a specified development milestone and recognized this amount as research and development expense in its consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2020 and the three months ended September 30, 2019, the Company did not make any payments to ImmunoGen or recognize any research and development expenses under the ImmunoGen Agreement.

License Agreements with Janssen Biotech, Inc.

First Janssen Agreement

In February 2017, the Company entered into a license agreement with Janssen Biotech, Inc. (“Janssen”) (the “Janssen Agreement”). Under the agreement (the “First Janssen Agreement”), the Company was granted an exclusive, sublicensable, worldwide license under Janssen’s patent rights to research, develop and commercialize licensed products containing the specified compound for certain alpha-emitting therapeutic and nuclear imaging uses in humans and animals. The Company was also granted non-exclusive, worldwide licenses under specified other patent rights for specified uses.

The Company had the right to terminate the First Janssen Agreement upon written notice to Janssen. In March 2019, the Company terminated the First Janssen Agreement upon written notice to Janssen.

During the three and nine months ended September 30, 2019, the Company did not make any payments to Janssen or recognize any research and development expenses under the First Janssen Agreement.

Second Janssen Agreement

Simultaneously with entering into the First Janssen Agreement, in February 2017, the Company entered into a second agreement with Janssen (the “Second Janssen Agreement”). Under the agreement, the Company was granted an exclusive, sublicensable, worldwide license under Janssen’s patent rights to research, develop and commercialize licensed products containing the specified compound for certain alpha-emitting therapeutic and nuclear imaging uses in humans and animals. The Company was also granted non-exclusive, worldwide licenses under specified other patent rights for specified uses.

The Company had the right to terminate the Second Janssen Agreement upon written notice to Janssen. In January 2020, the Company terminated the Second Janssen Agreement upon written notice to Janssen.

During the three and nine months ended September 30, 2020 and 2019, the Company did not make any payments to Janssen or recognize any research and development expenses under the Second Janssen Agreement.

Research and License Agreement with Isogenica Ltd.

In April 2018, the Company entered into a research and license agreement with Isogenica Ltd. (“Isogenica”) (the “Isogenica Agreement”). Under the agreement, the Company was granted a non-exclusive, sublicensable, worldwide license under Isogenica’s intellectual property and other technology to develop and commercialize a specified compound of antibody-like molecules that bind to targets with high affinity for all therapeutic uses or a product containing such compound. At the same time, the Company granted Isogenica a non-exclusive, non-sublicensable license to certain of Fusion’s intellectual property for research purposes. The initial term of the license was one year, and the Company had the option to extend the term of the Isogenica Agreement beyond the one-year period, which was exercised in April 2019.

The Company was not entitled to any payments from Isogenica for use of the license of its intellectual property granted to Isogenica.

The Company had the right to terminate the Isogenica Agreement upon written notice to Isogenica. In January 2020, the Company terminated the Isogenica Agreement upon written notice.

During the nine months ended September 30, 2019, the Company made payments of £0.6 million (equivalent to $0.7 million at the time of payment) to Isogenica. During the three and nine months ended September 30, 2020 and the three months ended September 30, 2019, the Company did not make any payments to Isogenica. During the three months ended September 30, 2019 the company recognized £0.1 million (equivalent to $0.1 million) related to amortization of the annual license fee. During the nine months ended September 30, 2019, the Company exercised its option to extend the term of the agreement and recognized £0.4 million (equivalent to $0.6 million at the time of the payments) as research and development expense in the consolidated statements of operations and comprehensive loss, primarily related to the option exercise fee and amortization of the annual license fee. The Company did not recognize any research and development expenses during the three and nine months ended September 30, 2020.

Asset Acquisition from and License Agreement with MediaPharma S.r.l.

In May 2019, the Company and MediaPharma S.r.l. (“MediaPharma”) entered into an asset acquisition and license agreement. Under the agreement, the Company purchased all right, title and interest to MediaPharma’s, and any of its affiliates’ and sublicensees’, patents to perform research and to develop, manufacture and commercialize a specified antibody that binds to targets for the prevention, treatment and diagnosis of all diseases and conditions. The Company accounted for this purchase as an asset acquisition. At the same time, the Company granted MediaPharma an exclusive, fully paid, worldwide, sublicensable license to use the specified compound for research, development, manufacturing and commercialization of a bispecific antibody drug conjugate, but not for use as a radiopharmaceutical.

In connection with the asset acquisition, the Company paid an upfront fee of $0.2 million to MediaPharma. In addition, the Company is obligated to make aggregate milestone payments to MediaPharma of up to $1.5 million upon the achievement of specified development milestones and of up to $23.0 million upon the achievement of specified sales milestones. The Company is also obligated to pay royalties of a low single-digit percentage based on annual net sales by the Company. Royalties will be paid by the Company on a country-by-country basis beginning upon the first commercial sale in such country and will expire, on a country-by-country basis, upon the earlier of (i) eight years from the first commercial sale of a licensed product in such country, (ii) the date upon which all issued patents under the agreement have expired or (iii) the date upon which a product highly similar in composition to the licensed product and having no clinically meaningful differences is sold or marketed for sale in such country by a third party.

The Company is not entitled to any payments from MediaPharma for use of the license to the specified compound granted to MediaPharma.

During the nine months ended September 30, 2019, the Company incurred the upfront fee due in connection with the asset agreement and subsequently made payment of and recognized $0.2 million as research and development expense in the consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2020 and the three months ended September 30, 2019, the Company did not make any payments to MediaPharma or recognize any research and development expenses under the MediaPharma Agreement.

Asset Acquisition from Rainier Therapeutics, Inc. and License Agreement with Genentech, Inc.

In March 2020 (the “Closing”), the Company and Rainier Therapeutics, Inc. (“Rainier”) entered into an asset acquisition agreement (the “Rainier Agreement”). Under the agreement, the Company purchased all right, title and interest to Rainier’s, and any of its affiliates’ and sublicensees’, patents and other tangible and intangible assets to perform research and to develop, manufacture and commercialize a specified compound of antibody molecules that bind to targets for the prevention, treatment and diagnosis of all diseases and conditions only using such compound as an antibody drug conjugate. The Company concluded to account for this purchase as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the license rights.

In connection with the asset acquisition, the Company paid an upfront fee of $1.0 million to Rainier and recognized this amount as research and development expense in the consolidated statement of operations and comprehensive loss during the three months ended March 31, 2020, as the IPR&D acquired had no alternative future use as of the acquisition date.

Unless the Rainier Agreement is terminated pursuant to its terms, which termination may not occur later than eight months following the Closing (the “Outside Date”), the Company is obligated to pay Rainier an additional amount of $3.5 million and to issue 313,359 of the Company’s non-voting common shares on the Outside Date. If the Rainier Agreement is not terminated by the Outside Date, the Company is also obligated to make aggregate milestone payments to Rainier of up to $22.5 million and to issue up to 156,679 of the Company’s non-voting common shares upon the achievement of specified development and regulatory milestones and of up to $42.0 million upon the achievement of specified sales milestones.

In the event the Company enters into a transaction with a non-affiliated party relating to the license or sale of substantially all the Company’s rights to develop the specified compound of antibody molecules, the Company will be obligated to pay Rainier a specified percentage of the revenue from such transaction, in an amount ranging from 10% to 30%, based on how long after the Closing the transaction takes place.

The Rainier Agreement may be terminated at any time prior to the Outside Date upon 30 days’ notice by the Company to Rainier or upon the mutual written consent of both parties. If the agreement is terminated prior to the Outside Date, the Company’s payment obligations, except for the non-refundable upfront fee of $1.0 million, become void and the Company will cease to have any rights to the antibody or the Genentech License Agreement (as defined below). On October 8, 2020, the Company and Rainier entered into a first amendment to the Rainier Agreement (the “Amended Rainier Agreement”) to extend certain terms of the Rainier Agreement. Specifically, the Outside Date, was amended such that termination may not occur later than eleven months following the Closing, or February 10, 2021 (the “Revised Outside Date”) (see Note 15).

During the three months ended September 30, 2020, the Company did not make any payments to Rainier or recognize any research and development expenses under the Rainier License Agreement. During the nine months ended September 30, 2020, the Company paid an upfront fee of $1.0 million to Rainier and recognized this as an expense as noted above.

In connection with the Rainier Agreement, in March 2020, the Company was assigned all of Rainier’s rights and obligations under an exclusive license agreement between BioClin Therapeutics, Inc. and Genentech, Inc. (“Genentech”) (the “Genentech License Agreement”). Pursuant to the Genentech License Agreement, the Company has an exclusive, worldwide, sublicensable license to make, use, research, develop, sell and import certain intellectual property and technology of Genentech relating to the a specified antibody and any mutant antibody thereof (the “Licensed Antibodies”), including any products that contain a Licensed Antibody as an active ingredient (the “Products”), for all human uses.

Pursuant to the Genentech License Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least one Product and the Company is solely responsible for the costs associated with the development, manufacturing, regulatory approval and commercialization of any Products. The manufacture of the antibody by any third-party contract manufacturing organization must be approved in advance by Genentech. Additionally, Genentech retains the right to use the Licensed Antibodies solely to research and develop molecules other than the Licensed Antibodies.

Under Genentech License Agreement, the Company is obligated to make aggregate milestone payments to Genentech of up to $44.0 million upon the achievement of specified sales milestones. The Company is also obligated to pay to Genentech tiered royalties of a mid to high single-digit percentage based on annual net sales by the Company, and any of its affiliates and sublicensees, for the specified compound of antibody molecules and of a mid to high single-digit percentage based on annual net sales by the Company, and any of its affiliates and sublicensees, for any other compound containing mutant antibody molecules of the specified compound. In addition, the Company is obligated to pay to Genentech royalties of a low single-digit percentage based on quarterly net sales in any country in which the specified compound is not covered by a valid patent claim, and those sales will not be subject to the tiered royalties described above. All royalties may be reduced if the Company obtains a license under a third-party patent that includes the specified compound. Royalties will be paid by the Company on a country-by-country basis beginning upon the first commercial sale in such country until the later of (i) ten years following the date of the first commercial sale of a Product or (ii) the date the specified compound is no longer covered by an enforceable patent. Upon the expiration of the royalty term, the Company will have a fully paid-up license.

The Company has the right to terminate the Genentech License Agreement upon written notice to Genentech if the Company determines in its sole discretion that development or commercialization of Products is not economically or scientifically feasible or appropriate. In addition, if the Company or Genentech fails to comply with any of its obligations or otherwise breaches the agreement, the other party may terminate the agreement. The Genentech License Agreement expires on the date on which all obligations under the agreement related to milestone payments or royalties have passed or expired.

During the three and nine months ended September 30, 2020, the Company did not make any payments to Genentech or recognize any research and development expenses under the Genentech License Agreement.

Master Services and License Agreement with Yumab GmbH

On May 15, 2020, the Company entered into a master services and license agreement with Yumab GmbH (“Yumab”) (the “Yumab Agreement”). Under the agreement, Yumab will assist the Company in discovering and developing certain antibodies from certain cell lines owned by Yumab. The Company plans to use the discovered antibodies in preclinical and clinical development. Under the Yumab Agreement, the Company is obligated to pay for services performed as defined in work orders under the agreement. In addition, the Company is obligated to make aggregate milestone payments to Yumab of up to $3.9 million upon the achievement of specified development and regulatory milestones.

During the three and nine months ended September 30, 2020, the Company recognized $0.2 million as research and development expense in the consolidated statements of operations and comprehensive loss under the Yumab Agreement.

10.	Income Taxes

The Company is domiciled in Canada and is primarily subject to taxation in that country. During the three and nine months ended September 30, 2020, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in Canada and Ireland in each period due to its uncertainty of realizing a benefit from those items. During the three months ended September 30, 2020, the Company recorded a tax benefit of $0.2 million as a result of the Company claiming a U.S. research and development tax credit to partially offset the current U.S. tax liability. During the three months ended September 30, 2019, the Company recorded a tax provision of $0.2 million primarily related to income tax obligations of its operating company in the U.S., which generates a profit for tax purposes. During the nine months ended September 30, 2020 and 2019, the Company recorded a tax provision of less than $0.1 million and $0.2 million, respectively, primarily related to income tax obligations of its operating company in the U.S., which generates a profit for tax purposes.

The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate (“AETR”), adjusted for the effect of discrete items arising in that quarter. The impact of such inclusions could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter. For the three and nine months ended September 30, 2020 and 2019, the Company excluded Canada and Ireland from the calculation of the AETR as the Company anticipates an ordinary loss in these jurisdictions for which no tax benefit can be recognized.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses in Canada and Ireland, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its Canadian and Irish deferred tax assets. As a result, as of September 30, 2020 and December 31, 2019, the Company has recorded a full valuation allowance against its net deferred tax assets in Canada and Ireland.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was passed by the U.S. Congress and signed into law by the President of the U.S. The CARES Act, among other things, includes certain provisions for individuals and corporations; however, these benefits do not impact the Company’s income tax provision.

11.	Net Loss per Share

Net Loss per Share Attributable to Common Shareholders

Basic and diluted net loss per share attributable to common shareholders was calculated as follows (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Numerator:
Net loss	$	(9,993	)	$	(594	)	$	(64,948	)	$	(7,983	)
Dividends paid to preferred shareholders in the form of warrants issued		—			—			(1,382	)		—
Net loss attributable to common shareholders	$	(9,993	)	$	(594	)	$	(66,330	)	$	(7,983	)
Denominator:
Weighted-average common shares outstanding—basic and diluted		41,682,797			1,929,555			15,422,375			1,910,695
Net loss per share attributable to common shareholders —basic and diluted	$	(0.24	)	$	(0.31	)	$	(4.30	)	$	(4.18	)

The Company’s potentially dilutive securities, which include stock options, convertible preferred shares, preferred exchangeable shares and common share warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:

	Nine Months Ended September 30,
	2020		2019
Options to purchase common shares		5,266,466		2,687,413
Convertible preferred shares (as converted to common shares)		—		13,696,513
Preferred exchangeable shares (as converted to convertible preferred shares and then to common shares)		—		4,577,106
Warrants to purchase common shares		651,816		—
		5,918,282		20,961,032

12.	Commitments and Contingencies

Operating Leases

In January 2018, the Company entered into an operating lease for office space in Boston, Massachusetts, which was to expire in July 2023 with no renewal options. In July 2020, the Company paid $0.1 million to terminate this lease, effective immediately.

In October 2019, the Company entered into an operating lease for office space in Boston, Massachusetts, which expires September 2025 and has no renewal options. In connection with entering into this lease agreement, the Company issued a letter of credit of $1.5 million, which is classified as restricted cash (non-current) on the consolidated balance sheets as of September 30, 2020 and December 31, 2019.

The lease agreements include payment escalations, rent holidays and other lease incentives, which are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term, recording deferred rent for rent expense incurred but not yet paid.

Rent expense was $0.3 million and $0.8 million for the three and nine months ended September 30, 2020, respectively. Rent expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2019, respectively.

Future minimum lease payments due under operating leases as of September 30, 2020 are as follows (in thousands):

Year Ending December 31,
2020 (three months)	$	274
2021		1,117
2022		1,147
2023		1,177
2024		1,208
Thereafter		1,592
	$	6,515

Manufacturing Commitments

In January 2019, and as amended in September 2020, the Company entered into an agreement with CPDC, a related party (see Note 13), to manufacture clinical trial materials. As of September 30, 2020, the Company had non-cancelable minimum purchase commitments under the agreement totaling $0.8 million over the following twelve months.

In February 2019, the Company entered into an agreement with a third-party contract manufacturing organization to manufacture clinical trial materials. As of September 30, 2020, the Company had non-cancelable minimum purchase commitments under the agreement totaling $0.8 million over the following twelve months.

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September 30, 2020 or December 31, 2019.

Legal Proceedings

The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

13.	Related Party Transactions

The Company has entered into license agreements with CPDC, a principal shareholder of the Company (see Note 9).

In addition, the Company has entered into a Master Services Agreement and a Supply Agreement with CPDC, under which CPDC provides services to the Company related to preclinical and manufacturing services, administrative support services and access to laboratory facilities. In connection with the Supply Agreement, the Company is obligated to pay CPDC an amount of $0.2 million per quarter, or $0.8 million in the aggregate per year, plus fees for materials, packaging and distribution of products supplied to the Company, unless the agreement is terminated by the Company. The Company recognized expenses in connection with the services performed under the Master Services Agreement and the Supply Agreement in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	141	$	326	$	780	$	785
General and administrative expenses		23		16		50		59
	$	164	$	342	$	830	$	844

During the three and nine months ended September 30, 2020, the Company made payments to CPDC in connection with the services described above of $0.2 million and $1.0 million, respectively. During the three and nine months ended September 30, 2019, the Company made payments to CPDC in connection with the services described above of $0.5 million and $0.8 million, respectively. Amounts due to CPDC by the Company in connection with the services described above totaled $0.1 million and $0.2 million as of September 30, 2020 and December 31, 2019, respectively, which amounts were included in accounts payable and accrued expenses on the consolidated balance sheets.

In addition to costs incurred in connection with the services described above, the Company also reimbursed CPDC for purchases on the Company’s behalf from parties with which the Company did not have an account. During the three and nine months ended September 30, 2020, the Company made payments to CPDC of less than $0.1 million and $0.1 million, respectively, for reimbursement of these pass-through costs. During the three and nine months ended September 30, 2019, the Company made payments to CPDC of less than $0.1 million and $0.1 million, respectively, for reimbursement of these pass-through costs.

14.	Geographical Information

The Company has operating companies in the United States and Canada and a non-operating company in Ireland. Information about the Company’s long-lived assets, consisting solely of property and equipment, net, by geographic region was as follows (in thousands):

	September 30, 2020		December 31, 2019
United States	$	115	$	127
Canada		1,866		1,145
	$	1,981	$	1,272

15.	Subsequent Events

Amendment to Asset Acquisition Agreement with Rainier Therapeutics, Inc.

On October 8, 2020, the Company and Rainier entered into the Amended Rainier Agreement (see Note 9). Pursuant to the Amended Rainier Agreement, the termination provisions of the Rainier Agreement were modified. Specifically, the Outside Date was amended such that termination may not occur later than eleven months following the Closing, or February 10, 2021. Aside from modifying the termination provisions to incorporate the Revised Outside Date, no other material terms were amended as part of the Amended Rainier Agreement.

Strategic Collaboration Agreement with AstraZeneca UK Limited

On October 30, 2020, the Company and AstraZeneca UK Limited (“AstraZeneca”) entered into a strategic collaboration agreement (the “AstraZeneca Agreement”) pursuant to which the Company and AstraZeneca will jointly discover, develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer globally by leveraging the Company’s Targeted Alpha Therapies, or TATs, platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DNA Damage Response Inhibitors, or DDRis. Each party retains full ownership over its existing assets.

For the novel TATs, the parties will utilize the Company’s Fast-Clear® linker technology to bind the alpha-emitting isotope Actinium-225 to certain antibodies in AstraZeneca’s oncology portfolio. Under the AstraZeneca Agreement, the parties may develop up to three (3) novel TATs. The Company will take the operational lead on preclinical development and clinical studies aimed at establishing safety for the novel TATs, referred to as the Stage 1 Development, while AstraZeneca will be responsible for subsequent clinical development, referred to as the Stage 2 Development. The Company and AstraZeneca will share development costs equally (with each party responsible for the cost of its own supply in connection with such development). Either party has the right to opt out of the co-development and co-commercialization arrangement at pre-determined timepoints and obtain exclusive rights to a novel TAT in exchange for milestone payments to the other party of up to $145.0 million per novel TAT and a low or high single-digit royalties on future sales (depending on the opt out time point). If neither party opts out, and unless otherwise agreed by the parties, AstraZeneca will lead worldwide commercialization activities for the novel TATs, subject to the Company’s option to co-promote the TATs in the U.S. as further described in the AstraZeneca Agreement. All profits and losses resulting from such commercialization activities will be shared equally.

For the combination therapies, the parties will evaluate up to five (5) potential combination strategies involving the Company’s existing assets, including the Company’s lead candidate FPI-1434, in combination with certain of AstraZeneca’s existing therapeutics for the treatment of various cancers. AstraZeneca will fully fund all research and development activities for the combination strategies, until such point as the Company may opt-in to the clinical development activities. The Company has the right to opt-out of clinical development activities relating to these combination therapies. In such instance, the Company will be responsible for repaying its share of the development costs via a royalty on the additional combination sales only if its drug is approved on the basis of clinical development solely conducted by AstraZeneca, in which case the royalty payments shall also include a variable risk premium based on the number of the Company’s product candidates to have received regulatory approval at that time. Each party will have the sole right, on a country-by-country basis, to commercialize its respective contributed compound as a component of any combination therapy for which such party’s contributed compound may be commercialized under a separate marketing authorization from the other party’s contributed compound to such combination therapy. The parties will negotiate in good faith on a combination therapy-by-combination therapy basis the terms and conditions to co-commercialize any combination therapy that is to be commercialized under a single marketing authorization. During the period of time commencing with the inclusion of an available molecular target in the selection pool for development as a combination therapy and ending upon the end of the nomination period (as more fully described in the AstraZeneca Agreement) or earlier removal of such combination target from such pool, the Company will not undertake any preclinical or clinical studies combining the Company’s TAT Platform with any compound modulating the activity of such combination target. Following selection of a target under the AstraZeneca Agreement and payment of an exclusivity fee by AstraZeneca, and provided that AstraZeneca enrolls its first patient in a clinical trial as further defined in the AstraZeneca Agreement within a pre-defined period of time of such selection, the Company will not undertake any preclinical or clinical studies combining the Company’s TAT Platform with compounds modulating the same combination target for the duration of the evaluation period for such combination target, as further defined in the AstraZeneca Agreement. Within a certain time period following initiation of the evaluation period with respect to a combination target, AstraZeneca has the exclusive right to undertake, alone or in collaboration with the Company, all further clinical or preclinical combination studies with respect to a combination target by paying certain exclusivity fees.

The Company received an upfront payment of $5.0 million from AstraZeneca. In addition, the Company is eligible to receive future payments of up to $40.0 million, including clinical milestones.

The AstraZeneca Agreement expires on a TAT-by-TAT and combination-by-combination basis upon the later of the expiration of development and exclusivity obligations relating to such TAT or combination or, if such TAT or combination is commercialized as a product under the AstraZeneca Agreement, the expiration of the commercial life of such product. The Company and AstraZeneca can each terminate the AstraZeneca Agreement for the other party’s uncured material breach following the applicable notice period. Each of the Company and AstraZeneca may also terminate the AstraZeneca Agreement with respect to any TAT or combination product if such party determines that the continued development of such TAT or combination product is not commercially viable, or for a material safety issue with respect to such TAT or combination product.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes appearing in Part I, Item I of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2019, included in our prospectus dated June 25, 2020 and filed on June 26, 2020 with the U.S. Securities and Exchange Commission, or the SEC, pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, which we prefer to as our Prospectus.

Some of the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, particularly including those risks identified in Part II-Item 1A “Risk Factors” and our other filings with the SEC.

Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Statements made herein are as of the date of the filing of this Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

We are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear® linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Our TAT platform is underpinned by our research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as our differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. We believe that our TATs have the potential to build on the successes of currently available radiopharmaceuticals and be broadly applicable across multiple targets and tumor types.

Our lead product candidate, FPI-1434, utilizes our Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor, or IGF-1R, with the alpha emitting isotope actinium-225, or 225Ac. IGF-1R is a well-established tumor target that is found on numerous types of cancer cells, but historical attempts to suppress tumors by inhibiting the IGF-1R signaling pathway have been unsuccessful in the clinic. For FPI-1434, we have designed the product candidate to rely on the IGF-1R antibody only as a way to identify and deliver our alpha emitting payload to the tumor, and the mechanism of action does not depend on the IGF-1R signaling pathway to kill the tumor. We are currently conducting a Phase 1 clinical trial of FPI-1434 as a monotherapy in patients with solid tumors expressing IGF-1R and convened a Safety Review Committee (“SRC”) meeting in the third quarter of 2020 to evaluate the safety and tolerability of the third dose escalation cohort of 40kBq/kg administered as a single dose. The available safety, dosimetry, pharmacokinetic and biodistribution data from the single dose escalation portion of the study provided justification for the initiation of FPI-1434 multi-dosing at 75kBq/kg and the SRC made the recommendation to proceed with dose escalation to 75kBq/kg administered as repeat doses. We expect to dose the first patient in the multi-dose escalation portion of the study in the fourth quarter of 2020. We anticipate reporting Phase 1 multiple-dose safety and imaging data, and the recommended Phase 2 dose/schedule, approximately nine to eighteen months after commencing this portion of the study. In preclinical studies, FPI-1434 has been evaluated in combination with approved checkpoint and DNA Damage Response Inhibitors, or DDRis, such as poly (ADP-ribose) Polymerase, or PARP, inhibitors, and we believe the synergies observed could expand the addressable patient populations for FPI-1434 and allow for potential use in earlier lines of treatment. We anticipate initiation of a Phase 1 combination study with FPI-1434 to occur six to nine months following determination of the recommended Phase 2 dose of FPI-1434 monotherapy. In addition, we are progressing our earlier-stage product candidate, FPI-1966, into clinical development, and expect to submit an investigational new drug application, or IND, for FPI-1966 in the first half of 2021 for the treatment of head and neck and bladder cancers expressing fibroblast growth factor receptor 3.

Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our Company, business planning, raising capital, acquiring or discovering product candidates and securing related intellectual property rights and conducting discovery, research and development activities for our product candidates. We do not have any products approved for sale and have not generated any revenue from any sources, including product sales. On June 30, 2020, we completed our initial public offering (“IPO”) of our common shares and issued and sold 12,500,000 common shares at a public offering price of $17.00 per share, resulting in net proceeds of approximately $193.1 million after deducting underwriting fees and offering costs. Prior to our IPO, we have funded our operations to date primarily with proceeds from sales of equity securities (including borrowings under a convertible promissory note, which converted into preferred shares). Through September 30, 2020, we had received net proceeds of $364.2 million from sales of equity securities (including borrowings under a convertible promissory note, which converted into preferred shares).

We have incurred significant operating losses since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $10.0 million and $64.9 million for the three and nine months ended September 30, 2020, respectively, and $0.6 million and $8.0 million for the three and nine months ended September 30, 2019. As of September 30, 2020, we had an accumulated deficit of $99.8 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital expenditure requirements will increase substantially in connection with our ongoing activities, particularly if and as we:

•

continue our research and development efforts and submit biologics license applications for our lead product candidate and submit investigational new drug applications, or INDs, for our other product candidates;

•

conduct preclinical studies and clinical trials for our current and future product candidates;

•

continue to develop our library of proprietary linkers for our Fast-Clear technology;

•

seek to identify additional product candidates;

•

acquire or in-license other product candidates, targeting molecules and technologies;

•

add operational, financial and management information systems and personnel, including personnel to support the development of our product candidates and help us comply with our obligations as a public company;

•

hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative personnel;

•

seek marketing approvals for any product candidates that successfully complete clinical trials;

•

establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities, whether alone or with third parties, to commercialize any product candidates for which we may obtain regulatory approval, if any;

•

expand, maintain and protect our intellectual property portfolio; and

•

operate as a public company.

We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capabilities to support product sales, marketing and distribution.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we would have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

As of September 30, 2020, we had cash, cash equivalents and investments of $303.1 million. We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into 2024.

Impact of the COVID-19 Pandemic

We are closely monitoring how the spread of COVID-19 is affecting our employees, business, preclinical studies and clinical trials. In response to the COVID-19 pandemic, most of our employees have transitioned to working remotely and travel has been restricted. We have completed enrollment and dosing in the third cohort of our ongoing Phase 1 clinical trial of FPI-1434 and are anticipating the initiation of the multi-dosing portion of this clinical trial in the fourth quarter of 2020. However, we are unable to predict how the COVID-19 pandemic may affect our ability to successfully progress this or any other clinical programs in the future. Although operations were not materially affected by the COVID-19 pandemic as of and for the nine months ended September 30, 2020, at this time, there is significant uncertainty relating to the future trajectory of the pandemic. The impact of related responses and disruptions caused by the COVID-19 pandemic may result in further difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing trials and the incurrence of unforeseen costs as a result of disruptions in clinical supply or preclinical study or clinical trial delays. The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States, Canada and other countries, business closures or business disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.

Components of Results of Operations

Revenue

To date, we have not generated any revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products for the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval or collaboration or license agreements with third parties, we may generate revenue in the future from product sales, payments from collaboration or license agreements that we may enter into with third parties or any combination thereof. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. These expenses include:

•

employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development functions;

•

expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with third parties, such as consultants and contract research organizations, or CROs;

•

the cost of manufacturing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants and contract manufacturing organizations, or CMOs;

•

facilities, depreciation and other expenses, which include direct or allocated expenses for rent, maintenance of facilities and insurance;

•

costs related to compliance with regulatory requirements; and

•

payments made in connection with third-party licensing agreements and asset acquisitions of incomplete technology.

We expense research and development costs as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense when the goods have been delivered or the services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.

Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under third-party license agreements. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and our TAT platform and Fast-Clear linker technology and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and our technology platform and, therefore, we do not track these costs by program.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we complete a Phase 1 clinical trial of FPI-1434 as a monotherapy in patients with solid tumors expressing IGF-1R, complete preclinical development and pursue initial stages of clinical development of our FPI-1434 combination therapies, and develop FPI-1966 and our other early-stage programs.

The successful development and commercialization of our product candidates are highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates. This is due to the numerous risks and uncertainties associated with product development, including the following:

•

timely completion of our preclinical studies and our current and future clinical trials, which may be significantly slower or more costly than we currently anticipate and will depend substantially upon the performance of third-party contractors;

•

our ability to complete IND-enabling studies and successfully submit INDs or comparable applications to allow us to initiate clinical trials for our current or any future product candidates;

•

whether we are required by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;

•

our ability to demonstrate to the satisfaction of the FDA or other foreign regulatory authorities the safety, potency, purity and acceptable risk-to-benefit profile of our product candidates or any future product candidates;

•

the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any;

•

the timely receipt of necessary marketing approvals from the FDA or similar foreign regulatory authorities;

•

the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates as potential cancer treatments;

•

our ability and the ability of third parties with whom we contract to manufacture adequate clinical supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain manufacturing processes that are compliant with current good manufacturing practices; and

•

our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates.

A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of these product candidates. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. In addition, we may never succeed in obtaining regulatory approval for any of our product candidates.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs, including share-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and technology platform. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company.

Other Income (Expense)

Change in Fair Value of Preferred Share Tranche Right Liability

In connection with our Class A preferred share financings in 2017, we issued shares under subscription agreements that provided investors the right, or obligated investors, to participate in subsequent offerings of either (i) Class A preferred shares or (ii) Class A preferred exchangeable shares together with Class A special voting shares, in the event that specified company-performance milestones were achieved. We classified this Class A preferred share tranche right as a liability on our consolidated balance sheet. We remeasured this preferred share tranche right to fair value at each reporting date and recognized changes in the fair value of the preferred share tranche right liability as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. We continued to recognize changes in the fair value of this preferred share tranche right liability until the specified milestones were achieved in November 2018. Upon the achievement of the specified milestones, the Class A preferred share tranche right was remeasured to fair value for the last time and the change in fair value was recognized as a component of other income (expense) in our consolidated statement of operations and comprehensive loss.

In connection with our Class B preferred share financings in March 2019 and January 2020, we issued shares under subscription agreements that provided investors the right, or obligated investors, to participate in subsequent offerings of either (i) Class B preferred shares or (ii) Class B preferred exchangeable shares together with Class B special voting shares in the event that specified development or regulatory milestones were achieved or upon the vote of at least two-thirds of the holders of the Class B preferred shares and Class B special voting shares. We classified this Class B preferred share tranche right as a liability on our consolidated balance sheets. We remeasured this preferred share tranche right to fair value at each reporting date and recognized changes in the fair value of the preferred share tranche right liability as a component of other income (expense) in our consolidated statements of operations and comprehensive loss. We continued to recognize changes in the fair value of this preferred share tranche right liability until the preferred share tranche right was settled on June 2, 2020 in connection with the achievement of the specified regulatory milestone. Upon the settlement of the preferred share tranche right, the Class B preferred share tranche right was remeasured to fair value for the last time and the change in fair value was recognized as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. As a result, in periods subsequent to June 2, 2020, we will no longer recognize changes in the preferred share tranche right liability in our condensed consolidated statements of operations and comprehensive loss.

Change in Fair Value of Preferred Share Warrant Liability

In connection with our Class B preferred share financing in January 2020, we issued to the existing holders of Class B preferred shares (excluding the investor in the January 2020 financing) warrants to purchase 3,126,391 of our Class B preferred shares and we issued to the existing holders of Class B preferred exchangeable shares warrants to purchase 873,609 Class B preferred exchangeable shares. We classify these warrants to purchase Class B preferred shares and Class B preferred exchangeable shares as a liability on our consolidated balance sheets. We remeasure these preferred share warrants to fair value at each reporting date and recognize changes in the fair value of the preferred share warrant liability as a component of other income (expense) in our consolidated statements of operations and comprehensive loss. We will continue to recognize changes in the fair value of this preferred share warrant liability until each respective preferred share warrant is exercised, expires or qualifies for equity classification. The preferred share warrants were immediately exercisable and expire two years from the date of issuance or upon the earlier occurrence of specified qualifying events, which include the consummation of a deemed liquidation event and the closing of a qualifying share sale.

Upon the closing of the IPO, the warrants to purchase our convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase shares of our common shares. As a result, the warrant liability was remeasured a final time on the closing date of the IPO and the change in fair value was recognized as a component of other income (expense) in our condensed consolidated statements of operations and comprehensive loss and reclassified to shareholders’ equity (deficit) as the warrants qualify for equity classification.

Interest Income (Expense), Net

Interest income (expense), net consists primarily of interest income earned on our cash, cash equivalents and investment balances and the amortization of premiums or accretion of discounts associated with our investments. We expect that our interest income will fluctuate based on the timing and ability to raise additional funds as well as the amount of expenditures for our clinical development of FPI-1434 and ongoing business operations.

Refundable Investment Tax Credits

Refundable investment tax credits consist of payments from the Canadian government for our scientific research and experimental development expenditures. We recognize such refundable investment tax credits in the year that the qualifying expenditures are made, provided that there is reasonable assurance of recoverability, based on our estimates of amounts expected to be recovered.

Other Income (Expense), Net

Other income (expense), net primarily consists of foreign currency transaction gains and losses as well as miscellaneous income and expense unrelated to our core operations.

Income Taxes

We are domiciled in Canada and are primarily subject to taxation in that country. Since our inception, we have recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year by our operations in Canada and Ireland due to our uncertainty of realizing a benefit from those items. As of December 31, 2019, we had $20.5 million of Canadian net operating loss carryforwards that begin to expire in 2035 and $4.9 million of Irish net operating loss carryforwards that can be carried forward indefinitely. We have recorded a full valuation allowance against our Canadian and Irish net deferred tax assets at each balance sheet date.

We have recorded an insignificant amount of income tax provisions or benefits in each period, which relate to income tax obligations of our operating company in Canada and our operating company in the U.S., which typically generates a profit for tax purposes.

Results of Operations

Comparison of the Three Months Ended September 30, 2020 and 2019

The following table summarizes our results of operations for the three months ended September 30, 2020 and 2019:

	Three Months Ended September 30,
	2020			2019			Change
				(in thousands)
Operating expenses:
Research and development	$	4,529		$	2,238		$	2,291
General and administrative		5,790			1,922			3,868
Total operating expenses		10,319			4,160			6,159
Loss from operations		(10,319	)		(4,160	)		(6,159	)
Other income (expense):
Change in fair value of preferred share tranche right liability		—			3,485			(3,485	)
Interest income (expense), net		80			247			(167	)
Refundable investment tax credits		41			44			(3	)
Other income (expense), net		20			(29	)		49
Total other income (expense), net		141			3,747			(3,606	)
Loss before (provision) benefit for income taxes		(10,178	)		(413	)		(9,765	)
Income tax (provision) benefit		185			(181	)		366
Net loss	$	(9,993	)	$	(594	)	$	(9,399	)

Research and Development Expenses

	Three Months Ended September 30,
	2020		2019		Change
	(in thousands)
Direct research and development expenses by program:
FPI-1434	$	1,401	$	924	$	477
Platform development and unallocated research and development expenses:
TAT platform and Fast-Clear linker technology		1,245		642		603
Personnel related (including share-based compensation)		1,634		527		1,107
Other		249		145		104
Total research and development expenses	$	4,529	$	2,238	$	2,291

Research and development expenses were $4.5 million for the three months ended September 30, 2020, compared to $2.2 million for the three months ended September 30, 2019. The increase of $2.3 million was primarily due to an increase of $1.8 million in platform development and unallocated research and development costs, described below, as well as an increase of $0.5 million in direct costs related to our FPI-1434 product candidate due to the continued expenditures related to our Phase 1 clinical trial of FPI-1434 as a monotherapy in patients with solid tumors expressing IGF-1R as well as preclinical research and manufacturing costs.

Platform development and unallocated research and development expenses were $3.1 million for the three months ended September 30, 2020, compared to $1.3 million for the three months ended September 30, 2019. The increase of $1.8 million was due to an increase of $1.1 million in personnel-related costs, an increase of $0.6 million in costs related to our TAT platform and Fast-Clear linker technology and an increase of $0.1 million in other costs. The increase in personnel-related costs was primarily due to the hiring of additional personnel in our research and development functions, particularly those responsible for managing our Phase 1 clinical trial of FPI-1434 and for conducting preclinical research. Personnel-related costs for the three months ended September 30, 2020 and 2019 included share-based compensation of $0.3 million and less than $0.1 million, respectively. The increase in TAT platform and Fast-Clear linker technology costs was primarily due to an increase of $0.6 million in external costs for preclinical studies and activities associated with our advancement of our TAT platform and Fast-Clear linker technology. The increase in other costs was primarily due to an increase in depreciation expense and facilities-related costs.

General and Administrative Expenses

General and administrative expenses were $5.8 million for the three months ended September 30, 2020, compared to $1.9 million for the three months ended September 30, 2019. The increase of $3.9 million was primarily due to a $1.5 million increase in corporate and other costs, a $1.3 million increase in professional fees and a $1.1 million increase in personnel-related costs. The increase in other costs was primarily due to increased general corporate, director and officer insurance and facilities expenses. Professional fees increased primarily due to higher audit, legal and consulting expenses, including legal costs incurred as part of operating as a public company and costs associated with our ongoing business operations. The increase in personnel-related costs was primarily due to the hiring of additional personnel in our general and administrative functions, including in finance, human resources and business development. Personnel-related costs for the three months ended September 30, 2020 and 2019 included share-based compensation of $1.0 million and $0.1 million, respectively.

Other Income (Expense)

Change in Fair Value of Preferred Share Tranche Right Liability. There was no change in fair value of the preferred share tranche right liability recorded for the three months ended September 30, 2020. The change in fair value of the preferred share tranche right liability was a gain of $3.5 million for the three months ended September 30, 2019. The decrease was a result of the preferred share tranche right liability being settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. The Class B preferred share tranche right liability was remeasured for accounting purposes for the final time in the second quarter of 2020.

Interest Income (Expense), Net. Interest income (expense), net for the three months ended September 30, 2020 and 2019 was $0.1 million and $0.2 million, respectively. The decrease in interest income was primarily due to lower interest rates for the three months ended September 30, 2020 compared to the three months ended September 30, 2019, as well as the recognition of the net accretion of discounts and amortization of premiums on investments for the three months ended September 30, 2020, partially offset by the increase in our cash, cash equivalents and investments balances.

Refundable Investment Tax Credits. Refundable investment tax credits recognized as other income for the three months ended September 30, 2020 and 2019 totaled less than $0.1 million.

Other Income (Expense), Net. Other income (expense), net was less than $0.1 million for the three months ended September 30, 2020, compared to less than ($0.1) million for the three months ended September 30, 2019.

Provision for Income Taxes

The income tax benefit was $0.2 million for the three months ended September 30, 2020, compared to income tax expense of $0.2 million for the three months ended September 30, 2019. The benefit for the three months ended September 30, 2020 is a result of the Company claiming a U.S. research and development tax credit to partially offset the current U.S. tax liability. The provision for the three months ended September 30, 2019 is primarily related to income tax obligations of our operating company in the U.S., which generates a profit for tax purposes.

Comparison of the Nine Months Ended September 30, 2020 and 2019

The following table summarizes our results of operations for the nine months ended September 30, 2020 and 2019:

	Nine Months Ended September 30,
	2020			2019			Change
	(in thousands)
Operating expenses:
Research and development	$	12,231		$	7,216		$	5,015
General and administrative		14,105			4,864			9,241
Total operating expenses		26,336			12,080			14,256
Loss from operations		(26,336	)		(12,080	)		(14,256	)
Other income (expense):
Change in fair value of preferred share tranche right liability		(32,722	)		3,707			(36,429	)
Change in fair value of preferred share warrant liability		(6,399	)		—			(6,399	)
Interest income (expense), net		249			395			(146	)
Refundable investment tax credits		139			132			7
Other income (expense), net		148			76			72
Total other income (expense), net		(38,585	)		4,310			(42,895	)
Loss before (provision) benefit for income taxes		(64,921	)		(7,770	)		(57,151	)
Income tax (provision) benefit		(27	)		(213	)		186
Net loss	$	(64,948	)	$	(7,983	)	$	(56,965	)

Research and Development Expenses

	Nine Months Ended September 30,
	2020		2019		Change
	(in thousands)
Direct research and development expenses by program:
FPI-1434	$	4,498	$	3,232	$	1,266
Platform development and unallocated research and development expenses:
TAT platform and Fast-Clear linker technology		3,251		2,078		1,173
Personnel related (including share-based compensation)		3,894		1,545		2,349
Other		588		361		227
Total research and development expenses	$	12,231	$	7,216	$	5,015

Research and development expenses were $12.2 million for the nine months ended September 30, 2020, compared to $7.2 million for the nine months ended September 30, 2019. The increase of $5.0 million was primarily due to an increase of $3.7 million in platform development and unallocated research and development costs, described below, as well as an increase of $1.3 million in direct costs related to our FPI-1434 product candidate due to the continued expenditures related to our Phase 1 clinical trial of FPI-1434 as a monotherapy in patients with solid tumors expressing IGF-1R as well as preclinical research and manufacturing costs.

Platform development and unallocated research and development expenses were $7.7 million for the nine months ended September 30, 2020, compared to $4.0 million for the nine months ended September 30, 2019. The increase of $3.7 million was due to an increase of $2.3 million in personnel-related costs, an increase of $1.2 million in costs related to our TAT platform and Fast-Clear linker technology and an increase of $0.2 million in other costs. The increase in personnel-related costs was primarily due to the hiring of additional personnel in our research and development functions, particularly those responsible for managing our Phase 1 clinical trial of FPI-1434 and for conducting preclinical research. Personnel-related costs for the nine months ended September 30, 2020 and 2019 included share-based compensation of $0.5 million and $0.1 million, respectively. The increase in TAT platform and Fast-Clear linker technology costs was primarily due to an increase of $0.3 million in costs associated with our asset purchase and licensing agreements as well as an increase of $0.8 million in external costs for preclinical studies and activities associated with our advancement of our TAT platform and Fast-Clear linker technology. The increase in other costs was primarily due to an increase in depreciation expense and facilities-related costs.

General and Administrative Expenses

General and administrative expenses were $14.1 million for the nine months ended September 30, 2020, compared to $4.9 million for the nine months ended September 30, 2019. The increase of $9.2 million was primarily due to a $4.0 million increase in professional fees, a $3.0 million increase in personnel-related costs and a $2.2 million increase in other costs. Professional fees increased primarily due to higher audit, legal and consulting expenses as well as legal costs incurred in preparation to operate, and operating as a public company and costs associated with our ongoing business operations. The increase in personnel-related costs was primarily due to the hiring of additional personnel in our general and administrative functions, including in finance, human resources and business development. Personnel-related costs for the nine months ended September 30, 2020 and 2019 included share-based compensation of $1.5 million and $0.2 million, respectively. The increase in other costs was primarily due to increased general corporate, director and officer insurance, facilities and depreciation expenses.

Other Income (Expense)

Change in Fair Value of Preferred Share Tranche Right Liability. The change in fair value of the preferred share tranche right liability was a loss of $32.7 million for the nine months ended September 30, 2020, compared to a gain of $3.7 million for the nine months ended September 30, 2019. The decrease was primarily due to an increase in the fair value of the underlying preferred shares and an increase in the probability of achieving the specified milestones underlying the preferred share tranche rights which occurred in May 2020, partially offset by a reduction in the remaining estimated time period of achievement of the specified milestones underlying the preferred share tranche rights. The preferred share tranche right liability was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. The Class B preferred share tranche right liability was remeasured for accounting purposes for the final time in the second quarter of 2020.

Change in Fair Value of Preferred Share Warrant Liability. The change in fair value of the preferred share warrant liability was a loss of $6.4 million for the nine months ended September 30, 2020, which was primarily due to an increase in the fair value of the underlying Class B preferred shares as a result of the fair value increase from the IPO. There was no preferred share warrant liability recorded as of September 30, 2019.

Interest Income (Expense), Net. Interest income (expense), net for the nine months ended September 30, 2020 and 2019 was $0.2 million and $0.4 million, respectively. The decrease in interest income was primarily due to lower interest rates for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019, as well as the recognition of the net accretion of discounts and amortization of premiums on investments for the three months ended September 30, 2020, partially offset by the increase in our cash, cash equivalents and investments balances.

Refundable Investment Tax Credits. Refundable investment tax credits recognized as other income for the nine months ended September 30, 2020 and September 30, 2019 was $0.1 million for each of the periods.

Other Income (Expense), Net. Other income (expense), net for the nine months ended September 30, 2020 and September 30, 2019 was $0.1 million for each of the periods.

Provision for Income Taxes

The provision for income taxes was less than $0.1 million for the nine months ended September 30, 2020, compared to $0.2 million for the nine months ended September 30, 2019. The provisions in each period were primarily related to income tax obligations of our operating company in the U.S., which generates a profit for tax purposes.

Liquidity and Capital Resources

Since our inception, we have not generated any revenue from any sources, including from product sales, and have incurred significant operating losses and negative cash flows from our operations. On June 30, 2020, we completed our IPO of our common shares and issued and sold 12,500,000 shares of our common shares at a public offering price of $17.00 per share, resulting in net proceeds of approximately $193.1 million after deducting underwriting fees and offering costs. Prior to our IPO, we have funded our operations to date primarily with proceeds from sales of equity securities (including borrowings under a convertible promissory note, which converted into preferred shares). Through September 30, 2020, we had received net proceeds of $364.2 million from sales of equity securities (including borrowings under a convertible promissory note, which converted into preferred shares).

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

	Nine Months Ended September 30,
	2020			2019
Net cash used in operating activities	$	(26,685	)	$	(9,857	)
Net cash used in investing activities		(55,349	)		(340	)
Net cash provided by financing activities		265,451			52,187
Net increase in cash, cash equivalents and restricted cash	$	183,417		$	41,990

Operating Activities

During the nine months ended September 30, 2020, operating activities used $26.7 million of cash primarily resulting from our net loss of $64.9 million and net cash used by changes in our operating assets and liabilities of $3.3 million, partially offset by non-cash charges of $41.5 million. Net cash used by changes in our operating assets and liabilities for the nine months ended September 30, 2020 consisted of a $3.8 million increase in prepaid expenses and other current assets, a $0.5 million increase in other non-current assets and a $0.1 million decrease in income taxes payable, partially offset by a $1.0 million increase in accrued expenses and a $0.2 million increase in accounts payable. The increase in prepaid expenses and other current assets was primarily due to the timing of payment of annual premiums for various corporate insurance policies.

During the nine months ended September 30, 2019, operating activities used $9.9 million of cash, primarily resulting from our net loss of $8.0 million and non-cash adjustments of $3.2 million, partially offset by net cash provided by changes in our operating assets and liabilities of $1.3 million. Net cash provided by changes in our operating assets and liabilities for the nine months ended September 30, 2019 consisted primarily of a $0.7 million increase in accrued expenses and a $0.4 million increase in accounts payable. The increase in accrued expenses was primarily due to increases in our research and development expenses and general and administrative expenses due to the growth in our business as well as the timing of vendor invoicing and payments.

Investing Activities

During the nine months ended September 30, 2020, net cash used in investing activities was $55.3 million, consisting of purchases of investments of $54.3 million and purchases of property and equipment of $1.1 million.

During the nine months ended September 30, 2019, net cash used in investing activities was $0.3 million, consisting of purchases of property and equipment.

Financing Activities

During the nine months ended September 30, 2020, net cash provided by financing activities was $265.5 million, consisting of net proceeds of $197.6 million from our issuance of common shares upon the closing of our IPO, net of underwriter fees before deducting for offering costs, $65.7 million from our issuance of Class B preferred shares and a Class B preferred share tranche right and $6.7 million from the issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited, partially offset by $4.6 million in payments of offering costs associated with our IPO.

During the nine months ended September 30, 2019, net cash provided by financing activities was $52.2 million, consisting primarily of net proceeds of $45.5 million from our issuance of Class B preferred shares and a Class B preferred share tranche right and $6.7 million from the issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and a Class B preferred share tranche right.

Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates in development. In addition, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on:

•

the scope, progress, results and costs of researching and developing FPI-1434 and our other product candidates;

•

the timing of, and the costs involved in, obtaining marketing approvals for our current and future product candidates;

•

the number of future product candidates and potential additional indications that we may pursue and their development requirements;

•

the cost of manufacturing our product candidates for clinical trials in preparation for regulatory approval and in preparation for commercialization;

•

the cost and availability of actinium-225 or any other medical isotope we may incorporate into our product candidates;

•

if approved, the costs of commercialization activities for any approved product candidate to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;

•

subject to receipt of regulatory approval and revenue, if any, received from commercial sales for any approved indications for any of our product candidates;

•

the extent to which we enter into collaborations with third parties, in-license or acquire rights to other products, product candidates or technologies;

•

our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial infrastructure;

•

the costs of preparing, filing and prosecuting patent applications and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and

•

the costs of operating as a public company.

We believe that our existing cash, cash equivalents and investments as of September 30, 2020 will be sufficient to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming shares or declaring dividends. If we raise funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Critical Accounting Policies and Significant Judgments and Estimates

Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our interim condensed consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our condensed consolidated financial statements.

Accrued Research and Development Expenses

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. At each end period, we confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:

•

vendors in connection with preclinical development activities;

•

CROs in connection with preclinical studies and clinical trials; and

•

CMOs in connection with the production of preclinical and clinical trial materials.

We record the expense and accrual related to contract research and manufacturing based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the CROs, CMOs and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

Share-Based Compensation

We measure all share-based awards granted to employees, directors and non-employee consultants based on their fair value on the date of the grant using the Black-Scholes option-pricing model and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. We issue share-based awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. We have not issued any share-based awards with performance-based vesting conditions that are within our control and that may be considered probable prior to occurrence or with market-based vesting conditions.

The Black-Scholes option-pricing model uses as inputs the fair value of our common shares and assumptions we make for the volatility of our common shares, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. Prior to our IPO, there was no public market for our common shares, we lack company-specific historical and implied volatility information. Therefore, we estimate our expected share volatility based on the historical volatility of a publicly traded set of peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded share price.

Valuation of Preferred Share Tranche Right Liability

preferred share tranche right was remeasured to fair value for the last time and the change in fair value was recognized as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. Immediately thereafter, upon the settlement of the tranche right, the balance of the Class A preferred share tranche right liability of $2.4 million was reclassified to Class A preferred shares in an amount of $1.6 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $0.8 million on our consolidated balance sheet.

In connection with our Class B preferred share financings in March 2019 and January 2020, we issued shares under subscription agreements that provided investors the right, or obligated investors, to participate in subsequent offerings of either (i) Class B preferred shares or (ii) Class B preferred exchangeable shares together with Class B special voting shares, in the event that specified development or regulatory milestones were achieved or upon the vote of at least two-thirds of the holders of the Class B preferred shares and Class B special voting shares. We classified this Class B preferred share tranche right as a liability on our consolidated balance sheets. We remeasured this preferred share tranche right to fair value at each reporting date and recognized changes in the fair value of the preferred share tranche right liability as a component of other income (expense) in our consolidated statements of operations and comprehensive loss. We continued to recognize changes in the fair value of this preferred share tranche right liability until the preferred share tranche right was settled on June 2, 2020 in connection with the achievement of the specified regulatory milestone. Upon the settlement of the preferred share tranche right, the Class B preferred share tranche right was remeasured to fair value for the last time and the change in fair value was recognized as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on our consolidated balance sheet.

We used the forward contract pricing model to determine the fair value of the preferred share tranche right liability associated with the rights to purchase Class A or Class B preferred shares and Class A or Class B preferred exchangeable shares with Class A or Class B special voting shares. We assessed these assumptions and estimates on a quarterly basis as additional information impacting the assumptions was obtained. Estimates and assumptions impacting the fair value measurement included the probability and timing of achieving the specified milestone as of each valuation date, the estimated fair value of the preferred shares as of each valuation date and the risk-free interest rate. The most significant assumption in the forward contract pricing model impacting the fair value of the preferred share tranche right liability was the fair value of our preferred shares as of each measurement date. We determined the fair value per share of our underlying preferred shares by taking into consideration the most recent sales of our preferred shares, results obtained from third-party valuations and additional factors we deemed relevant. In November 2018, upon the date of achievement of the specified milestone associated with the Class A preferred share tranche right and the settlement date of the related liability, the fair value of each Class A preferred share was $0.85 per share. As of June 2, 2020 and December 31, 2019, the fair value of each Class B preferred share was $2.47 per share and $1.45 per share, respectively. In June 2020, upon the date of achievement of the specified regulatory milestone associated with the Class B preferred share tranche right and the settlement date of the related liability, the fair value of each Class B preferred share was $2.47 per share. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time period of achievement of the specified milestones underlying the preferred share tranche rights.

Valuation of Preferred Share Warrant Liability

To determine the fair value of the preferred share warrant liability, we use a hybrid method, which is a PWERM where the equity value in one or more of the scenarios is calculated using an OPM. Under both methods, assumptions and estimates are used to value the preferred share warrants. We assess the assumptions and estimates on a quarterly basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement of the preferred share warrant liability include the fair value per share of the underlying Class B preferred shares, the timing, form and overall value of the expected exits for the shareholders, the risk-free interest rate, the expected dividend yield and the expected volatility of our shares. The most significant assumption impacting the fair value of the preferred share warrant liability is the fair value of our Class B preferred shares as of each measurement date. We determine the fair value per share of our underlying Class B preferred shares by taking into consideration the

most recent sales of our preferred shares, results obtained from third-party valuations and additional factors we deem relevant. In January 2020, upon issuance of the preferred share warrants, the fair value of each Class B preferred share was $1.45 per share. As of June 2, 2020, the fair value of each Class B preferred share was $2.47 per share. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. We estimated a 0% dividend yield based on the expected dividend yield and the fact that we have never paid or declared cash dividends.

Upon the closing of our IPO, the warrants to purchase its convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase shares of the Company’s common shares. As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) as the warrants qualify for equity classification.

For additional information about our preferred share financings and transactions with related parties, see “Certain Relationships and Related Person Transactions.”

Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies and our financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.

We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the closing of our IPO, (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.

Further, even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company,” which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

As of September 30, 2020, we had an aggregate cash, cash equivalents, restricted cash and investments balance of $304.8 million which consisted of cash, money market funds, U.S. government agency securities, corporate bonds and commercial paper. As of December 31, 2019, we had an aggregate cash and restricted cash balance of $67.1 million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority our investments are short-term in nature. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investment portfolio.

As of September 30, 2020 and December 31, 2019, we had no debt outstanding and are therefore not subject to interest rate risk related to debt.

Foreign Currency Exchange Risk

Our reporting currency is the U.S. dollar. The functional currency of our operating company in Canada, operating company in the U.S. and non-operating company in Ireland is also the U.S. dollar. As a result, we record no cumulative translation adjustments related to translation of unrealized foreign exchange gains or losses.

We do not believe that we are subject to significant risk related to foreign currency exchange rate changes, and we do not expect that foreign currency transaction gains and losses will have a material effect on our financial position or results of operations in the foreseeable future.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures as of September 30, 2020, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact in our internal controls over financial reporting despite our employees working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls including changes to their design and operating effectiveness.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.

Item 1A. Risk Factors.

There have been no material changes to the Company’s risk factors as disclosed in Part I, Item 1A. Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, other than the updates noted below. Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form 10-Q and in other documents that we file with the SEC, in evaluating our company and our business. Investing in our common shares involves a high degree of risk. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.

The strategic collaboration agreement with AstraZeneca is important to our business. We may depend on AztraZeneca or additional third parties for the development and commercialization of our other programs and future product candidates. Our current and future collaborators may control aspects of our clinical trials, which could result in delays or other obstacles in the commercialization of the product candidates we develop. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.

Under the strategic collaboration agreement, the Collaboration Agreement, entered into between us and AstraZeneca UK Limited, or AstraZeneca, in October 2020, we and AstraZeneca will jointly discover, develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer by leveraging our Targeted Alpha Therapies, or TATs, platform and expertise in radiopharmaceuticals with AstraZeneca’s portfolio of antibodies and cancer therapeutics. For the combination therapies, the parties will evaluate potential combination strategies involving our existing assets, including our lead candidate FPI-1434, in combination with certain of AstraZeneca’s existing therapeutics for the treatment of various cancers. AstraZeneca is obligated to fully fund all research and development activities for the combination strategies.

Our current Collaboration Agreement poses, and potential future collaborations involving our product candidates may pose, the following risks to us:

•

collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;

•

collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;

•

collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation, or other intellectual property proceedings;

•

disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;

•

if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and

•

collaboration agreements may restrict our right to independently pursue new product candidates.

As a result, if we enter into additional collaboration agreements and strategic partnerships or license our intellectual property or products, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that we will achieve the revenue or specific income expected of the Collaboration Agreement, or future strategic collaboration and licenses, which would harm our business prospects and financial condition.

We and AstraZeneca can each terminate the strategic collaboration agreement under certain circumstances. Termination of the strategic collaboration agreement could prevent us from further developing or commercializing products directed to the molecular targets which are the subject of the strategic collaboration agreement and could prevent us from obtaining milestones and revenues for such product candidates. Any of these events would have a material adverse effect on our results of operations and financial condition.

If the antibody targets or de novo radioconjugates subject to the AstraZeneca Collaboration Agreement fail to advance or experience unacceptable safety or efficacy results if clinically developed, this could adversely impact the reputation of our Fast-Clear technology and our ability to engage in future collaborations.

If the antibody targets or novel TATs associated with the Collaboration Agreement fail to advance into the clinic, or experience negative results with respect to safety, efficacy, manufacturability, or other features of research and development, this could adversely affect the reputation of our Fast-Clear linker technology and our ability to engage in future collaborations. To the extent these assets do not successfully advance through clinical development, this may impair our ability to leverage our platform or to further expand the use of our platform and generate future revenue, which could have a material adverse effect on our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Equity Securities

On June 30, 2020, upon the closing of our IPO, all 28,874,378 of the then-outstanding preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited, our majority-owned subsidiary, were redeemed in exchange for 28,874,378 of our preferred shares, and all 27,234,489 of our outstanding preferred shares, including the preferred shares issued upon the redemption of the preferred exchangeable shares, were automatically converted into 27,234,489 common shares. Upon the closing of our IPO, all 400,244 of our outstanding non-voting common shares were automatically converted into 400,244 voting common shares, and all 1,529,311 of our outstanding voting common shares automatically converted in 1,529,311 common shares. The issuances of common shares in connection with the closing of our IPO was exempt from the registration requirements of the Securities Act, pursuant to Section 3(a)(9) of the Securities Act, involving an exchange of securities exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. No underwriters were involved in the foregoing issuances of shares.

During the period between April 1, 2020 and June 30, 2020, we issued to employees and directors, options to purchase an aggregate of 1,442,806 common shares at a weighted-average exercise price of $16.40 per share. The options have a ten-year term. The options granted to our employees vest over four years, with 25% of the shares underlying the options vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% of the shares underlying the award vesting monthly thereafter for three years while the options granted to our directors vest monthly over three years. Vesting of the options to both our employees and directors is subject to continued service with the company through the applicable vesting date. We deemed these issuances to be exempt from registration under the Securities Act either in reliance on Rule 701 of the Securities Act as sales and offers under compensatory benefit plans and contracts relating to compensation in compliance with Rule 701, or in reliance on Section 4(a)(2), as transaction by an issuer not involving a public offering. No underwriters were involved in the foregoing issuances of securities.

On June 30, 2020, we filed a registration statement on Form S-8 under the Securities Act to register all of our common shares subject to outstanding options and all of our common shares otherwise issuable pursuant to our equity compensation plans.

Use of Proceeds from our Public Offering of Common Shares

On June 30, 2020, we completed our IPO pursuant to which we issued and sold 12,500,000 of our common shares, at a public offering price of $17.00 per share.

The offer and sale of all of our common shares were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-238968), which was declared effective by the SEC on June 25, 2020. Morgan Stanley & Co. LLC, Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers of the offering and as representatives of the underwriters.

We received aggregate gross proceeds from our IPO of $212.5 million, or aggregate net proceeds of $193.1 million after deducting underwriting fees and offering costs. None of the offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.

There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus dated June 25, 2020.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number		Description

10.1*		Amendment No. 1 to Asset Purchase Agreement, dated October 8, 2020, by and between Fusion Pharmaceuticals Inc. and Rainier Therapeutics, Inc.

10.2**		Strategic Collaboration Agreement by and between Fusion Pharmaceuticals Inc. and AstraZeneca UK Limited, dated October 30, 2020

31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1#		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2#		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

**	Previously filed.

This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Fusion Pharmaceuticals Inc.

Date: November 10, 2020	By:	/s/ John Valliant
		John Valliant
		Chief Executive Officer

Date: November 10, 2020	By:	/s/ John Crowley
		John Crowley
		Chief Financial Officer

EX-10.1 2 fusn-ex101_279.htm EX-10.1 fusn-ex101_279.htm

Exhibit 10.1

EXECUTION COPY

AMENDMENT NO. 1 TO
ASSET PURCHASE AGREEMENT

This Amendment No. 1 to Asset Purchase Agreement (this “Amendment”), effective as of October 8, 2020 (the “Amendment Effective Date”), is entered into by and among Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its principal place of business at 270 Longwood Road S., Hamilton, Ontario L8P 0A6 (“Purchaser”); Rainier Therapeutics, Inc., a Delaware corporation with its principal place of business at 500 Mercer Street, Suite C202, Seattle, Washington 98109 (“Seller”); and Fortis Advisors LLC, a Delaware limited liability company solely in its capacity as the representative for Seller for certain obligations (“Seller Representative”). Purchaser, Seller, and Seller Representative are referred to herein individually as a “Party” and collectively, as the “Parties”.

WHEREAS, the Parties previously executed that certain Asset Purchase Agreement, dated as of March 10, 2020 (the “Agreement”); and

WHEREAS, the Parties now desire to amend and restate certain provisions of the Agreement as set forth herein.

NOW, THEREFORE, in consideration of the mutual promises and undertakings set forth herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

1.	Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the Agreement.

2.	Escrow Terms.

Clause (b) of Section 1.02 of the Agreement is hereby deleted and removed from the Agreement in its entirety.

The final sentence of Section 5.02 of the Agreement is hereby amended and restated in its entirety as follows:

“Notwithstanding anything to the contrary in this Agreement, Purchaser shall have the right to a one-time reimbursement from Seller of any and all reasonable documented costs and expenses incurred by Purchaser prior to the Outside Date in connection with seeking or obtaining a grant of Request for Restoration of Priority Claim By Receiving Office Under 37 CFR §1.78 and 1.452, and under PCT Rule 26bis for PCT/US2020/020846 corresponding to U.S. non-provisional application 16/805,508 and claiming priority to U.S. provisional applications 62/812,929; 62/856,216; and 62/907,504; provided that such reimbursement shall only become due if the Signing Fee Second Tranche has been paid pursuant to Section 1.02 and shall not in any event exceed Two Hundred and Twenty Five Thousand Dollars ($225,000).”

Section 7.04(c) is hereby amended and restated in its entirety as follows:

“(c)If an indemnified party wishes to make an indemnification claim under this Article VII, such indemnified party shall, prior to 11:59 p.m. Eastern time of the last day of the survival period applicable to such indemnification claim, deliver a written notice (an “Indemnification Claim Notice”) to the indemnifying party (i) stating that an indemnified party has paid, incurred, suffered or sustained,or reasonably anticipates that it may pay, incur, suffer or sustain Losses, and (ii) specifying in reasonable detail the individual items of such Losses, the date each such item was paid, incurred, suffered or sustained, or the basis for such anticipated liability, and the nature of the misrepresentation, breach of warranty or covenant to which such item is related. An indemnified party may update an Indemnification Claim Notice from time to time to reflect any new information discovered with respect to the claim set forth in such Indemnification Claim Notice.”

Section 7.04(d) is hereby amended and restated in its entirety as follows:

“If the indemnifying party shall not object in writing within the 30-day period after receipt of an Indemnification Claim Notice by delivery of a written notice of objection containing a reasonably detailed description of the facts and circumstances supporting an objection to the applicable indemnification claim (an “Indemnification Claim Objection Notice”), such failure to so object shall be an irrevocable acknowledgment by the indemnifying party that the indemnified party is entitled to the full amount of the claim for Losses set forth in such Indemnification Claim Notice. In the event that the indemnifying party delivers an Indemnification Claim Objection Notice within 30 days after its receipt of such Indemnification Claim Notice, the Seller Representative and Purchaser shall attempt in good faith to agree upon the rights of the respective parties with respect to each of such claims.”

Section 7.08 of the Agreement is hereby deleted in its entirety and replaced with the following text:

“[INTENTIONALLY OMITTED]”

The following defined terms are hereby deleted in their entirety from Section 9.07(b) of the Agreement:

“Escrow Agent”, “Escrow Agreement”, “Escrow Fund”.

The definition of “Other Transaction Documents” in Section 9.07(b) of the Agreement is hereby amended and restated in its entirety as follows:

“Other Transaction Documents” means (i) the Bill of Sale and Assignment and Assumption Agreement, (ii) the Patent Assignment Agreement, and (iii) the BC Therapeutics Termination Agreement.

Section 9.15 of the Agreement is hereby amended and restated in its entirety as follows:

“Seller Representative. The Seller hereby appoints Fortis Advisors LLC, a Delaware limited liability company, as the sole and exclusive representative of the Seller solely with respect to Article VII and the express obligations of the Seller Representative in Article I and acknowledge and agree that the Seller Representative has the authority to act on the

Seller’s behalf with respect to the matters set forth therein, including giving and receiving all notices, communications and instructions to be given or received by the Seller and to take on the Seller’s behalf all actions necessary or appropriate in the judgment of the Seller Representative in connection with the Seller’s rights and obligations under Article VII and the express obligations of the Seller Representative in Article I.

The Escrow Agreement included as Exhibit B to the Agreement is deleted in its entirety and replaced with the following text:

“[INTENTIONALLY OMITTED]”

3.	Section 5.01(b) of the Agreement is hereby amended and restated in its entirety as follows:

“(b)Seller shall do or cause to be done all things necessary to preserve, maintain and keep in full force and effect its corporate existence from and after the Closing until the date that is twelve (12) months after the Closing Date or as otherwise required for Seller to satisfy its obligations under this Agreement, and shall comply in all material respects with all Applicable Laws.

4.	The “Outside Date” as defined in the first sentence of Section 8.01 of the Agreement is hereby amended and restated to be the date that is eleven (11) months after the Closing Date. For the avoidance of doubt, the Outside Date as amended herein is February 10, 2021.

5.	Section 7.04(b) is hereby amended to remove the text “(the “Release Date”)” found in the first sentence of 7.04(b).

Purchaser agrees to pay or, if so requested, to reimburse Seller for all costs, fees and expenses associated with preparing and filing any Tax Returns that Seller is required to file as a result of the amendment of Section 5.01(b) and the definition of “Outside Date” of the Agreement pursuant to Sections 3 and 4 of this Amendment, which Tax Returns Seller would otherwise not be required to file had Section 5.01(b) of the Agreement not been so amended, including without limitation any Tax Returns of the Seller, with respect to the Program, the Product, or the Acquired Assets for the year 2020 or 2021 (or any portion thereof).

7.	Purchaser agrees to pay or, if so requested, to reimburse Seller, all reasonable attorneys’ fees which may be incurred by Seller in connection with entering this Amendment.

8.	Except as amended hereby, the Agreement shall remain in full force and effect.

9.	This Amendment shall be governed by and construed in accordance with the internal laws of the State of Delaware applicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state.

10.	This Amendment may be executed in counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument.

[Remainder of page left intentionally blank]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

FUSION PHARMACEUTICALS INC.		RAINIER THERAPEUTICS, INC.
By:	/s/John Valliant	Date:	/s/Max Barker
Name:	John Valliant	Name:	Max Barker
Title:	CEO, Fusion Pharmaceuticals Inc.	Title:	President & Secretary
FORTIS ADVISORS LLC
By:	/s/Richard Fink
Name:	Richard Fink
Title:	Managing Director

EX-31.1 3 fusn-ex311_6.htm EX-31.1 fusn-ex311_6.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Valliant, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Fusion Pharmaceuticals Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

[paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 10, 2020	By:	/s/ John Valliant
		John Valliant
		Chief Executive Officer

EX-31.2 4 fusn-ex312_9.htm EX-31.2 fusn-ex312_9.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Crowley, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Fusion Pharmaceuticals Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

(b)

[paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];

(c)

(d)

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 10, 2020	By:	/s/ John Crowley
		John Crowley
		Chief Financial Officer

EX-32.1 5 fusn-ex321_7.htm EX-32.1 fusn-ex321_7.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Fusion Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John Valliant, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2020	By:	/s/ John Valliant
		John Valliant
		Chief Executive Officer

EX-32.2 6 fusn-ex322_8.htm EX-32.2 fusn-ex322_8.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Fusion Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John Crowley, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2020	By:	/s/ John Crowley
		John Crowley
		Chief Financial Officer

EX-101.INS 7 fusn-20200930.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:GBP 0001805890 2020-01-01 2020-09-30 0001805890 2020-11-03 0001805890 2020-09-30 0001805890 2019-12-31 0001805890 srt:SubsidiariesMember 2020-09-30 0001805890 srt:SubsidiariesMember 2019-12-31 0001805890 2020-07-01 2020-09-30 0001805890 2019-07-01 2019-09-30 0001805890 2019-01-01 2019-09-30 0001805890 us-gaap:NoncontrollingInterestMember 2019-12-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2019-12-31 0001805890 us-gaap:CommonStockMember 2019-12-31 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001805890 us-gaap:RetainedEarningsMember 2019-12-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember fusn:ClassBConvertiblePreferredSharesAndClassBPreferredShareTrancheRightMember 2020-01-01 2020-03-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001805890 us-gaap:AdditionalPaidInCapitalMember fusn:ClassBConvertiblePreferredSharesAndClassBPreferredExchangeableSharesMember 2020-01-01 2020-03-31 0001805890 us-gaap:RetainedEarningsMember fusn:ClassBConvertiblePreferredSharesAndClassBPreferredExchangeableSharesMember 2020-01-01 2020-03-31 0001805890 fusn:ClassBConvertiblePreferredSharesAndClassBPreferredExchangeableSharesMember 2020-01-01 2020-03-31 0001805890 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001805890 2020-01-01 2020-03-31 0001805890 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001805890 us-gaap:NoncontrollingInterestMember 2020-03-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2020-03-31 0001805890 us-gaap:CommonStockMember 2020-03-31 0001805890 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001805890 us-gaap:RetainedEarningsMember 2020-03-31 0001805890 2020-03-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember fusn:ClassBConvertiblePreferredSharesAndClassBPreferredShareTrancheRightMember 2020-04-01 2020-06-30 0001805890 us-gaap:NoncontrollingInterestMember fusn:ClassBPreferredExchangeableSharesAndClassBPreferredShareTrancheRightMember 2020-04-01 2020-06-30 0001805890 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001805890 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001805890 2020-04-01 2020-06-30 0001805890 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001805890 us-gaap:CommonStockMember 2020-06-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001805890 us-gaap:RetainedEarningsMember 2020-06-30 0001805890 2020-06-30 0001805890 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001805890 us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember 2020-07-01 2020-09-30 0001805890 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001805890 us-gaap:CommonStockMember 2020-09-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001805890 us-gaap:RetainedEarningsMember 2020-09-30 0001805890 us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember 2020-09-30 0001805890 fusn:ClassBConvertiblePreferredSharesMember 2020-01-01 2020-03-31 0001805890 fusn:ClassBConvertiblePreferredSharesMember 2020-04-01 2020-06-30 0001805890 fusn:ClassBConvertiblePreferredSharesMember 2019-01-01 2019-03-31 0001805890 fusn:ClassBPreferredExchangeableSharesAndClassBPreferredShareTrancheRightMember 2020-04-01 2020-06-30 0001805890 fusn:ClassBPreferredExchangeableSharesAndClassBPreferredShareTrancheRightMember 2019-01-01 2019-03-31 0001805890 us-gaap:NoncontrollingInterestMember 2018-12-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2018-12-31 0001805890 us-gaap:CommonStockMember 2018-12-31 0001805890 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001805890 us-gaap:RetainedEarningsMember 2018-12-31 0001805890 2018-12-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember fusn:ClassBConvertiblePreferredSharesAndClassBPreferredShareTrancheRightMember 2019-01-01 2019-03-31 0001805890 us-gaap:NoncontrollingInterestMember fusn:ClassBPreferredExchangeableSharesAndClassBPreferredShareTrancheRightMember 2019-01-01 2019-03-31 0001805890 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001805890 2019-01-01 2019-03-31 0001805890 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001805890 us-gaap:NoncontrollingInterestMember 2019-03-31 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2019-03-31 0001805890 us-gaap:CommonStockMember 2019-03-31 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001805890 us-gaap:RetainedEarningsMember 2019-03-31 0001805890 2019-03-31 0001805890 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001805890 2019-04-01 2019-06-30 0001805890 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001805890 us-gaap:NoncontrollingInterestMember 2019-06-30 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2019-06-30 0001805890 us-gaap:CommonStockMember 2019-06-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001805890 us-gaap:RetainedEarningsMember 2019-06-30 0001805890 2019-06-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001805890 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001805890 us-gaap:NoncontrollingInterestMember 2019-09-30 0001805890 fusn:ClassAAndBConvertiblePreferredStockMember 2019-09-30 0001805890 us-gaap:CommonStockMember 2019-09-30 0001805890 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001805890 us-gaap:RetainedEarningsMember 2019-09-30 0001805890 2019-09-30 0001805890 2020-01-01 2020-06-30 0001805890 us-gaap:PreferredClassBMember 2020-06-01 2020-06-02 0001805890 us-gaap:PreferredClassBMember 2020-06-02 0001805890 fusn:SpecialVotingSharesMember 2020-06-01 2020-06-02 0001805890 fusn:SpecialVotingSharesMember 2020-06-02 0001805890 fusn:PreferredExchangeableSharesMember srt:SubsidiariesMember 2020-06-01 2020-06-02 0001805890 fusn:PreferredExchangeableSharesMember srt:SubsidiariesMember 2020-06-02 0001805890 us-gaap:PreferredClassBMember fusn:MilestoneFinancingMember 2020-06-01 2020-06-02 0001805890 us-gaap:PreferredClassBMember fusn:MilestoneFinancingMember 2020-06-02 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:MilestoneFinancingMember 2020-06-02 0001805890 srt:SubsidiariesMember fusn:MilestoneFinancingMember us-gaap:NoncontrollingInterestMember 2020-06-02 0001805890 2020-06-19 2020-06-19 0001805890 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-25 2020-06-25 0001805890 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-25 0001805890 srt:MaximumMember 2020-07-01 2020-09-30 0001805890 srt:MaximumMember 2020-01-01 2020-09-30 0001805890 srt:MaximumMember 2019-07-01 2019-09-30 0001805890 srt:MaximumMember 2019-01-01 2019-09-30 0001805890 2019-10-31 0001805890 fusn:ClassBSpecialVotingSharesMember 2020-06-02 0001805890 fusn:ClassBPreferredExchangableSharesMember fusn:IrelandSubsidiaryMember 2020-06-02 0001805890 fusn:ClassBPreferredExchangableSharesMember fusn:IrelandSubsidiaryMember 2020-05-31 2020-06-02 0001805890 us-gaap:PreferredClassBMember 2020-01-01 2020-09-30 0001805890 us-gaap:PreferredClassBMember 2020-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember 2020-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:IrelandSubsidiaryMember 2020-01-01 2020-09-30 0001805890 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-09-30 0001805890 us-gaap:MoneyMarketFundsMember 2020-09-30 0001805890 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-09-30 0001805890 us-gaap:CommercialPaperMember 2020-09-30 0001805890 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2020-09-30 0001805890 us-gaap:CorporateBondSecuritiesMember 2020-09-30 0001805890 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2020-09-30 0001805890 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2020-09-30 0001805890 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001805890 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001805890 us-gaap:FairValueInputsLevel3Member fusn:PreferredShareTrancheRightLiabilityMember 2019-12-31 0001805890 fusn:PreferredShareTrancheRightLiabilityMember 2019-12-31 0001805890 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001805890 us-gaap:PreferredClassBMember 2019-12-31 0001805890 fusn:ClassBPreferredSharesTrancheMember 2020-01-01 2020-09-30 0001805890 fusn:ClassBPreferredSharesTrancheMember 2019-12-31 0001805890 fusn:ClassBPreferredSharesTrancheMember 2020-06-02 0001805890 us-gaap:MeasurementInputExpectedDividendRateMember 2020-01-01 2020-09-30 0001805890 us-gaap:PreferredClassBMember 2020-01-31 0001805890 us-gaap:PreferredClassBMember fusn:PreferredShareTrancheRightLiabilityMember 2020-01-01 2020-09-30 0001805890 fusn:PreferredShareWarrantLiabilityMember us-gaap:PreferredClassBMember 2020-01-01 2020-09-30 0001805890 us-gaap:CommercialPaperMember 2020-09-30 0001805890 us-gaap:CorporateBondSecuritiesMember 2020-09-30 0001805890 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001805890 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-29 2020-06-30 0001805890 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-30 0001805890 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001805890 us-gaap:PreferredClassAMember 2019-12-31 0001805890 us-gaap:PreferredClassBMember 2019-03-01 2019-03-31 0001805890 us-gaap:PreferredClassBMember 2019-03-31 0001805890 us-gaap:PreferredClassBMember 2020-01-01 2020-01-31 0001805890 us-gaap:PreferredClassBMember fusn:CanadaPensionPlanInvestmentBoardMember 2020-09-30 0001805890 us-gaap:PreferredClassBMember fusn:CanadaPensionPlanInvestmentBoardMember 2020-01-01 2020-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:IrelandSubsidiaryMember 2020-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:IrelandSubsidiaryMember 2019-12-31 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:SpecialVotingSharesMember 2020-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:SpecialVotingSharesMember 2019-12-31 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:IrelandSubsidiaryMember 2019-03-31 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:SpecialVotingSharesMember 2019-03-31 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:SpecialVotingSharesMember 2019-03-01 2019-03-31 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:IrelandSubsidiaryMember 2020-06-02 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:SpecialVotingSharesMember 2020-06-02 0001805890 us-gaap:ConvertiblePreferredStockMember fusn:SpecialVotingSharesMember 2020-06-01 2020-06-02 0001805890 fusn:ClassBConvertiblePreferredSharesMember 2020-01-31 0001805890 fusn:ClassBPreferredExchangableSharesMember 2020-01-31 0001805890 fusn:SpecialVotingSharesMember 2020-01-31 0001805890 2020-01-01 2020-01-31 0001805890 2020-01-31 0001805890 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001805890 us-gaap:WarrantMember 2020-10-17 0001805890 fusn:TwoThousandTwentyStockOptionAndIncentivePlanMember 2020-09-30 0001805890 fusn:TwoThousandTwentyStockOptionAndIncentivePlanMember 2020-01-01 2020-09-30 0001805890 fusn:TwoThousandSeventeenEquityIncentivePlanMember 2020-09-30 0001805890 fusn:TwoThousandSeventeenEquityIncentivePlanMember 2019-12-31 0001805890 fusn:TwoThousandTwentyEmployeeSharePurchasePlanMember 2020-09-30 0001805890 fusn:TwoThousandTwentyEmployeeSharePurchasePlanMember 2020-01-01 2020-09-30 0001805890 2019-01-01 2019-12-31 0001805890 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001805890 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001805890 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001805890 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001805890 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001805890 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001805890 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001805890 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001805890 fusn:CentreForProbeDevelopmentAndCommercializationIncMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:CentreForProbeDevelopmentAndCommercializationIncMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2019-01-01 2019-09-30 0001805890 fusn:CentreForProbeDevelopmentAndCommercializationIncMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:CentreForProbeDevelopmentAndCommercializationIncMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:ImmunoGenIncMember fusn:ResearchAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:ImmunoGenIncMember srt:MaximumMember fusn:DevelopmentAndRegulatoryMilestonesMember fusn:ResearchAndLicenseAgreementMember 2020-09-30 0001805890 fusn:ImmunoGenIncMember srt:MaximumMember fusn:SalesBasedMilestonesMember fusn:ResearchAndLicenseAgreementMember 2020-09-30 0001805890 fusn:ImmunoGenIncMember fusn:DevelopmentAndRegulatoryMilestonesMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:ImmunoGenIncMember fusn:DevelopmentAndRegulatoryMilestonesMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:ImmunoGenIncMember fusn:DevelopmentAndRegulatoryMilestonesMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:ImmunoGenIncMember fusn:DevelopmentAndRegulatoryMilestonesMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:ResearchAndLicenseAgreementMember 2019-01-01 2019-09-30 0001805890 fusn:ImmunoGenIncMember fusn:ResearchAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:ImmunoGenIncMember fusn:ResearchAndLicenseAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:JanssenBiotechIncMember fusn:ResearchAndLicenseAgreementMember fusn:FirstJanssenAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:JanssenBiotechIncMember fusn:ResearchAndLicenseAgreementMember fusn:FirstJanssenAgreementMember 2019-01-01 2019-09-30 0001805890 fusn:ImmunoGenIncMember fusn:SecondJanssenAgreementMember fusn:ResearchAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:ImmunoGenIncMember fusn:SecondJanssenAgreementMember fusn:ResearchAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:ImmunoGenIncMember fusn:SecondJanssenAgreementMember fusn:ResearchAndLicenseAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:ImmunoGenIncMember fusn:SecondJanssenAgreementMember fusn:ResearchAndLicenseAgreementMember 2019-01-01 2019-09-30 0001805890 fusn:IsogenicaLtdMember fusn:ResearchAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:IsogenicaLtdMember fusn:ResearchAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:IsogenicaLtdMember fusn:ResearchAndLicenseAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:IsogenicaLtdMember fusn:ResearchAndLicenseAgreementMember 2019-01-01 2019-09-30 0001805890 fusn:IsogenicaLtdMember fusn:ResearchAndLicenseAgreementMember us-gaap:LicenseMember 2019-07-01 2019-09-30 0001805890 fusn:MediaPharmaSRLMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:MediaPharmaSRLMember fusn:DevelopmentAndRegulatoryMilestonesMember fusn:AssetAcquisitionAndLicenseAgreementMember srt:MaximumMember 2020-09-30 0001805890 fusn:MediaPharmaSRLMember fusn:SalesBasedMilestonesMember fusn:AssetAcquisitionAndLicenseAgreementMember srt:MaximumMember 2020-09-30 0001805890 fusn:MediaPharmaSRLMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:MediaPharmaSRLMember fusn:AssetAcquisitionAndLicenseAgreementMember 2019-07-01 2019-09-30 0001805890 fusn:MediaPharmaSRLMember fusn:AssetAcquisitionAndLicenseAgreementMember 2019-01-01 2019-09-30 0001805890 fusn:RainierTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-01-01 2020-03-31 0001805890 fusn:RainierTherapeuticsIncMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember fusn:DevelopmentAndRegulatoryMilestonesMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember fusn:SalesBasedMilestonesMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember srt:MinimumMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember srt:MaximumMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001805890 fusn:RainierTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001805890 fusn:GenentechIncMember srt:MaximumMember fusn:SalesBasedMilestonesMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:GenentechIncMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:GenentechIncMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 fusn:YumabGmbHMember fusn:DevelopmentAndRegulatoryMilestonesMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-09-30 0001805890 fusn:YumabGmbHMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-07-01 2020-09-30 0001805890 fusn:YumabGmbHMember fusn:AssetAcquisitionAndLicenseAgreementMember 2020-01-01 2020-09-30 0001805890 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001805890 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001805890 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0001805890 fusn:PreferredExchangeableSharesMember 2019-01-01 2019-09-30 0001805890 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001805890 2020-07-01 2020-07-31 0001805890 2019-10-01 2019-10-31 0001805890 us-gaap:LetterOfCreditMember 2020-06-30 0001805890 us-gaap:LetterOfCreditMember 2019-12-31 0001805890 fusn:CPDCMember 2020-09-30 0001805890 fusn:CPDCMember 2020-07-01 2020-09-30 0001805890 fusn:CPDCMember 2019-07-01 2019-09-30 0001805890 fusn:CPDCMember 2020-01-01 2020-09-30 0001805890 fusn:CPDCMember 2019-01-01 2019-09-30 0001805890 fusn:CPDCMember 2019-12-31 0001805890 fusn:CPDCMember srt:MaximumMember 2020-07-01 2020-09-30 0001805890 fusn:CPDCMember srt:MaximumMember 2019-07-01 2019-09-30 0001805890 country:US 2020-09-30 0001805890 country:US 2019-12-31 0001805890 country:CA 2020-09-30 0001805890 country:CA 2019-12-31 0001805890 us-gaap:SubsequentEventMember 2020-10-06 2020-10-08 0001805890 us-gaap:SubsequentEventMember fusn:StrategicCollaborationAgreementMember fusn:AstraZenecaUKLimitedMember 2020-10-30 2020-10-30 10-Q false 2020-09-30 2020 Q3 FUSN Fusion Pharmaceuticals Inc. 0001805890 --12-31 Non-accelerated Filer true true false 41725797 001-39344 270 Longwood Rd., S. Hamilton ON CA L8P 0A6 289 799-0891 false Yes Yes true false CA Common shares, no par value per share NASDAQ

248793000

65344000

280000

43159000

4652000

929000

296884000

66553000

1981000

1272000

106000

78000

1465000

1497000

11102000

521000

312059000

69400000

956000

830000

4353000

3326000

117000

5309000

4273000

3000

28000

5741000 293000 293000

5605000

10335000

20961000 71592000

406273000

1286000

-1000

-99818000

-34774000

306454000

-33488000

312059000

69400000

132207290

73125790

77965000

41702384

1929555

41702384

1929555

4529000

2238000

12231000

7216000

5790000

1922000

14105000

4864000

10319000

4160000

26336000

12080000

-10319000

-4160000

-26336000

-12080000

3485000 -32722000 3707000 -6399000

80000

247000

249000

395000

41000 44000 139000 132000

20000

-29000

148000

76000

141000

3747000

-38585000

4310000

-10178000

-413000

-64921000

-7770000

-185000

181000

27000

213000

-9993000

-594000

-64948000

-7983000

-1000

-9994000

-594000

-64949000

-7983000

1382000

-9993000

-594000

-66330000

-7983000

-0.24

-0.31

-4.30

-4.18

41682797

1929555

15422375

1910695

20961000

73125790

71592000

1929555

1286000

-34774000

6598917

9907000

1105000 1286000 96000 1382000

358000

-10222000

20961000

79724707

80394000

1929555

358000

-45092000

-44734000

36806039

55769000

6722000

4257000 35311000 -31940000 28874378 31940000

-145405124

-203414000

27234489

203414000

7781000 7781000

12500000

193053000

426000

-44733000

41664044

405032000

-89825000

315207000

38340000

1241000

-1000

-9993000

41702384

406273000

-99818000

-1000

93000

6000

299000

2000

13000

19447000

15168000

42918661

32371000

1872975

668000

-18585000

-17917000

30207129

45476000

6711000

918000 6255000

102000

-3933000

20961000

73125790

71592000

1872975

770000

-22518000

-21748000

56580

88000

-3456000

20961000

73125790

71592000

1929555

858000

-25974000

-25116000

138000

-594000

20961000

73125790

71592000

1929555

996000

-26568000

-25572000

-64948000

-7983000

2025000

328000

373000

213000

3000 -2000

32722000

-3707000

6399000

-24000

-28000

3792000

-16000

521000

150000

408000

1025000

719000

-117000

151000

-26685000

-9857000

54286000

1063000

340000

-55349000

-340000

65676000 45476000 6722000 6711000

197625000

4572000

265451000

52187000

183417000

41990000

67121000

29080000

250538000

71070000

280000

40000

4000 57000 1382000

<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> 3.</td> <td valign="top"> Fair Value Measurements </td></tr></table></div> The following tables present information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020 Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,670</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,670</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,862</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,862</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government agencies</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,998</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,998</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government agencies</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,670</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,790</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019 Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred share tranche right liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> During the year ended December 31, 2019 and the nine months ended September 30, 2020, there were no transfers between Level 1, Level 2 and Level 3. <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Valuation of Preferred Share Tranche Right Liability The preferred share tranche right liability in the table below is composed of the fair value of rights to purchase Class B convertible preferred shares and Class B preferred exchangeable shares with Class B special voting shares (see Note 7). The fair value of the preferred share tranche right liability was determined based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The fair value of the preferred share tranche right liability was determined using the forward contract pricing model, which considered as inputs the probability and timing of achieving the specified milestones as of each valuation date, the estimated fair value of the preferred shares as of each valuation date, and the risk-free interest rate. The most significant assumption in the forward contract pricing model impacting the fair value of the preferred share tranche right liability is the fair value of the Company’s Class B convertible preferred shares as of each measurement date. The Company determines the fair value per share of the underlying Class B convertible preferred shares by taking into consideration the most recent sales of its convertible preferred shares, results obtained from third-party valuations and additional factors the Company deems relevant. As of June 2, 2020, the date of final measurement as described below, and December 31, 2019, the fair value of each Class B convertible preferred share was $2.47 per share and $1.45 per share, respectively. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time period of achievement of the specified milestones underlying the preferred share tranche rights. The preferred share tranche right liability was initially recorded at fair value upon the date of issuance of each preferred share tranche right and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share tranche right liability are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Changes in the fair value of the preferred share tranche right liability will continue to be recognized until the respective preferred share tranche right is settled upon achievement of the specified milestones or expires.   <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right (see Note 7), which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 36,806,039 Class B preferred shares at a price of $1.5154 per share and 4,437,189 Class B special voting shares at a price of $0.000001 per share and the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share, for aggregate gross proceeds of $62.5 million. <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet. <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Valuation of Preferred Share Warrant Liability The preferred share warrant liability in the table below is composed of the fair value of warrants to purchase Class B convertible preferred shares of the Company and warrants to purchase Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited that were issued in January 2020 in connection with the Company’s Class B preferred share financing (see Note 7). The fair value of the preferred share warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the preferred share warrant liability was determined using a hybrid method, which is a probability-weighted expected return method, or PWERM, where the equity value in one or more of the scenarios is calculated using an option-pricing model, or OPM. The PWERM is a scenario-based methodology that estimates the fair value of the Company’s different classes of equity based upon an analysis of future values for the Company, assuming various outcomes. Under both models, assumptions and estimates are used to value the preferred share warrants. The Company assesses these assumptions and estimates on a quarterly basis as additional information impacting the assumptions is obtained. The quantitative elements associated with the Company’s Level 3 inputs impacting the fair value measurement of the preferred share warrant liability include the fair value per share of the underlying Class B convertible preferred shares, the timing, form and overall value of the expected exits for the shareholders, the risk-free interest rate, the expected dividend yield and the expected volatility of the Company’s shares. The most significant assumption impacting the fair value of the preferred share warrant liability is the fair value of the Company’s Class B convertible preferred shares as of each measurement date. The Company determines the fair value per share of the underlying Class B convertible preferred shares by taking into consideration the most recent sales of its preferred shares, results obtained from third-party valuations and additional factors it deems relevant. In January 2020, upon issuance of the preferred share warrants, the fair value of each Class B convertible preferred share was $1.45 per share. As of June 2, 2020, the date of final measurement of the preferred share tranche right liability as described below, the fair value of each Class B convertible preferred share was $2.47 per share. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company estimated a 0% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared cash dividends. The preferred share warrant liability was initially recorded at fair value upon the date the warrants were issued and exercisable and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share warrant liability are recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Changes in the fair value of the preferred share warrant liability will continue to be recognized until each respective warrant is exercised, expires or qualifies for equity classification. Upon the closing of the IPO, the warrants to purchase its convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase shares of the Company’s common shares.  As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) as the warrants qualify for equity classification. The following table provides a roll-forward of the aggregate fair value of the Company’s preferred share tranche right liability and preferred share warrant liability, for which fair value is determined using Level 3 inputs (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Tranche <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Right Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Warrant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of Class B preferred share tranche right liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,105</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of Class B preferred share warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of Class B preferred share tranche right liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,722</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of Class B preferred share warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,399</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Class B preferred share tranche right liability upon settlement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,568</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Class B preferred shares warrants into common share warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,781</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> 8.</td> <td valign="top"> Share-based Compensation </td></tr></table></div> 2020 Stock Option and Incentive Plan On June 18, 2020, the Company’s board of directors adopted the 2020 Stock Option and Incentive Plan (the “2020 Plan”), which became effective on June 24, 2020. The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, non-employee directors and consultants. The number of shares initially reserved for issuance under the 2020 Plan was 4,273,350, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 4% of the number of the Company’s common shares outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s compensation committee of the board of directors. The common shares underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of shares, expire or are otherwise terminated (other than by exercise) under the 2020 Plan and the 2017 Plan will be added back to the common shares available for issuance under the 2020 Plan. The total number of common shares reserved for issuance under the 2020 Plan was 4,273,350 shares as of September 30, 2020. As of September 30, 2020, 2,933,366 shares, remained available for future grant under the 2020 Plan. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2020 Plan.   <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2017 Equity Incentive Plan The Company’s 2017 Equity Incentive Plan (the “2017 Plan”) provides for the Company to grant incentive stock options or nonqualified stock options, restricted share awards and restricted share units to employees, officers, directors and non-employee consultants of the Company. The total number of common shares reserved for issuance under the 2017 Plan was 0 and 4,700,393 shares as of September 30, 2020 and December 31, 2019, respectively. As of September 30, 2020 and December 31, 2019, 0 shares and 1,598,512 shares, respectively, remained available for future grant under the 2017 Plan. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2020 Plan. <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Employee Share Purchase Plan On June 18, 2020, the Company’s board of directors adopted the 2020 Employee Share Purchase Plan (the “ESPP”), which became effective on June 24, 2020. A total of 450,169 common shares were reserved for issuance under this plan. In addition, the number of common shares that may be issued under the ESPP will automatically increase on January 1, 2021 and each January 1 thereafter by the lesser of (i) 900,338 common shares, (ii) 1% of the number of the Company’s common shares outstanding on the immediately preceding December 31 and (iii) such lesser number of shares as determined by the Company’s compensation committee of the board of directors.   As of September 30, 2020, no shares were issued under the ESPP. <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Option Valuation The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected share volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.70</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> Stock Options The following table summarizes the Company’s stock option activity since December 31, 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,045,301</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.66</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,112</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,346,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/cancelled</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,480</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.63</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,266,466</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.95</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,696</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of September 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,266,466</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.95</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,696</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,810,276</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.51</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,699</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common shares for those options that had exercise prices lower than the fair value of the Company’s common shares. There were no stock options exercised during the nine months ended September 30, 2020 and 2019. The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2020 and 2019 was $11.54 and $2.33 per share, respectively. Share-based Compensation Share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">506</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,519</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,241</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of September 30, 2020, total unrecognized share-based compensation expense related to unvested share-based awards was $15.8 million, which is expected to be recognized over a weighted-average period of 3.0 years.

<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Closing of Class B Preferred Share Financing and Settlement of Class B Preferred Share Tranche Right Liability <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right (see Note 7), which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 36,806,039 Class B preferred shares at a price of $1.5154 per share and 4,437,189 Class B special voting shares at a price of $0.000001 per share and the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share, for aggregate gross proceeds of $62.5 million. <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet. <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Share Split <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 19, 2020, the Company effected a one-for-5.339 reverse share split of its issued and outstanding common shares and a proportional adjustment to the existing conversion ratios for each class of the Company’s Preferred Shares (see Note 7) and Preferred Exchangeable Shares (see Note 7). Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse share split and adjustment of the preferred share conversion ratios. <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public Offering <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 25, 2020, the Company completed an initial public offering (“IPO”) of its common shares and issued and sold 12,500,000 common shares at a public offering price of $17.00 per share, resulting in net proceeds of $193.1 million after deducting underwriting fees, and after deducting offering costs. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon closing of the IPO, the Company’s outstanding Preferred Exchangeable Shares automatically converted into convertible preferred shares then the outstanding convertible preferred shares automatically converted into shares of common shares (see Note 7). Upon conversion of the convertible preferred shares, the Company reclassified the carrying value of the convertible preferred shares to common shares and additional paid-in capital.  In addition, the warrants to purchase the Company’s Series B convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase the Company’s common shares upon the closing of the IPO. As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) (see Note 3). <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO on June 25, 2020, the Company filed an amended and restated articles of the corporation under laws governed by the Canada Business Corporations Act to authorize unlimited common shares with no par value.

<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of its convertible preferred shares, including borrowings under a convertible promissory note, which converted into convertible preferred shares, proceeds from sales of its Ireland subsidiary’s preferred exchangeable shares, and most recently with the proceeds from the IPO completed in June 2020. The Company has incurred recurring losses since its inception, including net losses of $10.0 million and $64.9 million for the three and nine months ended September 30, 2020, respectively and net losses of $0.6 million and $8.0 million for the three and nine months ended September 30, 2019, respectively. In addition, as of September 30, 2020, the Company had an accumulated deficit of $99.8 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.

Impact of the COVID-19 Pandemic The COVID-19 pandemic, which began in December 2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to enroll additional patient cohorts on its planned timeline due to disruptions at its clinical trial sites and is unable to predict how the COVID-19 pandemic may affect its ability to successfully progress its clinical programs in the future. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the potential impact of the COVID-19 pandemic on its business and condensed consolidated financial statements. To date, the Company has not experienced material business disruptions or incurred impairment losses in the carrying values of its assets as a result of the pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these condensed consolidated financial statements.

<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of common shares, stock options, preferred share tranche rights and preferred share warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Investments   The Company determines the appropriate classification of its investments in debt securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company classifies its investments as current or non-current based on each instrument’s underlying maturity date. Investments with original maturities of greater than three months and less than twelve months are classified as current and are included in short-term investments in the condensed consolidated balance sheets. Investments with original maturities greater than one year from the balance sheet date are classified as non-current and are included in long-term investments in the condensed consolidated balance sheets. The Company’s investments are classified as available-for-sale, are reported at fair value and consist of U.S. government agency securities, corporate bonds, and commercial paper. Unrealized gains and losses included in other comprehensive income (loss) as a component of shareholders’ equity (deficit) until realized. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains and losses on debt securities are included in other income (expense), net.   If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company’s condensed consolidated statements of operations and comprehensive loss.

<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> •</td> <td valign="top"> Level 1—Quoted prices in active markets for identical assets or liabilities. </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> •</td> <td valign="top"> Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> •</td> <td valign="top"> Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </td></tr></table></div> Prior to the settlement of the Company’s preferred share tranche right liability and prior to the conversion of the Company’s preferred share warrant liability, these instruments were carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (see Note 3). The Company’s cash equivalents and investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s amounts due for refundable investment tax credits and Canadian harmonized sales tax, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.

<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Share Tranche Right Liability The subscription agreements for the Company’s Class B convertible preferred shares (see Note 7) and its Ireland subsidiary’s Class B preferred exchangeable shares (see Note 7) provides investors the right, or obligates investors, to participate in subsequent offerings of Class B convertible preferred shares or Class B preferred exchangeable shares together with Class B special voting shares in the event that specified development or regulatory milestones are achieved (the “Class B preferred share tranche right liability”). The Company classifies these preferred share tranche rights as a liability on its consolidated balance sheets as each preferred share tranche right is a freestanding financial instrument that may require the Company to transfer assets upon the achievement of specified milestone events. Each preferred share tranche right liability was initially recorded at fair value upon the date of issuance of each preferred share tranche right and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share tranche right liability are recognized as a component of other income (expense) in the consolidated statement of operations and comprehensive loss. Changes in the fair value of the preferred share tranche right liability will continue to be recognized until the respective preferred share tranche right is settled upon achievement of the specified milestones or expires.   <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right (see Note 7), which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 36,806,039 Class B preferred shares at a price of $1.5154 per share and 4,437,189 Class B special voting shares at a price of $0.000001 per share and the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share, for aggregate gross proceeds of $62.5 million. <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet. <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Share Warrant Liability The Company classifies warrants to purchase its convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited as a liability on its consolidated balance sheets as these warrants are freestanding financial instruments that may require the Company to transfer assets upon exercise (see Note 7). The preferred share warrant liability, which consists of warrants to purchase Class B convertible preferred shares of the Company and warrants to purchase Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited, was initially recorded at fair value upon the date of issuance of each warrant and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred share warrant liability are recognized as a component of other income (expense) in the consolidated statement of operations and comprehensive loss. Changes in the fair value of the preferred share warrant liability will continue to be recognized until each respective warrant is exercised, expires or qualifies for equity classification. Upon the closing of the IPO, the warrants to purchase its convertible preferred shares and warrants to purchase preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited were converted into warrants to purchase shares of the Company’s common shares.  As a result, the warrant liability was remeasured a final time on the closing date of the IPO and reclassified to shareholders’ equity (deficit) as the warrants qualify for equity classification.

<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements The Company qualifies as “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to “opt in” to the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or financing lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing leases. Leases with a term of 12 months or less may be accounted for similar to prior guidance for operating leases today. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented. This guidance is effective for the Company for annual periods beginning after December 15, 2021, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. This guidance is effective for the Company for annual periods beginning after December 15, 2022, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.

The following tables present information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020 Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,670</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,670</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,862</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,862</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government agencies</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,998</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,998</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government agencies</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,670</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,790</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019 Using:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred share tranche right liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table provides a roll-forward of the aggregate fair value of the Company’s preferred share tranche right liability and preferred share warrant liability, for which fair value is determined using Level 3 inputs (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Tranche <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Right Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Warrant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of Class B preferred share tranche right liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,105</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of Class B preferred share warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of Class B preferred share tranche right liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,722</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of Class B preferred share warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,399</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Class B preferred share tranche right liability upon settlement</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,568</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Class B preferred shares warrants into common share warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,781</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Investments consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due within one year or less</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,160</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,159</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due after one year through three years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,262</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

As of September 30, 2020, the amortized cost and estimated fair value of investments, by contractual maturity, was as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government agencies</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,363</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,260</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,102</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,262</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,261</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,159</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Prepaid expenses and other current assets consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical trial expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,136</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software subscriptions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canadian harmonized sales tax receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refundable investment tax credits</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,652</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">929</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Accrued expenses consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation and benefits</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,524</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">991</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued external research and development expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,565</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">744</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,353</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,326</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.70</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

Share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">506</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,519</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,241</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Basic and diluted net loss per share attributable to common shareholders was calculated as follows (in thousands, except share and per share amounts):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,993</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,948</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,983</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends paid to preferred shareholders in the form of <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   warrants issued</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,382</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,993</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,330</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,983</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding—basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,682,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,929,555</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,422,375</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,695</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders —basic <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.24</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.31</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.18</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

The Company’s potentially dilutive securities, which include stock options, convertible preferred shares, preferred exchangeable shares and common share warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common shares</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,266,466</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687,413</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred shares (as converted to common shares)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,696,513</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred exchangeable shares (as converted to convertible <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   preferred shares and then to common shares)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,577,106</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651,816</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,918,282</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,961,032</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Future minimum lease payments due under operating leases as of September 30, 2020 are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (three months)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,117</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,147</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,208</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,592</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,515</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The Company recognized expenses in connection with the services performed under the Master Services Agreement and the Supply Agreement in the consolidated statements of operations and comprehensive loss as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">844</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Information about the Company’s long-lived assets, consisting solely of property and equipment, net, by geographic region was as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canada</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,866</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,145</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,272</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

2014-12-31

2020-06-02

36806039

1.5154

4437189

0.000001

4437189

1.5154

62500000

32700000 39600000 35300000 4300000

one-for-5.339

2020-06-25

12500000

17.00

193100000

-100000

100000

1500000

250500000

71100000

248800000

69300000

1700000

1800000

4600000

36806039

1.5154

4437189

0.000001

4437189

1.5154

62500000

32700000 39600000 35300000

4300000

28670000

2999000

1862000

20998000

6994000

905000

46362000

28670000

80120000

108790000

5741000

2.47 1.45 32700000 39600000 35300000

4300000

0.00 1.45

5741000

1105000 1382000 32722000 6399000 -39568000 -7781000

43160000

11102000

54262000

43159000

11102000

54261000

6994000

905000

46363000

54262000

1000

2000

6994000

905000

46362000

54261000

6994000

905000

35260000

43159000

11102000

-94000

3136000

11000

-173000 -129000

109000

229000

62000

-238000 -252000 315000 176000

452000

205000

1524000

991000

1715000 1565000

1048000

744000

66000 26000

4353000

3326000

0.187

12500000

17.00

193100000

Each common share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders.

132207290

30207129

1.5154

45800000

20000

1.5154

6598917

10000000

100000

1.5154

6598917 1100000 36806039

55800000

32700000 39600000 35300000

0.05339

28874378

29747987

0.001

28874378

29747987

0.000001

4437189

1.5154

4437189

0.000001

6700000

4437189

0.000001

4437189

1.5154

6700000

0.00187

3126391

1.5154

873609

1.5154

0.000001

P2Y 1400000

1300000

100000

749197

8.10

6400000

97381

38340

59041

651816

4273350

cumulatively increased on January 1, 2021 and each January 1 thereafter by 4% of the number of the Company’s common shares outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s compensation committee of the board of directors

0.04

2933366

4700393

1598512

450169

the number of common shares that may be issued under the ESPP will automatically increase on January 1, 2021 and each January 1 thereafter by the lesser of (i) 900,338 common shares, (ii) 1% of the number of the Company’s common shares outstanding on the immediately preceding December 31 and (iii) such lesser number of shares as determined by the Company’s compensation committee of the board of directors.

900338 0.01

0.0033

0.0158

0.0070

0.0158

P6Y

P5Y10M24D

P6Y

P5Y10M24D

0.670

0.645

0.655

0.645

0.00

3045301

2346645

125480

5266466

1810276

1.66

11.50

5.63

5.95

1.51

P8Y4M24D

P7Y

2112000

37696000

18699000

11.54

2.33

288000

37000

506000

110000

953000

101000

1519000

218000

1241000

138000

2025000

328000

15800000

P3Y

0 0 0 0 200000 15000000 35000000 0 0 0 500000

0 0

0 0 0 0

0 0 0 700000 600000

600000

400000

100000

200000 1500000 23000000

200000

1000000 3500000 313359 156679 22500000 42000000 0.10 0.30 1000000 1000000 0 44000000

3900000

200000

100000

-9993000

-594000

-66330000

-7983000

5266466

2687413

13696513

4577106

651816

5918282

20961032

100000 2023-07-31

2023-08-31

2025-09-30

P5Y P12M

false

1500000

In August 2018, the Company entered into an operating lease for office space in Hamilton, Ontario, Canada. This lease was amended in September 2020 (“New Lease Commencement Date”) with a new expiry date in August 2023. The lease can be renewed for an additional period of five years at the Company’s option, and if so renewed, can be terminated during the option period upon twelve months written notice any time after the fifth anniversary of the New Lease Commencement Date. In October 2019, the Company entered into an operating lease for office space in Boston, Massachusetts, which expires September 2025 and has no renewal options. In connection with entering into this lease agreement, the Company issued a letter of credit of $1.5 million, which is classified as restricted cash (non-current) on the consolidated balance sheets as of September 30, 2020 and December 31, 2019.

300000

100000

800000

200000

274000

1117000

1147000

1177000

1208000

1592000

6515000

800000

200000 800000

141000

326000

780000

785000

23000

16000

50000

59000

164000

342000

830000

844000

200000

1000000

500000

800000

100000

200000

100000 100000 100000 100000

115000

127000

1866000

1145000

2020-10-08

145000000 5000000 40000000

EX-101.SCH 8 fusn-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Nature of the Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Investments link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Equity link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Share-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - License Agreements and Asset Acquisitions link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Net Loss per Share link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Geographical Information link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Share-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Net Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Geographical Information (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Fair Value Measurements - Schedule of Fair Value from Preferred Share Tranche Liability and Warrant Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Investments - Schedule of Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Investments - Amortized Cost and Estimated Fair Value of Investments by Contractual Maturity (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Investments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Share-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Share-Based Compensation - Summary of Stock Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - License Agreements and Asset Acquisitions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Net Loss per Share - Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Commitments and Contingencies - Future Maturities of Lease Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Related Party Transactions - Schedule of Recognized Expenses in Connection with Services Performed Under Master Services Agreement and Supply Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Geographical Information - Schedule of Long-lived Assets by Geographic Areas (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 fusn-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 fusn-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 fusn-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Country Entity Address Country Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Shell Company Entity Shell Company Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Incorporation, State or Country Code Entity Incorporation State Country Code Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Preferred share tranche right liability. Income taxes payable noncurrent. Non-controlling interest by Parent. Convertible preferred shares. Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Consolidated Entities Consolidated Entities [Axis] Consolidated Entities Consolidated Entities [Domain] Fusion Pharmaceuticals (Ireland) Limited [Member] Subsidiaries [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Restricted cash Restricted Cash Current Short-term investments Short Term Investments Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Deferred tax assets Deferred Income Tax Assets Net Restricted cash Restricted Cash Noncurrent Long-term investments Long Term Investments Other non-current assets Other Assets Noncurrent Total assets Assets Liabilities, Non-Controlling Interest, Convertible Preferred Shares and Shareholders’ Equity (Deficit) Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Income taxes payable Accrued Income Taxes Current Total current liabilities Liabilities Current Deferred rent, net of current portion Deferred Rent Credit Noncurrent Preferred share tranche right liability Preferred Share Tranche Right Liability Income taxes payable, net of current portion Income Taxes Payable Noncurrent Special voting shares redemption right liability (Notes 2 and 7) Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 12) Commitments And Contingencies Non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited (Notes 2 and 7) Non Controlling Interest By Parent Convertible preferred shares, no par value; 0 shares and 132,207,290 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 0 shares and 73,125,790 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $77,965 as of September 30, 2020 and December 31, 2019, respectively Convertible Preferred Shares Shareholders’ equity (deficit): Stockholders Equity [Abstract] Common shares, no par value, unlimited shares authorized as of September 30, 2020 and December 31, 2019; 41,702,384 and 1,929,555 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders’ equity (deficit) Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities, non-controlling interest, convertible preferred shares and shareholders’ equity (deficit) Liabilities And Stockholders Equity Preferred stock, no par value Preferred Stock No Par Value Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Aggregation liquidity preference Temporary Equity Liquidation Preference Common stock, no par value Common Stock No Par Value Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Change in fair value of preferred share tranche right liability Change in fair value of preferred share warrant liability. Refundable investment tax credits Income Statement [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Other Nonoperating Income Expense [Abstract] Change in fair value of preferred share tranche right liability Change In Fair Value Of Preferred Share Tranche Right Liability Change in fair value of preferred share warrant liability Change In Fair Value Of Preferred Share Warrant Liability Interest income (expense), net Interest Income Expense Net Refundable investment tax credits Refundable Investment Tax Credits Other income (expense), net Other Nonoperating Income Expense Total other income (expense), net Nonoperating Income Expense Loss before (provision) benefit for income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax (provision) benefit Income Tax Expense Benefit Net loss Net Income Loss Unrealized loss on investments Unrealized Gain Loss On Investments Comprehensive loss Comprehensive Income Net Of Tax Reconciliation of net loss to net loss attributable to common shareholders: Net Income Loss Available To Common Stockholders Basic [Abstract] Net loss Dividends paid to preferred shareholders in the form of warrants issued Redeemable Preferred Stock Dividends Net loss attributable to common shareholders Net Income Loss Available To Common Stockholders Basic Net loss per share attributable to common shareholders—basic and diluted Earnings Per Share Basic And Diluted Weighted-average common shares outstanding—basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Shares of new stock classified as temporary equity issued during the period. Fair value adjustment of preferred share tranche right liability. Issuance of warrants to purchase preferred shares as a non-cash dividend to preferred shareholders. Reclassification of tranche right liability upon settlement. Conversion of Class A and B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) into Class A and B convertible preferred share. Conversion of Class A and B preferred exchangeable shares into Class A and convertible preferred shares. Conversion of convertible preferred share warrants into common share warrants. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Non-Controlling Interest in Fusion Pharmaceuticals (Ireland) Limited [Member] Noncontrolling Interest [Member] Class A and B Convertible Preferred Stock. Class A and B Convertible Preferred Shares [Member] Class A And B Convertible Preferred Stock [Member] Common Shares [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Net Investment Gain Loss Attributable To Noncontrolling Interest [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Class B Convertible Preferred Shares and Class B Preferred Share Tranche Right. Class B Convertible Preferred Shares and Class B Preferred Share Tranche Right [Member] Class B Convertible Preferred Shares And Class B Preferred Share Tranche Right [Member] Class B Preferred Exchangeable Shares and Class B Preferred Share Tranche Right. Class B Preferred Exchangeable Shares and Class B Preferred Share Tranche Right [Member] Class B Preferred Exchangeable Shares And Class B Preferred Share Tranche Right [Member] Class B Convertible Preferred Shares and Class B Preferred Exchangeable Shares. Class B Convertible Preferred Shares and Class B Preferred Exchangeable Shares [Member] Class B Convertible Preferred Shares And Class B Preferred Exchangeable Shares [Member] Beginning Balance Beginning Balance (in shares) Shares Outstanding Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs Temporary Equity Stock Issued During Period Value New Issues Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs (in shares) Temporary Equity Stock Issued During Period Shares New Issues Reclassification of Class B convertible preferred share and preferred exchangeable Reclassification Of Tranche Right Liability Upon Settlement Conversion of Class A and B preferred exchangeable shares into Class A and convertible preferred shares Conversion Of Preferred Exchangeable Shares Into Convertible Preferred Shares Conversion of Class A and B preferred exchangeable shares into Class A and B convertible preferred shares (in shares) Conversion Of Preferred Exchangeable Shares Into Class A And Convertible Preferred Shares Conversion of Class A and B convertible preferred shares into common shares Stock Issued During Period Value Conversion Of Convertible Securities Conversion of Class A and B convertible preferred shares into common shares (in shares) Stock Issued During Period Shares Conversion Of Convertible Securities Conversion of convertible preferred share warrants into common share warrants Conversion Of Convertible Preferred Share Warrants Into Common Share Warrants Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees Stock Issued During Period Value New Issues Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees (in shares) Stock Issued During Period Shares New Issues Issuance of common shares upon exercise of common share warrants (in shares) Stock Issued During Period Shares Stock Options Exercised Initial fair value of Class B convertible preferred share tranche right liability Fair Value Adjustment Of Preferred Share Tranche Right Liability Issuance of warrants to purchase Class B convertible preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders Issuance Of Warrants To Purchase Preferred Shares As Non Cash Dividend To Preferred Shareholders Share-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Ending Balance Ending Balance (in shares) Class B convertible preferred shares [Member]. Class B Convertible Preferred Shares and Class B Preferred Share Tranche Right [Member] Class B Convertible Preferred Shares [Member] Issuance of preferred shares and tranche right, issuance costs Payments Of Stock Issuance Costs Issuance of common shares upon closing of initial public offering, offering costs and underwriter fees Noninterest Expense Offering Cost Non-cash rent expense. Proceeds from issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs. Proceeds from issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs. Purchases of property and equipment included in accounts payable and accrued expenses. Issuance of common shares upon net settlement of stock option exercise. Issuance of warrants to purchase Class B preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Share-based compensation expense Share Based Compensation Depreciation and amortization expense Depreciation Depletion And Amortization Non-cash rent expense Non Cash Rent Expense Change in fair value of preferred share tranche right liability Adjustment Of Warrants Granted For Services Change in fair value of preferred share warrant liability Fair Value Adjustment Of Warrants Amortization of premiums (accretion of discounts) on investments, net Accretion Amortization Of Discounts And Premiums Investments Deferred tax benefit Deferred Income Tax Expense Benefit Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other non-current assets Increase Decrease In Other Noncurrent Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Income taxes payable Increase Decrease In Accrued Income Taxes Payable Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of investments Payments To Acquire Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs Proceeds From Issance Of Convertible Preferred Stocks Net Of Issuance Cost Proceeds from issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs Proceeds From Issuance Of Exchangeable Shares Tranche Right Net Of Issuance Cost Proceeds from the issuance of common shares upon closing of initial public offering, net of underwriter fees Proceeds From Issuance Initial Public Offering Payment of offering costs Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid Net Supplemental disclosure of non-cash investing and financing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Purchases of property and equipment included in accounts payable and accrued expenses Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses Issuance of common shares upon net settlement of stock option exercise Issuance Of Common Shares Upon Net Settlement Of Stock Option Exercise Issuance of warrants to purchase Class B preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders Issuance Of Exchangeable Preferred Shares Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of the Business and Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Investments Investment [Text Block] PrepaidExpenseAndOtherAssetsCurrentTextBlock Prepaid Expense And Other Assets Current [Abstract] Prepaid Expenses and Other Current Assets Prepaid Expense And Other Assets Current [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Equity [Abstract] Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Disclosure of license agreement and assets acquisitions. License agreement abstract. License Agreement [Abstract] License Agreements and Asset Acquisitions License Agreement And Asset Acquisitions [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss per Share EX-101.PRE 12 fusn-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 03, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	FUSN
Entity Registrant Name	Fusion Pharmaceuticals Inc.
Entity Central Index Key	0001805890
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		41,725,797
Entity File Number	001-39344
Entity Address, Address Line One	270 Longwood Rd., S.
Entity Address, City or Town	Hamilton
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L8P 0A6
City Area Code	289
Local Phone Number	799-0891
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	CA
Title of 12(b) Security	Common shares, no par value per share
Security Exchange Name	NASDAQ

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 248,793	$ 65,344
Restricted cash	280	280
Short-term investments	43,159
Prepaid expenses and other current assets	4,652	929
Total current assets	296,884	66,553
Property and equipment, net	1,981	1,272
Deferred tax assets	106	78
Restricted cash	1,465	1,497
Long-term investments	11,102
Other non-current assets	521
Total assets	312,059	69,400
Current liabilities:
Accounts payable	956	830
Accrued expenses	4,353	3,326
Income taxes payable		117
Total current liabilities	5,309	4,273
Deferred rent, net of current portion	3	28
Preferred share tranche right liability		5,741
Income taxes payable, net of current portion	293	293
Special voting shares redemption right liability (Notes 2 and 7)
Total liabilities	5,605	10,335
Commitments and contingencies (Note 12)
Convertible preferred shares, no par value; 0 shares and 132,207,290 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 0 shares and 73,125,790 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $77,965 as of September 30, 2020 and December 31, 2019, respectively		71,592
Shareholders’ equity (deficit):
Common shares, no par value, unlimited shares authorized as of September 30, 2020 and December 31, 2019; 41,702,384 and 1,929,555 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively
Additional paid-in capital	406,273	1,286
Accumulated other comprehensive income	(1)
Accumulated deficit	(99,818)	(34,774)
Total shareholders’ equity (deficit)	306,454	(33,488)
Total liabilities, non-controlling interest, convertible preferred shares and shareholders’ equity (deficit)	312,059	69,400
Fusion Pharmaceuticals (Ireland) Limited [Member]
Current liabilities:
Non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited (Notes 2 and 7)		$ 20,961

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, no par value
Preferred stock, shares authorized	0	132,207,290
Preferred stock, shares issued	0	73,125,790
Preferred stock, shares outstanding	0	73,125,790
Aggregation liquidity preference	$ 0	$ 77,965
Common stock, no par value
Common stock, shares issued	41,702,384	1,929,555
Common stock, shares outstanding	41,702,384	1,929,555

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 4,529	$ 2,238	$ 12,231	$ 7,216
General and administrative	5,790	1,922	14,105	4,864
Total operating expenses	10,319	4,160	26,336	12,080
Loss from operations	(10,319)	(4,160)	(26,336)	(12,080)
Other income (expense):
Change in fair value of preferred share tranche right liability		3,485	(32,722)	3,707
Change in fair value of preferred share warrant liability			(6,399)
Interest income (expense), net	80	247	249	395
Refundable investment tax credits	41	44	139	132
Other income (expense), net	20	(29)	148	76
Total other income (expense), net	141	3,747	(38,585)	4,310
Loss before (provision) benefit for income taxes	(10,178)	(413)	(64,921)	(7,770)
Income tax (provision) benefit	185	(181)	(27)	(213)
Net loss	(9,993)	(594)	(64,948)	(7,983)
Unrealized loss on investments	(1)		(1)
Comprehensive loss	(9,994)	(594)	(64,949)	(7,983)
Reconciliation of net loss to net loss attributable to common shareholders:
Net loss	(9,993)	(594)	(64,948)	(7,983)
Dividends paid to preferred shareholders in the form of warrants issued			(1,382)
Net loss attributable to common shareholders	$ (9,993)	$ (594)	$ (66,330)	$ (7,983)
Net loss per share attributable to common shareholders—basic and diluted	$ (0.24)	$ (0.31)	$ (4.30)	$ (4.18)
Weighted-average common shares outstanding—basic and diluted	41,682,797	1,929,555	15,422,375	1,910,695

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Class B Convertible Preferred Shares and Class B Preferred Exchangeable Shares [Member]	Non-Controlling Interest in Fusion Pharmaceuticals (Ireland) Limited [Member]	Non-Controlling Interest in Fusion Pharmaceuticals (Ireland) Limited [Member] Class B Preferred Exchangeable Shares and Class B Preferred Share Tranche Right [Member]	Class A and B Convertible Preferred Shares [Member]	Class A and B Convertible Preferred Shares [Member] Class B Convertible Preferred Shares and Class B Preferred Share Tranche Right [Member]	Common Shares [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Class B Convertible Preferred Shares and Class B Preferred Exchangeable Shares [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Class B Convertible Preferred Shares and Class B Preferred Exchangeable Shares [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2018	$ (17,917)		$ 15,168		$ 32,371			$ 668		$ (18,585)
Beginning Balance (in shares) at Dec. 31, 2018					42,918,661		1,872,975
Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs				$ 6,711		$ 45,476
Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs (in shares)						30,207,129
Initial fair value of Class B convertible preferred share tranche right liability			(918)		$ (6,255)
Share-based compensation expense	102							102
Net loss	(3,933)									(3,933)
Ending Balance at Mar. 31, 2019	(21,748)		20,961		$ 71,592			770		(22,518)
Ending Balance (in shares) at Mar. 31, 2019					73,125,790		1,872,975
Beginning Balance at Dec. 31, 2018	$ (17,917)		15,168		$ 32,371			668		(18,585)
Beginning Balance (in shares) at Dec. 31, 2018					42,918,661		1,872,975
Issuance of common shares upon exercise of common share warrants (in shares)	0
Net loss	$ (7,983)
Ending Balance at Sep. 30, 2019	(25,572)		20,961		$ 71,592			996		(26,568)
Ending Balance (in shares) at Sep. 30, 2019					73,125,790		1,929,555
Beginning Balance at Mar. 31, 2019	(21,748)		20,961		$ 71,592			770		(22,518)
Beginning Balance (in shares) at Mar. 31, 2019					73,125,790		1,872,975
Issuance of common shares upon exercise of common share warrants (in shares)							56,580
Share-based compensation expense	88							88
Net loss	(3,456)									(3,456)
Ending Balance at Jun. 30, 2019	(25,116)		20,961		$ 71,592			858		(25,974)
Ending Balance (in shares) at Jun. 30, 2019					73,125,790		1,929,555
Share-based compensation expense	138							138
Net loss	(594)									(594)
Ending Balance at Sep. 30, 2019	(25,572)		20,961		$ 71,592			996		(26,568)
Ending Balance (in shares) at Sep. 30, 2019					73,125,790		1,929,555
Beginning Balance at Dec. 31, 2019	(33,488)		20,961		$ 71,592			1,286		(34,774)
Beginning Balance (in shares) at Dec. 31, 2019					73,125,790		1,929,555
Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs						$ 9,907
Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs (in shares)						6,598,917
Initial fair value of Class B convertible preferred share tranche right liability					$ (1,105)
Issuance of warrants to purchase Class B convertible preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders		$ (1,382)							$ (1,286)		$ (96)
Share-based compensation expense	358							358
Net loss	(10,222)									(10,222)
Ending Balance at Mar. 31, 2020	(44,734)		20,961		$ 80,394			358		(45,092)
Ending Balance (in shares) at Mar. 31, 2020					79,724,707		1,929,555
Beginning Balance at Dec. 31, 2019	$ (33,488)		20,961		$ 71,592			1,286		(34,774)
Beginning Balance (in shares) at Dec. 31, 2019					73,125,790		1,929,555
Issuance of common shares upon exercise of common share warrants (in shares)	0
Unrealized loss on investments	$ (1)
Net loss	(64,948)
Ending Balance at Sep. 30, 2020	306,454							406,273		(99,818)		$ (1)
Ending Balance (in shares) at Sep. 30, 2020							41,702,384
Beginning Balance at Mar. 31, 2020	(44,734)		20,961		$ 80,394			358		(45,092)
Beginning Balance (in shares) at Mar. 31, 2020					79,724,707		1,929,555
Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs				$ 6,722		$ 55,769
Issuance of Class B convertible/exchangeable preferred shares and Class B preferred share tranche right, net of issuance costs (in shares)						36,806,039
Reclassification of Class B convertible preferred share and preferred exchangeable			4,257		$ 35,311
Conversion of Class A and B preferred exchangeable shares into Class A and convertible preferred shares			$ (31,940)		$ 31,940
Conversion of Class A and B preferred exchangeable shares into Class A and B convertible preferred shares (in shares)					28,874,378
Conversion of Class A and B convertible preferred shares into common shares	203,414				$ (203,414)			203,414
Conversion of Class A and B convertible preferred shares into common shares (in shares)					(145,405,124)		27,234,489
Conversion of convertible preferred share warrants into common share warrants	7,781							7,781
Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees	193,053							193,053
Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees (in shares)							12,500,000
Share-based compensation expense	426							426
Net loss	(44,733)									(44,733)
Ending Balance at Jun. 30, 2020	315,207							405,032		(89,825)
Ending Balance (in shares) at Jun. 30, 2020							41,664,044
Issuance of common shares upon exercise of common share warrants (in shares)							38,340,000
Share-based compensation expense	1,241							1,241
Unrealized loss on investments	(1)											(1)
Net loss	(9,993)									(9,993)
Ending Balance at Sep. 30, 2020	$ 306,454							$ 406,273		$ (99,818)		$ (1)
Ending Balance (in shares) at Sep. 30, 2020							41,702,384

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2019
Issuance of common shares upon closing of initial public offering, offering costs and underwriter fees	$ 19,447
Class B Convertible Preferred Shares and Class B Preferred Share Tranche Right [Member]
Issuance of preferred shares and tranche right, issuance costs	6	$ 299
Class B Preferred Exchangeable Shares and Class B Preferred Share Tranche Right [Member]
Issuance of preferred shares and tranche right, issuance costs	$ 2	$ 13

XML 19 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (64,948)	$ (7,983)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	2,025	328
Depreciation and amortization expense	373	213
Non-cash rent expense	3	(2)
Change in fair value of preferred share tranche right liability	32,722	(3,707)
Change in fair value of preferred share warrant liability	6,399
Amortization of premiums (accretion of discounts) on investments, net	24
Deferred tax benefit	(28)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,792)	16
Other non-current assets	(521)
Accounts payable	150	408
Accrued expenses	1,025	719
Income taxes payable	(117)	151
Net cash used in operating activities	(26,685)	(9,857)
Cash flows from investing activities:
Purchases of investments	(54,286)
Purchases of property and equipment	(1,063)	(340)
Net cash used in investing activities	(55,349)	(340)
Cash flows from financing activities:
Proceeds from issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs	65,676	45,476
Proceeds from issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs	6,722	6,711
Proceeds from the issuance of common shares upon closing of initial public offering, net of underwriter fees	197,625
Payment of offering costs	(4,572)
Net cash provided by financing activities	265,451	52,187
Net increase in cash, cash equivalents and restricted cash	183,417	41,990
Cash, cash equivalents and restricted cash at beginning of period	67,121	29,080
Cash, cash equivalents and restricted cash at end of period	250,538	71,070
Supplemental disclosure of cash flow information:
Cash paid for income taxes	280	40
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses		4
Issuance of common shares upon net settlement of stock option exercise		$ 57
Issuance of warrants to purchase Class B preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders	$ 1,382

XML 20 R8.htm IDEA: XBRL DOCUMENT

Nature of the Business and Basis of Presentation

9 Months Ended

Sep. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of the Business and Basis of Presentation

1.	Nature of the Business and Basis of Presentation

Closing of Class B Preferred Share Financing and Settlement of Class B Preferred Share Tranche Right Liability

Reverse Share Split

Initial Public Offering

Basis of Presentation

Impact of the COVID-19 Pandemic

XML 21 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Use of Estimates

Unaudited Interim Financial Information

Foreign Currency and Currency Translation

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of standard checking accounts, money market accounts, and all highly liquid investments with an original maturity of three months or less at the date of purchase.

Investments

Deferred Offering Costs

Business Combinations

To date, the Company has not recorded any asset acquisitions as a business combination.

Asset Acquisitions

Fair Value Measurements

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Preferred Share Tranche Right Liability

The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Preferred Share Warrant Liability

Research, Development and Manufacturing Contract Costs and Accruals

Net Loss per Share

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

XML 22 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements

	Fair Value Measurements as of September 30, 2020 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	28,670	$	—	$	—	$	28,670
Commercial paper		—		2,999		—		2,999
Corporate bonds		—		1,862		—		1,862
U.S. Government agencies		—		20,998		—		20,998
Investments:
Commercial paper		—		6,994		—		6,994
Corporate bonds		—		905		—		905
U.S. Government agencies		—		46,362		—		46,362
	$	28,670	$	80,120	$	—	$	108,790

	Fair Value Measurements as of December 31, 2019 Using:
	Level 1		Level 2		Level 3		Total
Liabilities:
Preferred share tranche right liability	$	—	$	—	$	5,741	$	5,741
	$	—	$	—	$	5,741	$	5,741

During the year ended December 31, 2019 and the nine months ended September 30, 2020, there were no transfers between Level 1, Level 2 and Level 3.

Valuation of Preferred Share Tranche Right Liability

The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Valuation of Preferred Share Warrant Liability

	Preferred Share Tranche Right Liability			Preferred Share Warrant Liability
Balance as of December 31, 2019	$	5,741		$	—
Initial fair value of Class B preferred share tranche right liability		1,105			—
Initial fair value of Class B preferred share warrant liability		—			1,382
Change in fair value of Class B preferred share tranche right liability		32,722			—
Change in fair value of Class B preferred share warrant liability		—			6,399
Reclassification of Class B preferred share tranche right liability upon settlement		(39,568	)		—
Conversion of Class B preferred shares warrants into common share warrants		—			(7,781	)
Balance as of September 30, 2020	$	—		$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Investments

9 Months Ended

Sep. 30, 2020

Investments Debt And Equity Securities [Abstract]

Investments

4.	Investments

Investments consisted of the following (in thousands):

	September 30, 2020
	Amortized Cost		Fair Value
Due within one year or less	$	43,160	$	43,159
Due after one year through three years		11,102		11,102
	$	54,262	$	54,261

As of September 30, 2020, the amortized cost and estimated fair value of investments, by contractual maturity, was as follows (in thousands):

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Current		Non-Current
Commercial paper	$	6,994	$	—	$	—		$	6,994	$	6,994	$	—
Corporate bonds		905		—		—			905		905		—
U.S. Government agencies		46,363		1		(2	)		46,362		35,260		11,102
	$	54,262	$	1	$	(2	)	$	54,261	$	43,159	$	11,102

The Company did not hold any investments as of December 31, 2019.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2020

Prepaid Expense And Other Assets Current [Abstract]

Prepaid Expenses and Other Current Assets

5.	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Prepaid clinical trial expenses	$	—	$	94
Prepaid insurance		3,136		11
Prepaid software subscriptions		173		129
Income tax receivable		109		—
Interest receivable		229		62
Canadian harmonized sales tax receivable		238		252
Refundable investment tax credits		315		176
Other		452		205
	$	4,652	$	929

XML 25 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2020

Payables And Accruals [Abstract]

Accrued Expenses

6.	Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Accrued employee compensation and benefits	$	1,524	$	991
Accrued external research and development expenses		1,715		1,565
Accrued professional and consulting fees		1,048		744
Other		66		26
	$	4,353	$	3,326

XML 26 R14.htm IDEA: XBRL DOCUMENT

Equity

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Equity

Common Shares

On June 19, 2020, the Company effected a one-for-5.339 reverse share split of its issued and outstanding common shares and a proportional adjustment to the existing conversion ratios for each class of the Company’s Preferred Shares and Preferred Exchangeable Shares. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse share split and adjustment of the preferred share conversion ratios.

As of September 30, 2020, the Company’s articles of the corporation, as amended and restated, authorized the Company to issue unlimited common shares, each with no par value per share.

Convertible Preferred Shares

Upon the closing of the IPO, the Company converted the then outstanding Class A and Class B preferred shares into common shares at a conversion ratio of 5.339 Preferred Share to one common share.

Preferred Exchangeable Shares and Special Voting Shares

In May 2020, the Company achieved the specified regulatory milestone associated with the Class B preferred share tranche right, which triggered the requirement of the Class B shareholders to participate in the Milestone Financing. Upon closing of the Milestone Financing on June 2, 2020, the Company issued and sold 4,437,189 Class B special voting shares at a price of $0.000001 per share and the Company’s Ireland subsidiary issued and sold 4,437,189 Class B preferred exchangeable shares at a price of $1.5154 per share, for aggregate gross proceeds of $6.7 million.

Warrants

XML 27 R15.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

8.	Share-based Compensation

2020 Stock Option and Incentive Plan

The total number of common shares reserved for issuance under the 2020 Plan was 4,273,350 shares as of September 30, 2020.

2017 Equity Incentive Plan

The total number of common shares reserved for issuance under the 2017 Plan was 0 and 4,700,393 shares as of September 30, 2020 and December 31, 2019, respectively.

2020 Employee Share Purchase Plan

As of September 30, 2020, no shares were issued under the ESPP.

Stock Option Valuation

The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Risk-free interest rate		0.33	%		1.58	%		0.70	%		1.58	%
Expected term (in years)		6.0			5.9			6.0			5.9
Expected volatility		67.0	%		64.5	%		65.5	%		64.5	%
Expected dividend yield		0	%		0	%		0	%		0	%

Stock Options

The following table summarizes the Company’s stock option activity since December 31, 2019:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding as of December 31, 2019		3,045,301		$	1.66		8.4	$	2,112
Granted		2,346,645			11.50
Forfeited/cancelled		(125,480	)		5.63
Outstanding as of September 30, 2020		5,266,466		$	5.95		8.4	$	37,696
Vested and expected to vest as of September 30, 2020		5,266,466		$	5.95		8.4	$	37,696
Options exercisable as of September 30, 2020		1,810,276		$	1.51		7.0	$	18,699

Share-based Compensation

Share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	288	$	37	$	506	$	110
General and administrative expenses		953		101		1,519		218
	$	1,241	$	138	$	2,025	$	328

XML 28 R16.htm IDEA: XBRL DOCUMENT

License Agreements and Asset Acquisitions

9 Months Ended

Sep. 30, 2020

License Agreement [Abstract]

License Agreements and Asset Acquisitions

9.	License Agreements and Asset Acquisitions

License Agreement with the Centre for Probe Development and Commercialization Inc.

Under all agreements with CPDC, the Company has no obligations to make any milestone payments or to pay any royalties or annual maintenance fees to CPDC.

License Agreement with ImmunoGen, Inc.

License Agreements with Janssen Biotech, Inc.

First Janssen Agreement

The Company had the right to terminate the First Janssen Agreement upon written notice to Janssen. In March 2019, the Company terminated the First Janssen Agreement upon written notice to Janssen.

During the three and nine months ended September 30, 2019, the Company did not make any payments to Janssen or recognize any research and development expenses under the First Janssen Agreement.

Second Janssen Agreement

Research and License Agreement with Isogenica Ltd.

The Company was not entitled to any payments from Isogenica for use of the license of its intellectual property granted to Isogenica.

The Company had the right to terminate the Isogenica Agreement upon written notice to Isogenica. In January 2020, the Company terminated the Isogenica Agreement upon written notice.

Asset Acquisition from and License Agreement with MediaPharma S.r.l.

The Company is not entitled to any payments from MediaPharma for use of the license to the specified compound granted to MediaPharma.

Asset Acquisition from Rainier Therapeutics, Inc. and License Agreement with Genentech, Inc.

During the three and nine months ended September 30, 2020, the Company did not make any payments to Genentech or recognize any research and development expenses under the Genentech License Agreement.

Master Services and License Agreement with Yumab GmbH

XML 29 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

10.	Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

Net Loss per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Net Loss per Share

11.	Net Loss per Share

Net Loss per Share Attributable to Common Shareholders

Basic and diluted net loss per share attributable to common shareholders was calculated as follows (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Numerator:
Net loss	$	(9,993	)	$	(594	)	$	(64,948	)	$	(7,983	)
Dividends paid to preferred shareholders in the form of warrants issued		—			—			(1,382	)		—
Net loss attributable to common shareholders	$	(9,993	)	$	(594	)	$	(66,330	)	$	(7,983	)
Denominator:
Weighted-average common shares outstanding—basic and diluted		41,682,797			1,929,555			15,422,375			1,910,695
Net loss per share attributable to common shareholders —basic and diluted	$	(0.24	)	$	(0.31	)	$	(4.30	)	$	(4.18	)

	Nine Months Ended September 30,
	2020		2019
Options to purchase common shares		5,266,466		2,687,413
Convertible preferred shares (as converted to common shares)		—		13,696,513
Preferred exchangeable shares (as converted to convertible preferred shares and then to common shares)		—		4,577,106
Warrants to purchase common shares		651,816		—
		5,918,282		20,961,032

XML 31 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

12.	Commitments and Contingencies

Operating Leases

Future minimum lease payments due under operating leases as of September 30, 2020 are as follows (in thousands):

Year Ending December 31,
2020 (three months)	$	274
2021		1,117
2022		1,147
2023		1,177
2024		1,208
Thereafter		1,592
	$	6,515

Manufacturing Commitments

Indemnification Agreements

Legal Proceedings

XML 32 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions

13.	Related Party Transactions

The Company has entered into license agreements with CPDC, a principal shareholder of the Company (see Note 9).

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	141	$	326	$	780	$	785
General and administrative expenses		23		16		50		59
	$	164	$	342	$	830	$	844

XML 33 R21.htm IDEA: XBRL DOCUMENT

Geographical Information

6 Months Ended

Jun. 30, 2020

Geographic Areas Long Lived Assets [Abstract]

Geographical Information

14.	Geographical Information

	September 30, 2020		December 31, 2019
United States	$	115	$	127
Canada		1,866		1,145
	$	1,981	$	1,272

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 34 R22.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

15.	Subsequent Events

Amendment to Asset Acquisition Agreement with Rainier Therapeutics, Inc.

Strategic Collaboration Agreement with AstraZeneca UK Limited

The Company received an upfront payment of $5.0 million from AstraZeneca. In addition, the Company is eligible to receive future payments of up to $40.0 million, including clinical milestones.

XML 35 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Closing of Class B Preferred Share Financing and Settlement of Class B Preferred Share Tranche Right Liability

Reverse Share Split

Initial Public Offering

Basis of Presentation

Impact of the COVID-19 Pandemic

Use of Estimates

Unaudited Interim Financial Information

Foreign Currency and Currency Translation

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of standard checking accounts, money market accounts, and all highly liquid investments with an original maturity of three months or less at the date of purchase.

Investments

Deferred Offering Costs

Business Combinations

To date, the Company has not recorded any asset acquisitions as a business combination.

Asset Acquisitions

Fair Value Measurements

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Preferred Share Tranche Right Liability and Preferred Share Warrant Liability

Preferred Share Tranche Right Liability

The Class B preferred share tranche right liability (see Note 7) was settled in connection with the achievement of the regulatory milestone associated with the Class B preferred share tranche right. Specifically, the fair value of the Class B preferred share tranche right liability was remeasured for the last time as of the Milestone Financing closing date, resulting in the Company recognizing a loss in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2020 of $32.7 million for the change in the fair value of the tranche right liability between December 31, 2019 and June 2, 2020. Immediately thereafter, the balance of the Class B preferred share tranche right liability of $39.6 million was reclassified to Class B convertible preferred shares in an amount of $35.3 million and to non-controlling interest in Fusion Pharmaceuticals (Ireland) Limited in an amount of $4.3 million on the consolidated balance sheet.

Preferred Share Warrant Liability

Research, Development and Manufacturing Contract Costs and Accruals

Net Loss per Share

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

XML 36 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

	Fair Value Measurements as of September 30, 2020 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	28,670	$	—	$	—	$	28,670
Commercial paper		—		2,999		—		2,999
Corporate bonds		—		1,862		—		1,862
U.S. Government agencies		—		20,998		—		20,998
Investments:
Commercial paper		—		6,994		—		6,994
Corporate bonds		—		905		—		905
U.S. Government agencies		—		46,362		—		46,362
	$	28,670	$	80,120	$	—	$	108,790

	Fair Value Measurements as of December 31, 2019 Using:
	Level 1		Level 2		Level 3		Total
Liabilities:
Preferred share tranche right liability	$	—	$	—	$	5,741	$	5,741
	$	—	$	—	$	5,741	$	5,741

Schedule of Fair Value from Preferred Share Tranche Liability and Warrant Liability

	Preferred Share Tranche Right Liability			Preferred Share Warrant Liability
Balance as of December 31, 2019	$	5,741		$	—
Initial fair value of Class B preferred share tranche right liability		1,105			—
Initial fair value of Class B preferred share warrant liability		—			1,382
Change in fair value of Class B preferred share tranche right liability		32,722			—
Change in fair value of Class B preferred share warrant liability		—			6,399
Reclassification of Class B preferred share tranche right liability upon settlement		(39,568	)		—
Conversion of Class B preferred shares warrants into common share warrants		—			(7,781	)
Balance as of September 30, 2020	$	—		$	—

XML 37 R25.htm IDEA: XBRL DOCUMENT

Investments (Tables)

9 Months Ended

Sep. 30, 2020

Investments Debt And Equity Securities [Abstract]

Schedule of Investments

Investments consisted of the following (in thousands):

	September 30, 2020
	Amortized Cost		Fair Value
Due within one year or less	$	43,160	$	43,159
Due after one year through three years		11,102		11,102
	$	54,262	$	54,261

Amortized Cost and Estimated Fair Value of Investments by Contractual Maturity

As of September 30, 2020, the amortized cost and estimated fair value of investments, by contractual maturity, was as follows (in thousands):

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Current		Non-Current
Commercial paper	$	6,994	$	—	$	—		$	6,994	$	6,994	$	—
Corporate bonds		905		—		—			905		905		—
U.S. Government agencies		46,363		1		(2	)		46,362		35,260		11,102
	$	54,262	$	1	$	(2	)	$	54,261	$	43,159	$	11,102

XML 38 R26.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2020

Prepaid Expense And Other Assets Current [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Prepaid clinical trial expenses	$	—	$	94
Prepaid insurance		3,136		11
Prepaid software subscriptions		173		129
Income tax receivable		109		—
Interest receivable		229		62
Canadian harmonized sales tax receivable		238		252
Refundable investment tax credits		315		176
Other		452		205
	$	4,652	$	929

XML 39 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2020

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Accrued employee compensation and benefits	$	1,524	$	991
Accrued external research and development expenses		1,715		1,565
Accrued professional and consulting fees		1,048		744
Other		66		26
	$	4,353	$	3,326

XML 40 R28.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model

The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Risk-free interest rate		0.33	%		1.58	%		0.70	%		1.58	%
Expected term (in years)		6.0			5.9			6.0			5.9
Expected volatility		67.0	%		64.5	%		65.5	%		64.5	%
Expected dividend yield		0	%		0	%		0	%		0	%

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity since December 31, 2019:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding as of December 31, 2019		3,045,301		$	1.66		8.4	$	2,112
Granted		2,346,645			11.50
Forfeited/cancelled		(125,480	)		5.63
Outstanding as of September 30, 2020		5,266,466		$	5.95		8.4	$	37,696
Vested and expected to vest as of September 30, 2020		5,266,466		$	5.95		8.4	$	37,696
Options exercisable as of September 30, 2020		1,810,276		$	1.51		7.0	$	18,699

Summary of Stock Based Compensation Expense

Share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	288	$	37	$	506	$	110
General and administrative expenses		953		101		1,519		218
	$	1,241	$	138	$	2,025	$	328

XML 41 R29.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Basic and Diluted Net Loss per Share

Basic and diluted net loss per share attributable to common shareholders was calculated as follows (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Numerator:
Net loss	$	(9,993	)	$	(594	)	$	(64,948	)	$	(7,983	)
Dividends paid to preferred shareholders in the form of warrants issued		—			—			(1,382	)		—
Net loss attributable to common shareholders	$	(9,993	)	$	(594	)	$	(66,330	)	$	(7,983	)
Denominator:
Weighted-average common shares outstanding—basic and diluted		41,682,797			1,929,555			15,422,375			1,910,695
Net loss per share attributable to common shareholders —basic and diluted	$	(0.24	)	$	(0.31	)	$	(4.30	)	$	(4.18	)

Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share

	Nine Months Ended September 30,
	2020		2019
Options to purchase common shares		5,266,466		2,687,413
Convertible preferred shares (as converted to common shares)		—		13,696,513
Preferred exchangeable shares (as converted to convertible preferred shares and then to common shares)		—		4,577,106
Warrants to purchase common shares		651,816		—
		5,918,282		20,961,032

XML 42 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

Future minimum lease payments due under operating leases as of September 30, 2020 are as follows (in thousands):

Year Ending December 31,
2020 (three months)	$	274
2021		1,117
2022		1,147
2023		1,177
2024		1,208
Thereafter		1,592
	$	6,515

XML 43 R31.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Recognized Expenses in Connection with Services Performed Under Master Services Agreement and Supply Agreement

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	141	$	326	$	780	$	785
General and administrative expenses		23		16		50		59
	$	164	$	342	$	830	$	844

XML 44 R32.htm IDEA: XBRL DOCUMENT

Geographical Information (Tables)

9 Months Ended

Sep. 30, 2020

Geographic Areas Long Lived Assets [Abstract]

Schedule of Long-lived Assets by Geographic Areas

Information about the Company’s long-lived assets, consisting solely of property and equipment, net, by geographic region was as follows (in thousands):

	September 30, 2020		December 31, 2019
United States	$	115	$	127
Canada		1,866		1,145
	$	1,981	$	1,272

XML 45 R33.htm IDEA: XBRL DOCUMENT

Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended		3 Months Ended						9 Months Ended
	Jun. 30, 2020	Jun. 25, 2020	Jun. 19, 2020	Jun. 02, 2020	Jan. 31, 2020	Mar. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Subsidiary Sale Of Stock [Line Items]
Formation and incorporation date													Dec. 31, 2014
Preferred share tranche right liability															$ 5,741
Reverse share split, description			one-for-5.339
Net loss							9,993	$ 44,733	$ 10,222	$ 594	$ 3,456	$ 3,933	64,948	$ 7,983
Accumulated deficit					$ (100)		99,818						99,818		$ 34,774
Initial Public Ooffering [Member] \| Common Shares [Member]
Subsidiary Sale Of Stock [Line Items]
Shares issued and sold, date		Jun. 25, 2020
Shares issued and sold	12,500,000	12,500,000
Shares issued and sold, per share	$ 17.00	$ 17.00						$ 17.00
Net proceeds of common shares	$ 193,100	$ 193,100
Fusion Pharmaceuticals (Ireland) Limited [Member] \| Milestone Financing [Member] \| Non-Controlling Interest in Fusion Pharmaceuticals (Ireland) Limited [Member]
Subsidiary Sale Of Stock [Line Items]
Preferred share tranche right liability				$ 4,300
Preferred Class B
Subsidiary Sale Of Stock [Line Items]
Shares issued and sold, date				Jun. 02, 2020
Shares issued and sold				36,806,039
Shares issued and sold, per share				$ 1.5154
Aggregate gross proceeds				$ 55,800	10,000	$ 45,800
Preferred share tranche right liability					$ 1,100		39,600						39,600
Preferred Class B \| Milestone Financing [Member]
Subsidiary Sale Of Stock [Line Items]
Loss on change in the fair value of the tranche right liability				32,700
Preferred share tranche right liability				$ 39,600
Class B Special Voting Shares [Member]
Subsidiary Sale Of Stock [Line Items]
Shares issued and sold				4,437,189
Shares issued and sold, per share				$ 0.000001
Class B Preferred Exchangeable Shares [Member] \| Fusion Pharmaceuticals (Ireland) Limited [Member]
Subsidiary Sale Of Stock [Line Items]
Shares issued and sold				4,437,189
Shares issued and sold, per share				$ 1.5154
Aggregate gross proceeds				$ 62,500
Class B Convertible Preferred Shares [Member]
Subsidiary Sale Of Stock [Line Items]
Preferred share tranche right liability							$ 35,300						$ 35,300
Class B Convertible Preferred Shares [Member] \| Milestone Financing [Member]
Subsidiary Sale Of Stock [Line Items]
Preferred share tranche right liability				$ 35,300

XML 46 R34.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)			1 Months Ended		3 Months Ended			9 Months Ended
	Jun. 02, 2020	Jun. 02, 2020	Jan. 31, 2020	Mar. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Oct. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Restricted cash					$ 280,000			$ 280,000		$ 280,000
Letters of credit											$ 1,500,000
Cash, cash equivalents and restricted cash					250,500,000		$ 71,100,000	250,500,000	$ 71,100,000
Cash and cash equivalents					248,800,000		69,300,000	248,800,000	69,300,000
Restricted Cash					1,700,000		1,800,000	1,700,000	1,800,000
Deferred offering costs					$ 0			0		$ 0
Issuance of common shares upon closing of initial public offering, offering costs and underwriter fees						$ 19,447,000		$ 4,600,000
Preferred stock shares issued					0			0		73,125,790
Change in fair value of preferred share tranche right liability							3,485,000	$ (32,722,000)	3,707,000
Preferred share tranche right liability										$ 5,741,000
Preferred Class B
Summary Of Significant Accounting Policies [Line Items]
Preferred stock shares issued	36,806,039	36,806,039
Preferred stock price per share	$ 1.5154	$ 1.5154	$ 1.5154	$ 1.5154
Aggregate gross proceeds		$ 55,800,000	$ 10,000,000	$ 45,800,000
Change in fair value of preferred share tranche right liability								32,700,000
Preferred share tranche right liability			$ 1,100,000		39,600,000			39,600,000
Class B Special Voting Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Preferred stock shares issued	4,437,189	4,437,189
Preferred stock price per share	$ 0.000001	$ 0.000001
Class B Preferred Exchangable Shares [Member] \| Ireland Subsidiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Preferred stock shares issued	4,437,189	4,437,189
Preferred stock price per share	$ 1.5154	$ 1.5154
Aggregate gross proceeds	$ 62,500,000
Class B Convertible Preferred Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Preferred stock shares issued										132,207,290
Preferred share tranche right liability					$ 35,300,000			$ 35,300,000
Class B Convertible Preferred Shares [Member] \| Ireland Subsidiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Preferred stock shares issued	4,437,189	4,437,189		4,437,189	28,874,378			28,874,378		29,747,987
Preferred stock price per share	$ 0.000001	$ 0.000001		$ 1.5154	$ 0.001			$ 0.001		$ 0.001
Increase in noncontrolling interest								$ 4,300,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Foreign currency transaction gains (losses)					$ (100,000)		$ (100,000)	$ (100,000)	$ 100,000

XML 47 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Investments
Investments	$ 108,790
Liabilities:
Liabilities		$ 5,741
Preferred Share Tranche Right Liability [Member]
Liabilities:
Liabilities		5,741
Corporate Bond Securities [Member]
Cash equivalents
Cash equivalents	1,862
Investments
Investments	905
Money Market Funds [Member]
Cash equivalents
Cash equivalents	28,670
Commercial Paper [Member]
Cash equivalents
Cash equivalents	2,999
Investments
Investments	6,994
U.S Goverment agencies [Member]
Cash equivalents
Cash equivalents	20,998
Investments
Investments	46,362
Level 1
Investments
Investments	28,670
Level 1 \| Money Market Funds [Member]
Cash equivalents
Cash equivalents	28,670
Level 2
Investments
Investments	80,120
Level 2 \| Corporate Bond Securities [Member]
Cash equivalents
Cash equivalents	1,862
Investments
Investments	905
Level 2 \| Commercial Paper [Member]
Cash equivalents
Cash equivalents	2,999
Investments
Investments	6,994
Level 2 \| U.S Goverment agencies [Member]
Cash equivalents
Cash equivalents	20,998
Investments
Investments	$ 46,362
Level 3
Liabilities:
Liabilities		5,741
Level 3 \| Preferred Share Tranche Right Liability [Member]
Liabilities:
Liabilities		$ 5,741

XML 48 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended	9 Months Ended
	Jun. 02, 2020	Jun. 02, 2020	Jan. 31, 2020	Mar. 31, 2019	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock, shares issued						0		73,125,790
Change in fair value of preferred share tranche right liability					$ 3,485	$ (32,722)	$ 3,707
Measurement Input, Expected Dividend Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Estimated dividend yield						0.00%
Class B Preferred Shares Tranche [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of preferred share tranche right liability						$ 32,700
Preferred shares tranche liability	$ 35,300	$ 35,300						$ 39,600
Increase in noncontrolling interest						4,300
Preferred Class B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible preferred stock fair value per share	$ 2.47	$ 2.47	$ 1.45					$ 1.45
Preferred stock, shares issued	36,806,039	36,806,039
Preferred stock par value per share	$ 1.5154	$ 1.5154	$ 1.5154	$ 1.5154
Aggregate gross proceeds		$ 55,800	$ 10,000	$ 45,800
Change in fair value of preferred share tranche right liability						32,700
Preferred shares tranche liability						$ 39,600
Class B Special Voting Shares [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock, shares issued	4,437,189	4,437,189
Preferred stock par value per share	$ 0.000001	$ 0.000001
Class B Preferred Exchangable Shares [Member] \| Ireland Subsidiary [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock, shares issued	4,437,189	4,437,189
Preferred stock par value per share	$ 1.5154	$ 1.5154
Aggregate gross proceeds	$ 62,500

XML 49 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value from Preferred Share Tranche Liability and Warrant Liability (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of preferred share warrant liability	$ (6,399)
Preferred Share Tranche Right Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance as of December 31, 2019	5,741
Preferred Share Tranche Right Liability [Member] \| Preferred Class B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Initial fair value of Class B preferred share tranche right liability	1,105
Change in fair value of Class B preferred share tranche right liability	32,722
Reclassification of Class B convertible preferred share and preferred exchangeable	(39,568)
Preferred Share Warrant Liability [Member] \| Preferred Class B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Initial fair value of Class B preferred share warrant liability	1,382
Change in fair value of preferred share warrant liability	6,399
Conversion of Class B preferred shares warrants into common share warrants	$ (7,781)

XML 50 R38.htm IDEA: XBRL DOCUMENT

Investments - Schedule of Investments (Detail) $ in Thousands	Sep. 30, 2020 USD ($)
Available-for-sale securities, debt maturities, amortized cost [Abstract]
Amortized Cost, Due within one year or less	$ 43,160
Amortized Cost, Due after one year through three years	11,102
Amortized Cost, Investments	54,262
Available-for-sale securities, debt maturities, Fair Value [Abstract]
Fair Value, Due within one year or less	43,159
Fair Value, Due after one year through three years	11,102
Fair value, Investments	$ 54,261

XML 51 R39.htm IDEA: XBRL DOCUMENT

Investments - Amortized Cost and Estimated Fair Value of Investments by Contractual Maturity (Detail) $ in Thousands	Sep. 30, 2020 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Investments, Amortized Cost	$ 54,262
Available-for-sale Investments, Gross Unrealized Gains	1
Available-for-sale Investments, Gross Unrealized Losses	(2)
Available-for-sale Investments, Fair Value	54,261
Available-for-sale Investments, Current	43,159
Available-for-sale Investments, Non Current	11,102
Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Investments, Amortized Cost	6,994
Available-for-sale Investments, Fair Value	6,994
Available-for-sale Investments, Current	6,994
Corporate Bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Investments, Amortized Cost	905
Available-for-sale Investments, Fair Value	905
Available-for-sale Investments, Current	905
U.S. Government Agencies [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Investments, Amortized Cost	46,363
Available-for-sale Investments, Gross Unrealized Gains	1
Available-for-sale Investments, Gross Unrealized Losses	(2)
Available-for-sale Investments, Fair Value	46,362
Available-for-sale Investments, Current	35,260
Available-for-sale Investments, Non Current	$ 11,102

XML 52 R40.htm IDEA: XBRL DOCUMENT

Investments - Additional Information (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Investments Debt And Equity Securities [Abstract]
Investments	$ 0

XML 53 R41.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Prepaid clinical trial expenses		$ 94
Prepaid insurance	$ 3,136	11
Prepaid software subscriptions	173	129
Income tax receivable	109
Interest receivable	229	62
Canadian harmonized sales tax receivable	238	252
Refundable investment tax credits	315	176
Other	452	205
Prepaid expenses and other current assets	$ 4,652	$ 929

XML 54 R42.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued employee compensation and benefits	$ 1,524	$ 991
Accrued external research and development expenses	1,715	1,565
Accrued professional and consulting fees	1,048	744
Other	66	26
Accrued expenses	$ 4,353	$ 3,326

XML 55 R43.htm IDEA: XBRL DOCUMENT

Equity - Additional Information (Detail)						1 Months Ended		3 Months Ended			6 Months Ended	9 Months Ended
Equity - Additional Information (Detail)	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 25, 2020 USD ($) $ / shares shares	Jun. 19, 2020	Jun. 02, 2020 USD ($) $ / shares shares	Jun. 02, 2020 USD ($) $ / shares shares	Jan. 31, 2020 USD ($) $ / shares shares	Mar. 31, 2019 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares	Sep. 30, 2020 USD ($) $ / shares shares	Oct. 17, 2020 shares	Dec. 31, 2019 USD ($) $ / shares shares
Class Of Stock [Line Items]
Reverse share split, description			one-for-5.339
Stockholders equity note stock split conversion ratio			0.187
Common stock, no par value \| $ / shares
Common stock, voting rights description												Each common share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders.
Cash dividends												$ 0
Preferred stock, shares issued \| shares												0		73,125,790
Preferred stock, no par value \| $ / shares
Issuance of preferred shares and tranche right, issuance costs												$ 4,572,000
Preferred share tranche right liability														$ 5,741,000
Number of shares issuable upon exercise of outstanding warrants (in shares) \| shares						749,197
Weighted-average exercise price per share (in dollars per share) \| $ / shares						$ 8.10
Expiration period						2 years
Preferred share warrant liability						$ 1,400,000
Decrease in additional Paid in Capital						1,300,000
Accumulated deficit						$ 100,000						$ (99,818,000)		$ (34,774,000)
Common stock, shares issued \| shares												41,702,384		1,929,555
Class B Convertible Preferred Shares [Member]
Class Of Stock [Line Items]
Stockholders equity note stock split conversion ratio												0.05339
Preferred stock, shares issued \| shares														132,207,290
Preferred share tranche right liability												$ 35,300,000
Preferred shares tranche liability												$ 35,300,000
Class B Convertible Preferred Shares [Member] \| Ireland Subsidiary [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued \| shares				4,437,189	4,437,189		4,437,189			4,437,189		28,874,378		29,747,987
Preferred stock par value per share \| $ / shares				$ 0.000001	$ 0.000001		$ 1.5154			$ 1.5154		$ 0.001		$ 0.001
Increase in noncontrolling interest												$ 4,300,000
Preferred Class A
Class Of Stock [Line Items]
Preferred stock, no par value \| $ / shares
Preferred Class B
Class Of Stock [Line Items]
Shares issued and sold, date					Jun. 02, 2020
Shares issued and sold \| shares					36,806,039
Shares issued and sold, per share \| $ / shares				$ 1.5154	$ 1.5154
Preferred stock, shares issued \| shares				36,806,039	36,806,039
Preferred stock, no par value \| $ / shares
Sold and issued of common stock \| shares					36,806,039	6,598,917	30,207,129
Preferred stock par value per share \| $ / shares				$ 1.5154	$ 1.5154	$ 1.5154	$ 1.5154			$ 1.5154
Aggregate gross proceeds					$ 55,800,000	$ 10,000,000	$ 45,800,000
Purchase an aggregate preferred share						20,000
Issuance of preferred shares and tranche right, issuance costs						100,000
Preferred share tranche right liability						$ 1,100,000						39,600,000
Loss on tranche liability contract												32,700,000
Preferred shares tranche liability												$ 39,600,000
Convertible preferred stock fair value per share \| $ / shares				$ 2.47	$ 2.47	$ 1.45								$ 1.45
Preferred Class B \| Canada Pension Plan Investment Board
Class Of Stock [Line Items]
Sold and issued of common stock \| shares												6,598,917
Preferred stock par value per share \| $ / shares												$ 1.5154
Class B Convertible Preferred Shares and Class B Preferred Share Tranche Right [Member]
Class Of Stock [Line Items]
Issuance of preferred shares and tranche right, issuance costs								$ 6,000	$ 93,000	$ 299,000
Number of shares issuable upon exercise of outstanding warrants (in shares) \| shares						3,126,391
Weighted-average exercise price per share (in dollars per share) \| $ / shares						$ 1.5154
Class B Preferred Exchangable Shares [Member]
Class Of Stock [Line Items]
Number of shares issuable upon exercise of outstanding warrants (in shares) \| shares						873,609
Weighted-average exercise price per share (in dollars per share) \| $ / shares						$ 1.5154
Class B Preferred Exchangable Shares [Member] \| Ireland Subsidiary [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued \| shares				4,437,189	4,437,189
Preferred stock par value per share \| $ / shares				$ 1.5154	$ 1.5154
Aggregate gross proceeds				$ 62,500,000
Class B Special Voting Shares [Member]
Class Of Stock [Line Items]
Preferred stock par value per share \| $ / shares						$ 0.000001
Class B Special Voting Shares [Member] \| Class B Convertible Preferred Shares [Member]
Class Of Stock [Line Items]
Stockholders equity note stock split conversion ratio					0.00187
Preferred stock, shares issued \| shares				4,437,189	4,437,189		4,437,189			4,437,189		28,874,378		29,747,987
Preferred stock par value per share \| $ / shares				$ 1.5154	$ 1.5154		$ 0.000001			$ 0.000001		$ 0.000001		$ 0.000001
Aggregate gross proceeds					$ 6,700,000		$ 6,700,000
Warrant Liability [Member]
Class Of Stock [Line Items]
Loss related to increase in fair value of the Preferred Share Warrants											$ 6,400,000
Common share warrants, exercised \| shares													97,381
Common stock, shares issued \| shares													38,340
Number of warrants cancelled \| shares													59,041
Common share warrants remained outstanding \| shares													651,816
IPO [Member] \| Common Shares [Member]
Class Of Stock [Line Items]
Shares issued and sold, date		Jun. 25, 2020
Shares issued and sold \| shares	12,500,000	12,500,000
Shares issued and sold, per share \| $ / shares	$ 17.00	$ 17.00						$ 17.00			$ 17.00
Net proceeds of common shares	$ 193,100,000	$ 193,100,000

XML 56 R44.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares option, exercised	0	0
Weighted average grant-date fair value of stock options granted	$ 11.54	$ 2.33
Aggregate unrecognized share-based compensation expense	$ 15.8
Unrecognized share-based compensation expense, weighted average period expects for recognition	3 years
2020 Stock Option and incentive plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock reserved for future issuance	4,273,350
Stock incentive plan description	cumulatively increased on January 1, 2021 and each January 1 thereafter by 4% of the number of the Company’s common shares outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s compensation committee of the board of directors
Annual percentage increase in common stock reserved for future issuance	4.00%
Number of shares remained available for future grant	2,933,366
2017 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock reserved for future issuance	0		4,700,393
Number of shares remained available for future grant	0		1,598,512
2020 Employee Share Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock reserved for future issuance	450,169
Stock incentive plan description	the number of common shares that may be issued under the ESPP will automatically increase on January 1, 2021 and each January 1 thereafter by the lesser of (i) 900,338 common shares, (ii) 1% of the number of the Company’s common shares outstanding on the immediately preceding December 31 and (iii) such lesser number of shares as determined by the Company’s compensation committee of the board of directors.
Annual percentage increase in common stock reserved for future issuance	1.00%
Maximum annual increase in common stock reserved for future issuance	900,338
Shares, Issued	0

XML 57 R45.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	0.33%	1.58%	0.70%	1.58%
Expected term (in years)	6 years	5 years 10 months 24 days	6 years	5 years 10 months 24 days
Expected volatility	67.00%	64.50%	65.50%	64.50%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

XML 58 R46.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Beginning balance	3,045,301
Number of Shares, Granted	2,346,645
Number of Shares, Forfeited/cancelled	(125,480)
Number of Shares, Ending balance	5,266,466	3,045,301
Number of Shares, Options vested and expected to vest	5,266,466
Number of Shares, Options exercisable	1,810,276
Weighted Average Exercise Price, Beginning balance	$ 1.66
Weighted Average Exercise Price, Granted	11.50
Weighted Average Exercise Price, Forfeited/cancelled	5.63
Weighted Average Exercise Price, Ending balance	5.95	$ 1.66
Weighted Average Exercise Price, Options vested and expected to vest	5.95
Weighted Average Exercise Price, Options exercisable	$ 1.51
Weighted-Average Remaining Contractual Term, Outstanding	8 years 4 months 24 days	8 years 4 months 24 days
Weighted Average Remaining Contractual Term, Options vested and expected to vest	8 years 4 months 24 days
Weighted Average Remaining Contractual Term, Options exercisable	7 years
Aggregate Intrinsic Value	$ 37,696	$ 2,112
Aggregate Intrinsic Value, Options vested and expected to vest	37,696
Aggregate Intrinsic Value, Options exercisable	$ 18,699

XML 59 R47.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Summary of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,241	$ 138	$ 2,025	$ 328
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	288	37	506	110
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 953	$ 101	$ 1,519	$ 218

XML 60 R48.htm IDEA: XBRL DOCUMENT

License Agreements and Asset Acquisitions - Additional Information (Detail) £ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2020 USD ($) shares	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2019 GBP (£)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2019 GBP (£)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development	$ 4,529,000		$ 2,238,000		$ 12,231,000	$ 7,216,000
CPDC [Member] \| Research and License Agreement [Member] \| Research and Development Expense [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment	0		0		0	0
ImmunoGen [Member] \| Research and License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid					200,000
Research and development	0		0		0
ImmunoGen [Member] \| Research and License Agreement [Member] \| Second Janssen Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid	0		0		0	0
Research and development	0		0		0	0
ImmunoGen [Member] \| Research and License Agreement [Member] \| Maximum [Member] \| Development And Regulatory Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	15,000,000				15,000,000
ImmunoGen [Member] \| Research and License Agreement [Member] \| Maximum [Member] \| Sales Based Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	35,000,000				35,000,000
ImmunoGen [Member] \| Research and License Agreement [Member] \| Research and Development Expense [Member] \| Development And Regulatory Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid	0		0		0	500,000
ImmunoGen [Member] \| Research and License Agreement [Member] \| First Janssen Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid			0			0
Research and development			0			0
Isogenica Ltd [Member] \| Research and License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development	0				0	600,000	£ 0.4
Licensing, development and commercialization agreement, upfront payment	0		0		0	700,000	£ 0.6
Isogenica Ltd [Member] \| Research and License Agreement [Member] \| License Fee [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Amortization of intangible assets			100,000	£ 0.1
MediaPharma [Member] \| Asset Acquisition and License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid					200,000
Research and development	0		$ 0		0	$ 200,000
MediaPharma [Member] \| Asset Acquisition and License Agreement [Member] \| Maximum [Member] \| Development And Regulatory Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	1,500,000				1,500,000
MediaPharma [Member] \| Asset Acquisition and License Agreement [Member] \| Maximum [Member] \| Sales Based Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	23,000,000				23,000,000
Rainier Therapeutics, Inc. [Member] \| Research and Development Expense [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid	0				1,000,000
Rainier Therapeutics, Inc. [Member] \| Asset Acquisition and License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional amount payable under agreement	$ 3,500,000				$ 3,500,000
Non-voting common stock, issued \| shares	313,359				313,359
Non-refundable upfront license fee					$ 1,000,000
Rainier Therapeutics, Inc. [Member] \| Asset Acquisition and License Agreement [Member] \| Development And Regulatory Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	$ 22,500,000				$ 22,500,000
Non-voting common stock, issued \| shares	156,679				156,679
Rainier Therapeutics, Inc. [Member] \| Asset Acquisition and License Agreement [Member] \| Sales Based Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	$ 42,000,000				$ 42,000,000
Rainier Therapeutics, Inc. [Member] \| Asset Acquisition and License Agreement [Member] \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential future payment as percentage of amount the Company receives under sublicense agreements	30.00%				30.00%
Rainier Therapeutics, Inc. [Member] \| Asset Acquisition and License Agreement [Member] \| Minimum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential future payment as percentage of amount the Company receives under sublicense agreements	10.00%				10.00%
Rainier Therapeutics, Inc. [Member] \| Asset Acquisition and License Agreement [Member] \| Research and Development Expense [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront license fee paid		$ 1,000,000
Genentech, Inc. [Member] \| Asset Acquisition and License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development	$ 0				$ 0
Genentech, Inc. [Member] \| Asset Acquisition and License Agreement [Member] \| Maximum [Member] \| Sales Based Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	44,000,000				44,000,000
Yumab GmbH [Member] \| Asset Acquisition and License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development	200,000				200,000
Yumab GmbH [Member] \| Asset Acquisition and License Agreement [Member] \| Development And Regulatory Milestone [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Performance milestone payments based on successful development	$ 3,900,000				$ 3,900,000

XML 61 R49.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating Loss Carryforwards [Line Items]
Income tax provision	$ (185)	$ 181	$ 27	$ 213
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Income tax provision			$ 100

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 62 R50.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Basic and Diluted Net Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net loss	$ (9,993)	$ (44,733)	$ (10,222)	$ (594)	$ (3,456)	$ (3,933)	$ (64,948)	$ (7,983)
Dividends paid to preferred shareholders in the form of warrants issued							(1,382)
Net loss attributable to common shareholders	$ (9,993)			$ (594)			$ (66,330)	$ (7,983)
Denominator:
Weighted-average common shares outstanding—basic and diluted	41,682,797			1,929,555			15,422,375	1,910,695
Net loss per share attributable to common shareholders—basic and diluted	$ (0.24)			$ (0.31)			$ (4.30)	$ (4.18)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 63 R51.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	5,918,282	20,961,032
Convertible Preferred shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share		13,696,513
Options to purchase common shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	5,266,466	2,687,413
Class B Preferred Exchangeable Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share		4,577,106
Warrant Liability [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential common shares excluded from calculation of diluted net loss per share	651,816

XML 64 R52.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2020	Oct. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Non-cancelable minimum purchase commitments	$ 100
Lease expiration date	Jul. 31, 2023
Operating lease expiration period		Sep. 30, 2025			Aug. 31, 2023
Operating lease additional lease period					5 years
Operating lease termination notice period					12 months
Operating lease, option to extend by lessee					false
Restricted cash			$ 1,465		$ 1,465			$ 1,497
Lessee, operating lease, description					In August 2018, the Company entered into an operating lease for office space in Hamilton, Ontario, Canada. This lease was amended in September 2020 (“New Lease Commencement Date”) with a new expiry date in August 2023. The lease can be renewed for an additional period of five years at the Company’s option, and if so renewed, can be terminated during the option period upon twelve months written notice any time after the fifth anniversary of the New Lease Commencement Date. In October 2019, the Company entered into an operating lease for office space in Boston, Massachusetts, which expires September 2025 and has no renewal options. In connection with entering into this lease agreement, the Company issued a letter of credit of $1.5 million, which is classified as restricted cash (non-current) on the consolidated balance sheets as of September 30, 2020 and December 31, 2019.
Rent Expense			300	$ 100	$ 800	$ 200
CPDC [Member]
Defined Benefit Plan Disclosure [Line Items]
Non-cancelable minimum purchase commitments			$ 800		$ 800
Letter Of Credit [Member]
Defined Benefit Plan Disclosure [Line Items]
Restricted cash							$ 1,500	$ 1,500

XML 65 R53.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Future Maturities of Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2020 USD ($)
Operating Leases
2020 (three months)	$ 274
2021	1,117
2022	1,147
2023	1,177
2024	1,208
Thereafter	1,592
Total lease payments	$ 6,515

XML 66 R54.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - CPDC [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Payment related to supply agreement per quarter	$ 0.2		$ 0.2
Payment related to supply agreement aggregate per year	0.8		0.8
Amounts of transaction related to service	0.2	$ 0.5	1.0	$ 0.8
Amount due to related parties	0.1		0.1		$ 0.2
Payment for reimbursement of pass through costs			$ 0.1	$ 0.1
Maximum [Member]
Related Party Transaction [Line Items]
Payment for reimbursement of pass through costs	$ 0.1	$ 0.1

XML 67 R55.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Schedule of Recognized Expenses in Connection with Services Performed Under Master Services Agreement and Supply Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Related Party Transaction [Line Items]
Research and development expenses	$ 4,529	$ 2,238	$ 12,231	$ 7,216
General and administrative expenses	5,790	1,922	14,105	4,864
CPDC [Member]
Related Party Transaction [Line Items]
Research and development expenses	141	326	780	785
General and administrative expenses	23	16	50	59
Total operating expenses	$ 164	$ 342	$ 830	$ 844

XML 68 R56.htm IDEA: XBRL DOCUMENT

Geographical Information - Schedule of Long-lived Assets by Geographic Areas (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	$ 1,981	$ 1,272
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	115	127
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	$ 1,866	$ 1,145

XML 69 R57.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - USD ($)	Oct. 30, 2020	Oct. 08, 2020
Subsequent Event [Line Items]
Subsequent event, date		Oct. 08, 2020
Subsequent event, description		On October 8, 2020, the Company and Rainier entered into the Amended Rainier Agreement (see Note 9). Pursuant to the Amended Rainier Agreement, the termination provisions of the Rainier Agreement were modified. Specifically, the Outside Date was amended such that termination may not occur later than eleven months following the Closing, or February 10, 2021. Aside from modifying the termination provisions to incorporate the Revised Outside Date, no other material terms were amended as part of the Amended Rainier Agreement
AstraZeneca UK Limited [Member] \| Strategic Collaboration Agreement [Member]
Subsequent Event [Line Items]
Maximum amount for milestones payments to other party	$ 145,000,000
Upfront payment received	5,000,000
Maximum amount of payments to be received for development milestones	$ 40,000,000

EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 250 383 1 false 70 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://fusionpharma.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://fusionpharma.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://fusionpharma.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://fusionpharma.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) Sheet http://fusionpharma.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfNonControllingInterestConvertiblePreferredSharesAndShareholdersEquityDeficitUnaudited Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://fusionpharma.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfNonControllingInterestConvertiblePreferredSharesAndShareholdersEquityDeficitUnauditedParenthetical Condensed Consolidated Statements of Non-Controlling Interest, Convertible Preferred Shares and Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://fusionpharma.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 100070 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Investments Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureInvestments Investments Notes 11 false false R12.htm 100110 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 12 false false R13.htm 100120 - Disclosure - Accrued Expenses Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 100130 - Disclosure - Equity Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureEquity Equity Notes 14 false false R15.htm 100140 - Disclosure - Share-Based Compensation Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 15 false false R16.htm 100150 - Disclosure - License Agreements and Asset Acquisitions Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureLicenseAgreementsAndAssetAcquisitions License Agreements and Asset Acquisitions Notes 16 false false R17.htm 100160 - Disclosure - Income Taxes Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 100170 - Disclosure - Net Loss per Share Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureNetLossPerShare Net Loss per Share Notes 18 false false R19.htm 100180 - Disclosure - Commitments and Contingencies Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 100190 - Disclosure - Related Party Transactions Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 100200 - Disclosure - Geographical Information Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureGeographicalInformation Geographical Information Notes 21 false false R22.htm 100210 - Disclosure - Subsequent Events Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 22 false false R23.htm 100220 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://fusionpharma.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 100230 - Disclosure - Fair Value Measurements (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureFairValueMeasurements 24 false false R25.htm 100240 - Disclosure - Investments (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureInvestmentsTables Investments (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureInvestments 25 false false R26.htm 100250 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 26 false false R27.htm 100260 - Disclosure - Accrued Expenses (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureAccruedExpenses 27 false false R28.htm 100270 - Disclosure - Share-Based Compensation (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensation 28 false false R29.htm 100280 - Disclosure - Net Loss per Share (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureNetLossPerShare 29 false false R30.htm 100290 - Disclosure - Commitments and Contingencies (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies 30 false false R31.htm 100300 - Disclosure - Related Party Transactions (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactions 31 false false R32.htm 100310 - Disclosure - Geographical Information (Tables) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureGeographicalInformationTables Geographical Information (Tables) Tables http://fusionpharma.com/20200930/taxonomy/role/DisclosureGeographicalInformation 32 false false R33.htm 100320 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of the Business and Basis of Presentation - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) Details 35 false false R36.htm 100350 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 36 false false R37.htm 100360 - Disclosure - Fair Value Measurements - Schedule of Fair Value from Preferred Share Tranche Liability and Warrant Liability (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueFromPreferredShareTrancheLiabilityAndWarrantLiabilityDetail Fair Value Measurements - Schedule of Fair Value from Preferred Share Tranche Liability and Warrant Liability (Detail) Details 37 false false R38.htm 100370 - Disclosure - Investments - Schedule of Investments (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureInvestmentsScheduleOfInvestmentsDetail Investments - Schedule of Investments (Detail) Details 38 false false R39.htm 100380 - Disclosure - Investments - Amortized Cost and Estimated Fair Value of Investments by Contractual Maturity (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureInvestmentsAmortizedCostAndEstimatedFairValueOfInvestmentsByContractualMaturityDetail Investments - Amortized Cost and Estimated Fair Value of Investments by Contractual Maturity (Detail) Details 39 false false R40.htm 100390 - Disclosure - Investments - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetail Investments - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Details 41 false false R42.htm 100410 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 42 false false R43.htm 100420 - Disclosure - Equity - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureEquityAdditionalInformationDetail Equity - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 44 false false R45.htm 100440 - Disclosure - Share-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensationFairValueOfOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetail Share-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail) Details 45 false false R46.htm 100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail Share-Based Compensation - Summary of Stock Option Activity (Detail) Details 46 false false R47.htm 100460 - Disclosure - Share-Based Compensation - Summary of Stock Based Compensation Expense (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetail Share-Based Compensation - Summary of Stock Based Compensation Expense (Detail) Details 47 false false R48.htm 100470 - Disclosure - License Agreements and Asset Acquisitions - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureLicenseAgreementsAndAssetAcquisitionsAdditionalInformationDetail License Agreements and Asset Acquisitions - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 49 false false R50.htm 100490 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetail Net Loss per Share - Basic and Diluted Net Loss per Share (Detail) Details 50 false false R51.htm 100500 - Disclosure - Net Loss per Share - Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentialCommonSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail Net Loss per Share - Summary of Potential Common Shares Excluded from Calculation of Diluted Net Loss per Share (Detail) Details 51 false false R52.htm 100510 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 52 false false R53.htm 100520 - Disclosure - Commitments and Contingencies - Future Maturities of Lease Liabilities (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMaturitiesOfLeaseLiabilitiesDetail Commitments and Contingencies - Future Maturities of Lease Liabilities (Detail) Details 53 false false R54.htm 100530 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 54 false false R55.htm 100540 - Disclosure - Related Party Transactions - Schedule of Recognized Expenses in Connection with Services Performed Under Master Services Agreement and Supply Agreement (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactionsScheduleOfRecognizedExpensesInConnectionWithServicesPerformedUnderMasterServicesAgreementAndSupplyAgreementDetail Related Party Transactions - Schedule of Recognized Expenses in Connection with Services Performed Under Master Services Agreement and Supply Agreement (Detail) Details 55 false false R56.htm 100550 - Disclosure - Geographical Information - Schedule of Long-lived Assets by Geographic Areas (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureGeographicalInformationScheduleOfLongLivedAssetsByGeographicAreasDetail Geographical Information - Schedule of Long-lived Assets by Geographic Areas (Detail) Details 56 false false R57.htm 100560 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://fusionpharma.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 57 false false All Reports Book All Reports fusn-20200930.xml fusn-20200930.xsd fusn-20200930_cal.xml fusn-20200930_def.xml fusn-20200930_lab.xml fusn-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 75 0001564590-20-052755-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-052755-xbrl.zip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ɑ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